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1. Introduction  
 Silicone gel breast implants have been implanted world-wide, for cosmetic 
augmentation and breast reconstruction, since 1962
[1]
.  Research studies have focused 
on the potential adverse health effects of silicone implants, particularly, possible links 
with cancer or connective tissue disorders, but none have yet shown an increased risk of 
other diseases associated with those implants
[2],[3],[4],[5],[6],[7],[8],[9],[10],[11]
. Additional 
reports have focused on postoperative local complications, and patient safety issues in 
women receiving silicone breast implants
[12],[13],[14],[15],[16],[17],[18],[19]
.  
 Capsular contracture is the formation of fibrous scar tissue investing a foreign 
body or surgically implanted device and is the most common severe chronic 
complication associated with silicone breast implants
[12],[13],[14],[15],[16],[17],[18],[19]
, with a 
clinical realistic incidence ranging from 8 to 45%
[20],[21],[22],[23],[24],[25]
. 
 Silicone breast implants have been certified according to European Union’s 
safety and efficacy requirements as class III medical devices and reclassified by the 
European Union into the strictest category of medical devices for sale to the public. 
Silicone breast implants are the most widely applied medical implants in European 
countries. Saline-based implants, on the other hand, have been almost exclusively used 
in North America and are related to much more complications than silicone-based 
implants, such us rippling, firmer consistency, leaking and complete deflation
[26]
. So far, 
there is a lack of current prospective data comparing capsule contracture with saline 
versus silicone breast implants
[27]
. Recently McCarthy et al. 
[28]
 concluded in the setting 
of postmastectomy reconstruction, patients who received silicone breast implants (n = 
176) reported significantly higher satisfaction with the results of reconstruction than 
those who received saline implants (n = 306). The first-generation of silicone implants 
had a thick shell and viscous gel, while the second-generation possessed a much thinner 
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gel and shell
[29]
. However, with these implants, excessive silicone gel bleed and rupture 
rates occurred
[30]
. The development of the third-generation gave birth to the “low bleed” 
implant containing a barrier-coated shell
[29]
. Ever since polyurethane-coated implants 
were reported to be associated with lower rates of capsular 
contracture
[31],[32],[33],[34],[35],[36]
, the use of breast implants with a textured surface have 
been the subject of recent reviews
[37]
. 
 Several studies have shown that textured implants have a lower tendency to 
develop capsular contracture than smooth-surface implants
[22],[38],[39],[40],[41],[42]
, although 
others have reported the opposite
[43],[44],[45]
. In addition, there is substantial evidence that 
placement in the subglandular plane is associated with a higher incidence of capsular 
contracture
[46]
 and is less satisfactory for mammography
[47]
. On the contrary, other 
studies show a lower proportion of capsular contracture, which was not however 
statistically significant
[22],[48]
. That observation may be attributed to a greater difficulty 
in appreciating capsular contracture in a deeper submuscular plane or to the fact that 
textured surface implants have no impact on capsular contracture when placed 
submuscularly.   
 The polyurethane foam-covered breast implant, a silicone gel-filled device 
surrounded by a 1- to 2mm-thick layer of polyurethane foam, is associated with a lower 
incidence of capsular contracture
[49],[50]
. In the late 1980s it was reported that in vitro 
degradation of polyurethane could lead to formation of substances known to be 
carcinogenic in animals
[51]
. In a retrospective study comprised of individuals receiving 
either polyurethane breast implants (n = 568) or other types of silicone gel-filled breast 
implants (n = 963), between 1981 and 2004 (23 years), Handel
[52]
 concluded that the 
incidence of capsular contracture was dramatically lower with polyurethane foam-
covered implants compared to smooth or textured implants. This beneficial effect 
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persisted at least 10 years after implantation. Aside from skin rash, the polyurethane 
foam-covered implants appear to have a safety profile similar to other silicone gel-filled 
devices. The polyurethane used in the manufacture of breast implants is a 
polyesterurethane made from polyethylene glycol adipate (PEGA) and toluene 
diisocyanate (TDI). The TDI is unstable in an aqueous environment and converts slowly 
into toluenediamine (TDA). The carcinogenic effect of toluenediamine (TDA) has never 
been established in humans
[53]
. To quantify in vivo release of TDA, Hester et al.
[54]
 
collected urine and serum samples from 61 patients with polyurethane foam-covered 
implants and 61 controls on two occasions separated by 10 +/- 3 days. No patients or 
controls had detectable free 2,4-TDA in their sera. Eighteen patients with polyurethane 
foam-covered implants had detectable levels in their urine, compared to 7 control 
subjects. The biodegradative half-life of the polyurethane foam was estimated to be 2 
years. The risk assessment of approximately one in one million derived from this study 
strengthens earlier conclusions by the Health Protection Branch (Canada) that there is 
no significant risk of cancer from exposure to the 2,4-TDA formed from this 
biodegradation. In a review of the literature, McGrath and Burkhardt
[55]
 concluded there 
was no evidence to link breast implants of any kind with an increased risk of breast 
cancer. So far, the polyurethane foam-covered breast implants are not FDA-approved in 
the USA. One reason is the fact that the polyurethane disappears over time; the lack of a 
surgical plane of dissection, high rate of intraoperative bleeding, and difficult 
postexplantation reconstruction make this operation very demanding
[56]
. Where 
polyurethane goes and what effects it might cause will take many years of study to 
answer. The fact that we are again noticing an interest in using polyurethane implants 
should remind us of the real problem of capsule contracture with silicone gel breast 
implants.  
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 In a consecutive, population-based study consisting of 1529 patients receiving 
3495 implants at a multidisciplinary breast center between 1979 and 2004 (25 years), by 
Handel et al.
[57]
,  the authors concluded: 1) the longer implants were in place, the greater 
the cumulative risk of developing contracture, consistent with other studies
[9],[20],[58],[59]
; 
2) hematoma significantly increased the risk of contracture, consistent with other 
studies
[16],[60]
; 3) smooth and textured implants had similar contracture rates, 
controversial in many studies
[22],[38],[39],[40],[41],[42],[43],[44],[45]
; 4) polyurethane foam-
covered implants had a reduced risk of contracture persisting for at least 10 years after 
implantation, consistent with other studies
[31],[32],[33],[34],[35],[36],[52]
. On a systemic review 
of the literature by Shaub, Ahmad and Rohrich
[27]
, the authors were unable to conclude 
which implants, silicone versus saline, have a higher incidence of CC.  
 
1.1 Etiology of capsular contracture 
The true etiology and subsequent treatment of capsular contracture remains yet 
elusive. Two prevailing theories have 
emerged
[21],[39],[61],[62],[63],[64],[65],[66],[67],[68],[69],[70],[71],[72],[73],[74],[75],[76]
: the infectious 
hypothesis and the hypertrophic scar hypothesis.  The infectious hypothesis, which has 
been championed by Burkhardt
[61],[63] 
, supported by others
[71],[72],[73],[74],[76],[77],[78],[79]
 and 
more recently studied by Rohrich and Adams et al
 [21],[62],[64]
, implicated subclinical 
infection in the development of capsular contracture. The hypertrophic scar 
hypothesis
[61],[68],[69],[70],[75],[76],[80],[81],[82],[83]
, implicated non-infectious stimuli, namely 
hematoma, granuloma, or hereditary factors, which may confer a foreign body reaction 
and result in formation of a hypertrophic scar around an implanted device.  
  In our opinion the cause of capsular contracture is multifactorial. We purpose 
this point of view in the publication I
[84]
, which was refuted by Burkhardt in the 
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discussion of this paper. The purpose of this thesis is to clarify its etiology as an 
extension of this first publication. 
 
1.2 Classification of capsular contracture 
 The tables I
[25]
 and II
[78]
 describe the two classifications of capsular contracture. 
Because the Baker classification is widely used, it will be the one reported in this thesis.  
 
Table I.  Baker Classification 
Grade Description 
I Breast absolutely natural, no one could tell breast was augmented 
II Minimal contracture; surgeon can tell surgery was performed but patient 
has no complaint 
III Moderate contracture; patient feels some firmness 
IV Severe contracture; obvious just from observation 
 
 
Table II.  Breast Augmentation Classification 
Grade Description 
I Soft; no deformation 
II Slightly thickened consistency; none to slight deformation 
III Firm to hard; none to slight deformation 
IV Hard; severe deformation 
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Figure 1 (a, b, c).  Right breast: reconstruction with implant; Baker grade II. Left 
breast: reconstruction with latissimus dorsi muscle flap and implant; Baker grade IV 
(with patient authorization) 
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 The Baker classification system defines stages of breast capsule clinical 
presentation into distinct grades
[25]
. Grade II (Figure 1 a/b/c) is the first stage of capsular 
contracture and clinical interpretation of grade II may be highly dependent on individual 
surgeons’ opinions. Although the clinical impact of grade II is relevant to the continuum 
of breast capsule formation, the majority of retrospective and prospective reports do not 
include grade II subjects as breast capsule cases
[85],[86],[87],[88]
. The exclusion of grade II 
subjects in these reports may result in under-reporting of capsular contracture rates. The 
purpose of this thesis (Study 1) was to report the incidence of complications with breast 
implants in a Portuguese population, in aesthetic and reconstructive groups and to 
perform a comprehensive evaluation of the importance of grade II and the follow-up 
time period. In this study we analyse the possible associations among surgical route, 
implant placement, body index mass, smoking habits, alcohol consumption, and 
capsular contracture.  
 
1.2.1 Baker classification rates and follow-up 
Table III
[12],[13],[14],[18],[19],[57] ,[85],[86],[87],[88],[89],[90],[91],[92],[93],[94]
 demonstrates that 
reported capsular contracture rates vary widely due to authors’ reporting Baker 
classification and follow-up time periods. These data showed incidence complications 
were elevated in reconstruction patients compared to cosmetic augmentation 
patients
[13],[95]
.  
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Table III. Studies average follow-up versus capsular contracture 
 
Studies Type of 
study 
Number of patients Average 
follow-up 
Capsular contracture  
Spear et al., 2003 Prospective 85 cosmetic revisions 11.5 months 2% Baker II 
No Baker III-IV 
Adams et al., 
2006 
 
Prospective 235 (172 cosmetic 
primary augmentation; 
63 reconstructive) 
14 months Baker III-IV: 
1.8% cosmetic primary 
augmentation 
9.5% reconstructive 
Henriksen et al., 
2005 
Retrospective 2277 19.5 months 4.3% (Baker II-IV) 
Brown et al., 
2005 
 
Retrospective 150 (118 cosmetic; 32 
reconstructive) 
21 months Cosm: 2 cases  
Reconst: 3 cases 
Just Baker II; no cases Baker III-
IV 
Fruhstorfer et al., 
2004 
Prospective 35 23 months 0% 
Henriksen et al., 
2003 
Prospective 1090 2 years 4.1% (Baker II-IV) 
Cunningham et 
al., 2007  
 
Prospective 955 (572 primary 
augmentation ; 123 
revisions-
augmentation ; 191 
reconstruction ; 69 
revisions-
reconstruction) 
2 years Baker III-IV: 
0.8% primary augmentation 
5.4 revisions-augmentation 
2.2% primary reconstruction 
6% revisions-reconstruction 
Camirand et al., 
1999 
Prospective 830 2.39 years 0% 
Seify et al., 2005  Retrospective 44 34 months 20% (Baker II-IV) 
Cunningham et 
al., 2007  
 
Prospective 1007 (551 primary 
augmentation ; 146 
revisions-
augmentation ; 251 
reconstruction ; 59 
revisions-
reconstruction) 
3 years Baker III-IV: 
8.1% primary augmentation 
18.9 revisions-augmentation 
8.3% primary reconstruction 
16.3% revisions-reconstruction 
Bengtson et al., 
2007 
 
Prospective 941 (492 cosmetic 
primary augmentation; 
225 reconstructive; 
224 revisions) 
3 years Baker III-IV: 
5.9% 
Spear et al., 2007  Prospective 940 (455 cosmetic 
primary augmentation; 
98 reconstructive; 162 
revisions) 
6 years Baker III-IV: 
14.8% primary augmentation 
20.5% revisions-augmentation 
15.9% primary reconstruction 
Kjoller et al., 
2002  
Retrospective 754 7 years 11.4% of implantation 
Kulmala et al., 
2004 
Retrospective 685 10.9 years 17.7% ( 15.4% of implantation) 
Baker II-IV 
Holmich et al., 
2007 
Retrospective 190 19 years 62% 
Handel et al., 
2006 
 
Retrospective 1529 (825 cosmetic; 
264 reconstructive) 
23.3 years Baker III-IV per 1000 patient-
month: 
1.99 cosmetic 
5.37 reconstructive 
4.36 revision 
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Capsular contracture may be apparent within the first year after 
implantation
[13],[14],[20],[58]
.  Breiting et al.
[9]
 reported 18% of severe breast pain, 
indicative of severe capsular contracture and in a previous study, involving a subgroup 
of this population they had diagnosed 45% of capsular contracture (Baker II to IV) of 
the breast after a 5-year period following breast implantation
[96]
. Capsular contracture 
may also be symptomatic several years after surgery
[9],[20],[58],[59]
. The follow-up time 
period remains, until now, unclear. 
 
 1.3 Estrogens  
 It is well known the protective role of estrogens in the progression of liver 
fibrosis
[97],[98]
 and the fact that estrogen deprivation has been associated with declining 
dermal collagen content and impaired wound healing
[99]
. Nevertheless there are no 
studies reporting menopause or estrogens versus capsular contracture. In this thesis 
(Study 1) we purpose to analyse the association between capsular contracture and 
menopause or estrogen status.  
 
1.3.1 Estrogens review of the literature 
 By 1990s, there were estimates that up to 50% of postmenopausal women in 
western Europe
[100]
 and about 35% in United States
[101] 
were on hormone replacement 
therapy because of numerous beneficial effects attributed to such therapy
[102],[103]
. 
 In 2002 the Women´s Health Initiative (WHI)
[104]
 trial reported that combined 
use of an estrogen and progestogen regimen increased the risk of breast cancer and 
cardiovascular events and decreased the risks of fracture and colorectal cancer. Since 
the publication of results from the WHI
[104]
, many women have either stopped or 
become reluctant to use hormone replacement therapy
[104],[105]
 and clinicians have had to 
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revise their treatment algorithms. The relative risk (RR) to benefit ratio of hormone 
replacement therapy was shifted toward excess risk by this study, and the use of 
hormone replacement therapy after publication of this trial dramatically declined. A 
significant minority of postmenopausal women remains on hormone replacement 
therapy for treatment of menopausal symptoms, osteopenia, or personal preference. 
 The three most commonly used hormonal replacement therapy regimens are: 
estrogen-only, continuous combined (estrogen and progesterone) and sequential 
combined (estrogen followed by progesterone). In postmenopausal breast, the number 
of estrogen receptors-positive cells within lobules is increased to about 50% in the 
absence of hormone therapy
[106]
. In animal studies, long-term estrogen or combination 
estrogen/progesterone therapy increases cell proliferation and the percentage of 
glandular tissue in the breast
[107],[108],[109]
 but the pathology of the breast with hormone 
replacement therapy has not been well established
[104],[110],[111],[112],[113],[114]
. 
 Staa et al.
[115] 
reported that hormone therapy used for 5 years initiated at age 45 
increased the absolute risk of myocardial infarction by 0.04% and breast cancer by 0.3% 
and reduced the risk of hip fracture by 0.03%. In most of the younger hormone therapy 
users, the frequency of risks exceeds that of the benefits, although the absolute excess 
risks are small.  
 Even though estrogen therapy can significantly improve vasomotor symptoms, 
postmenopausal Portuguese have a low rate of estrogen replacement therapy use, just as 
surgically menopausal women in Taiwan
[116]
. 
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1.4 The subclinical infection in the development of capsular contracture 
 Investigation of capsular contracture associated with breast implants has 
focused on microorganisms found in the periprosthetic capsule or outer implant 
surface
[61],[62],[74],[76],[87],[117],[118],[119],[120],[121],[122],[123]
, inflammatory responses
[81],[82],[124]
 
and histological characteristics of the capsule
[44],[60],[84],[125],[126],[127],[128],[129]
.  
There is evidence that bacterial colonization of mammary implants is partially 
responsible for capsule contracture, and coagulase-negative Staphylococci, particularly 
S. epidermidis, have been largely implicated 
[71],[72],[130],[131],[132],[133],[134],[135],[136],[137],[138],[139],[140],[141],[142]
. Adams et al.
[62],[64]
 results 
explained that S. epidermidis colonization of mammary implants is more likely to occur 
because of bacterial contamination at the time of implantation than because of ongoing 
contamination from the adjacent ductal system. Because of the low pathogenicity of 
coagulase-negative Staphylococci and the existence of organisms in a dormant phase 
within the biofilm around the implant, capsular contracture does not usually clinically 
manifestate until some remote time after placement of mammary implants.  
The authors perform microbial analysis of rabbits’ skin, operation air, capsules, 
tissue expander and breast implants, to clarify the contamination surrounding the 
procedure (Studies 2, 3, 4 and 5). In study 3, infection surrounding breast implants in 
the presence of coagulase-negative Staphylococci was performed. 
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1.5 Histology and capsular pressure 
Histologically, fibrous capsules showed three-layered composition (Figure 2): 
 - A inner layer abutting the silicone surface: single or multilayered formed basically by 
macrophages (histiocytes) not with abundant fibroblast
[124]
 .
 
- A thicker layer of collagen bundles arranged in a parallel array
[59],[143]
 or 
haphazard
[144]
.
 
- A outer layer comprised loose or dense connective tissue with vascular supply
[124]
 .
 
 
Figure 2. a) Inner layer; b) Middle layer c) Outer layer (hematoxylin-eosin stain 
magnification 100x; from the Control group in Study 4) 
a)
b)
c)
 
 From a clinical perspective, most authors consider the degree of capsule 
thicknesses to be commensurate with the severity of capsular contracture; this has never 
been definitively proven as some reports found no correlation between microbiological 
contamination, thickness and clinical contracture
[66]
.  
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In publication I
[84]
, on gross examination of the capsules, the Control group 
capsule appeared more transparent and had less vessel predominance on the capsular 
surface. The Fibrin group had a more opacified capsule and in many cases appeared 
thicker. The average capsular thickness (histologically measured) was 0.6 mm in the 
rabbit Control group, 1.0 mm in the rabbit Fibrin group and in human capsules, and 2.5 
mm in human capsule contractures. There was a non–statistically significant increase in 
capsular thickness in the Fibrin group. Hematoxylin and eosin sections of rabbit Control 
capsules at 8 weeks, rabbit Fibrin capsules at 8 weeks, human capsules, and human 
contractures were compared. Synovial-like reaction of fibrohistiocytic cells (synovial 
metaplasia) was most pronounced in the rabbit Control capsule at 8 weeks, focal in the 
rabbit Fibrin capsules at 8 weeks, and absent in the human contractures and control 
capsules. The differences in synovial metaplasia in the specimens constitute a 
histological detail that carries no clinicopathological significance; however, they were 
reported for the sake of completeness. Inflammation (consisting of lymphocytes, 
histiocytes, and eosinophils) was moderate in the 8-week rabbit Control capsule and 
mild in the 8-week rabbit Fibrin capsule. The human capsule demonstrated minimal 
inflammation, whereas the human contracture showed mild inflammation. The degree of 
fibrosis was greater in the 8-week rabbit Fibrin capsules and human contracture than in 
their counterparts (the 8-week rabbit Control and human capsules, respectively). 
 In the revision article from Broughton et al.
[145] 
about wound healing, it is known 
that early in the wound healing process the matrix is thin and compliant and allows 
fibroblasts, neutrophils, lymphocytes and macrophages to easily maneuver through it; as 
the matrix becomes denser with thicker, stronger collagen fibrils, it becomes stiff and 
less compliant. Isometric tension is defined as a situation in which internal and external 
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mechanical forces are balanced such that cell contraction occurs without cell shortening 
or lengthening which explains the higher pressure in capsule with contracture.  
In Adams and Marisa et al.
[84]
 (Publication I) the pressure-volume curve was 
generated at 2 and 8 weeks. There was no significant difference between the Fibrin and 
the Control groups at 2 weeks; however, at 8 weeks there was a significant increase in 
intracapsular pressure in the Fibrin group. The limitation of this study was the 
measurement of intracapsular pressure, given that it was not recorded directly but 
through a small capsular window. The purpose of this study was to record directly the 
pressure and to realize how fibrin modulates the capsule formation.  
The underlying mechanism behind this process involves the activation of the 
myofibroblast cells within the capsule, which supposes that contractile elements exert 
the force necessary to produce capsular contracture. Myofibroblasts contain the 
contractile elements actin and myosin and have been identified inconsistently within the 
capsules of implanted devices; however, they have proven difficult to culture and study 
in detail and, when found in the capsule, are found in exceedingly small quantities, are 
located sporadically throughout the capsule, and are not found to attach to each other. 
This scenario poses an inconsistent model for the development of contractile forces 
necessary to produce contracture. 
 To study capsule firmness and the contracture development, we measured the 
capsule pressure directly
[146]
, reason why studies 2, 3 and 5 were performed with tissue 
expanders. 
 Histological analysis of the capsule was performed in all studies. 
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1.6 The immunology of fibrosis  
 Fibrosis is an excessive extracellular matrix (ECM) due to the formation and 
production cells and the occurrence of mononuclear inflammatory infiltrates, with 
proliferation and activation of myofibroblasts. In this context, macrophages and mast 
cells have been implicated as important participants in the inflammatory process 
involving fibrosis. 
 Fibrosis is a major global health problem, but its etiology, pathogenesis, 
diagnosis and therapy have yet not been addressed. Fibrosis can occur as a consequence 
of many pathological conditions: 1) spontaneous (keloids, Dupuytren´s contracture); 2) 
from tissue damage (post-operative adhesions, burns, alcoholic and post-infection liver 
fibrosis, silica dust, asbestos, antibiotic bleomycin); 3) inflammatory disease (infections, 
scleroderma); 4) in response to foreign implants (breast implants, cardiac pacemakers, 
heart valves, artificial joints, central venous catheter ports); and 5) from tumors 
(fibromas, neurofibromatosis). 
 Several mutually non-exclusive hypotheses have been proposed: 1) infection; 2) 
reaction to altered self; 3) overproduction of reactive oxygen species (ROS) and nitric 
oxide (NO); and 4) mechanical stress. 
 In all cases studied, the early stages of fibrotic conditions are characterized by a 
perivascular infiltration of mononuclear cells and the subsequent imbalance of anti and 
profibrotic cytokine profiles. One of the most prominent activators of mononuclear cells 
and fibroblasts are hyaluron fragments that not only induce the expression of various 
cytokines (IL-1, IL-12 and TNF-α), chemokines (MPI-1A, MCP-1, IL-8) and inducible 
nitric oxide synthase (iNOS), but also trigger the expression and secretion of 
macrophage-derivated matrix metalloproteinases (MMP), enzymes essential for ECM 
cleavage
[147]
.  
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 Mast cells can play a role in fibrosis by their secretion of tryptases, contributing 
to connective tissue breakdown. As a consequence of activation of procollagenase and 
induction of a cascade of MMPs, the connective tissue becomes more penetrable for 
infiltrating leucocytes during inflammation. Mast cell-derived tryptase indirectly 
induces fibroblasts proliferation by stimulating the synthesis of cyclooxygenase and 
prostaglandins
[148],[149]
. Natural killer (NK) cells display predominantly anti-fibrotic 
properties in several fibrosis model systems
[150]
. Furthermore, NKT-derived interferon 
(IFN)-y inhibits the production of the profibrotic cytokine transforming growth factor 
beta (TGF-β1)[151]. 
 Cells and cytokines play a prominent role in the initiation and progression to 
fibrosis and Th1 and Th2 cytokines play opposing roles in fibrosis
[152]
: 
- Th1 cytokines (IFN-y and IL-12) suppress the development of tissue fibrosis. 
- Th2 cytokines (IL-4 and IL-13) are strongly pro-fibrotic. 
 Fibroblasts can be derived from local quiescent connective tissue fibroblasts by 
proliferation, but there is also ample evidence that at least some of them originate from 
myeloid precursors in the blood or bone marrow that then migrate to sites of injury
[153]
. 
Once in an active state, fibroblasts are designated as myofibroblasts which express α-
smooth muscle cell actin (α-SMA), produce increased amounts of ECM proteins, such 
as collagen type I and fibronectin, proliferate and show contractile properties. Their 
usual activators are IL-6 and TGF-β1, although they can also be activated by a variety 
of other cytokines, chemokines, growth factors, components of microbial cells walls 
and members of oxidative burns cascade
[152]
. Fibroblasts also receive stimuli from 
lymphocytes via the CD40-CD40 ligand (CD40L or CD154); CD40 ligation results in 
the synthesis of IL-6, IL-8, hyaluronan and the adhesion molecules ICAM-1 and 
VCAM-1
[154]
.  Among the various pro-and anti-fibrotic cytokines, TGF-β isoforms seem 
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to play a key role in the development of fibrosis
[155],[156]
. TGF-β1 has a fibrogenic role 
while TGF-β3 has anti-fibrotic properties. Studies on the role of TGF-β2 are rare and 
the results contradictory. TGF-β1 is a central mediator of fibrosis, but alone it is 
insufficient to cause a persistent fibrotic response; only in synergy with other pro-
fibrotic cytokines, such as connective tissue growth factor (CTGF), results in chronic 
fibrosis
[157]
. 
  In summary TGF-β1, CTGF, osteopontin (OPN), IL-4, IL-6, IL-10, IL-13, IL-
21, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin like 
growth factor-1 (IGF-1), platelet-derived growth factor ( PDGF), oncostatin M and 
endothelin 1 (ET-1)
[158]
 all promote fibrosis , whereas IFN-y, TGF-β3, IL-10 and IL-12 
are anti-fibrotic. IL-5
[152]
, TGF-β2 and TNF-α[159], exerting either pro-or anti-fibrotic 
activities depending on the disease, animal model and experimental settings. 
 
1.6.1 Pathophysiological hallmarks of breast implant capsule formation 
- Fibroblasts and macrophages (by its location in connective tissue namely histiocytes), 
formed a palisade-like multilayered cell wall toward the silicone implant, and represents 
the major cell population
[124]
 .
 
- Ample presence of T cells (CD4+/CD8+), macrophages, dendritic cells (DCs), CD25 
and CD45RO expressing cells; Langerhans-cell like denditric cells are found at the 
frontier layer zone abutting the silicone implant
[59],[124],[125]
 .  
- No accumulation of B-cells
[59],[124],[125]
. 
- Cells at the frontier layer, endothelial cells and smooth muscle cells showed massive 
HSP60 expression (reflecting the mechanical effect or other forms of stress exerted on 
implant and capsule); HSP60 positively predominantly in fibroblast, followed by 
macrophages and T-cells
[124]
.
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- The layers in closest proximity to the silicone showed massive expression of adhesion 
molecules namely intercellular adhesion molecule (ICAM-1) but not to E-selectine or 
VCAM-1; the endothelial cells of the neovasculative vessels in the fibrous capsules 
were P-selectine positive
[124]
.
 
- Actin+ smooth muscle cells found in vascular walls but also in interstitium, 
occasionally formed dense bands
[124]
. 
- Collagenous extracellular matrix (ECM) proteins: high procollagen (type I and III) 
expression correlated with high fibrotic activity; the proportion of procollagen to 
collagen, showed a decreased in procollagen expression and an increase of mature 
collagen deposition with longer implant duration
[124]
.
 
- Non-collagenous extracellular matrix (ECM) proteins: fibronectin shows a high 
affinity for silicone and for cellular components such as macrophages, fibroblasts and 
T-cells; tenascin, mainly synthesized for fibroblasts, mediate adhesion of mononuclear 
cells in on the frontier zone
[124]
.
 
- Serum proteins from many protein families adhere to silicone surface and mediate 
adhesion of fibroblasts, macrophages and ECM proteins
[160]
. 
- Macrophages are activated by cryptic or altered protein domains exposed on silicone 
surfaces or by silicone degradation products
[161]
.
 
- Activated intracapsular lymphoid cells stimulate transdifferentiation of fibroblasts to 
myofibroblasts by CTGF, IL-1 and TNF-α. Macrophages contribute to this process by 
the production of TGF-β1 and IL-6[162]. 
- Soluble ICAM-1, procollagen III, circulating immune complexes and anti-polymer 
antibodies are elevated in sera of women with strong fibrotic reactions to silicone
[163]
 .
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- A special ELISA-based system (SILISA®) demonstrating the “signature” of serum 
protein adhesion to different silicone types can be used to determine the potential risk of 
fibrosis development around silicone breast implants
[164]
.
 
 
Summary: 
- The immune response comprises primarily T-cells. 
- The preferential distribution of dendritic cells in the frontier layer zone underlines that 
this immunological process is not identical or comparable with an unspecific local 
immune reaction or so called foreign body granuloma formation. 
- The constant presence of CD1a+ cells in the frontier zone adjacent to the silicone 
implant as well as next accumulation of CD4+ cells support the hypothesis that silicone 
is not inert, as postulated by the manufacturers, but induces directly or indirectly a T-
cell immune response. The peri-implant connective tissue capsule may represent a 
possible site of antigen processing and presentation
[163]
.
 
- The massive deposition of tenascin in the frontier layer zone supports the theory of 
mechanical stress depending of tenascin expression
[163]
. T-lymphocytes significantly 
increase the synthesis rate of tenascin via certain cytokines such as IL-4 and TNF-α[165]. 
- The mechanical stress to which breast implant is exposed is associated with HSP60 
expression, a family of highly conserved proteins produced by all cells in response to 
various physiological and non-physiological stress-situations to protect the cells from 
potential lethal assaults
[163]
; HSP70 was associated with structural changes of the 
implant capsule, in terms of capsular thickness and the Baker score
[166]
. 
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1.6.2 Microdialysis, IL-8 and TNF-α 
 Microdialysis enables measurement of the chemistry of the capsule extracellular 
fluid. Although initially developed over 30 years ago
[167]
, microdialysis studies in 
humans have been mainly limited to head injury
[168],[169],[170],[171]
, subarachnoid 
haemorrahage
[172]
, epilepsy
[173]
 and cerebral tumors
[174],[175]
. 
 The chemotatic cytokine (chemokin) IL-8 (CXCL8) is an important mediator in 
pathogenesis of many acute and chronic inflammatory disorders
[176]
. IL-8 mainly targets 
polymorphonuclear cells (PMN), the major phagocyte cell, but also mediates attraction 
of basophils, eosinophils and T-cells to the inflammatory site
[177]
. 
 Interleukin-8 (IL-8) is induced by a wide range of stimuli, including: TNF-α, IL-
1
[178]
, bacterial agents
[179]
, formyl-methionyl-leucyl-phenylalanine (f-MLP)
[180]
, 
zymosan
[181]
, plated factor 4 (PF-4)
[182]
, and P-selectin together with RANTES 
(regulated upon activation normal T-cell expressed presumed secreted)
[183]
. The many 
cell types thus responding are: monocytes
[184]
, PMN
[185]
, endothelial cells
[186]
, 
fibroblasts
[187]
, T-lymphocytes
[188]
, natural killer cells (NK)
[182] 
and human mast cell line 
[189]
. In the study by Lund et al.
[190]
, lipopolysaccharide (LPS), a component of the outer 
membrane of Gram-negative bacteria, potentially induced IL-8 release in monocytes, 
while TNF-α was a good inducter of IL-8 in PMN. Furthermore, a relatively high level 
of IL-8 was associated with PMN cells. Lund et al.
[190]
 concluded that under 
pathophysiological condition-associated exposure of blood to LPS, one may anticipate 
that IL-8 is generated as a direct effect of LPS acting on monocytes and that it is further 
amplified due to TNF-α endogenously produced by monocytes. 
 IL-8 is an important chemotactic regulator of neutrophil in vivo
[177]
, and its 
concentration increases during different infections, such as bacteraemia
[191]
 and 
meningococcal infection
[192]
. IL-8 concentrations have also been demonstrated to play 
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an important role in the immunological response to inflammatory disorders 
characterized by neuthrophilic infiltration including psoriasis
[193]
, rheumatoid arthritis 
and asthma.   
 To monitor levels of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α), 
the authors utilized microdialysis, and to our knowledge, this had never been previously 
studied in capsule extracellular fluid by this technically demanding method. 
 
1.7 Prevention and treatment of capsular contracture 
Despite innovations in shell surface textures, implant shapes, inner gel 
composition, surgical implantation techniques and pocket 
irrigation
[20],[38],[39],[55],[62],[63],[64],[194],[195],[196],[197],[198],[199],[200],[201],[202],[203],[204],[205]
 to 
prevent capsular contracture, this major complication remains a serious problem.  
In a pre-clinical study by Tamboto et al.
[206]
, the authors concluded that 
Staphylococcus epidermidis biofilm formation was associated with a fourfold increased 
risk of developing CC. To prevent CC, many plastic surgeons follow the general 
principles of the “Betadine Era”[62] and the “Post-Betadine Era”[64],[87]. However, it also 
known that other factors related to wound healing influence the development of this 
clinical condition
[124]
. In preclinical studies, the treatment with mesna
[126]
, mitomicina 
C
[207]
, zafirlukast
[208],[209]
,  pirfenidone
[210]
 or halofuginone
[211] 
reduced capsule 
thickness, fibroblast cell proliferation and collagen deposition. Nevertheless, these 
drugs are not commonly used in clinical practice, with the exception of the the 
antileukotriene drugs (zafirlukast, montelukast and pranlukast). Scuderi et 
al.
[212],[213],[214]  
reported clinical experience with zafirlukast and suggests that this drug 
may be effective in reducing pain and breast capsule distortion in patients with 
longstanding contracture who are either not surgical candidates or who do not wish to 
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undergo surgery. The antileukotriene drugs are currently used in asthma and lung 
diseases, however, the experience is limited to severe CC because of the severity of 
possible side effects such as liver failure
[215] 
or Churg-Strauss syndrome
[216]
. Research 
concerning cause and prevention has moved forward; however, in clinical practice is 
still a difficult issue, especially when comparing decreased CC rates achieved with 
polyurethane implants. 
 Some reports correlate clinical contracture and hematoma
[16],[60]
; to clarify this 
implication, the authors perform study 2 with tissue expanders surrounded by rabbit´s 
blood to simulate a hematoma, and tissue expanders in the presence of thrombin 
(FloSeal®), an absorbable hemostatic agent and in the presence of a fibrin wound 
healing agent (Tisseel/Tissucol®).  
 Recent evidence investigating the chitosan and the chitooligosaccharide, have 
revealed that they have intrinsic antibacterial and antifungal activity
[217],[218],[219],[220]
 and 
ability to bind growth factors
[221]
. In study 4, breast implants impregnated with 
chitooligosaccharide mixture (COS) and low molecular weight chitosan (LMWC) were 
introduced in the rabbit model. 
 Steroids have shown to be effective in treatment of others pathologic disorders 
characterized for an unorganized scar tissue in dermal structures
[222],[223],[224],[225]
, as 
keloids , hypertrophic scars and burn scar contractures
[226]
. Corticosteroids administered 
during wound healing showed to stop the growth of granulation completely, the 
proliferation of fibroblasts, diminish the new outgrowths of endothelial buds from blood 
vessels and stop the maturation of the fibroblasts already present in connective 
tissue
[227]
.  Also when administered early
 
after injury, corticosteroid delay the 
appearance
 
of inflammatory cells, fibroblasts, the deposition of ground
 
substance, 
collagen, regenerating capillaries, contraction,
 
and epithelial migration
[228]
. These data 
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raised the interest on the use of steroids in the treatment and prevention of CC. The data 
available in the literature regarding the effect of steroids in the prevention and treatment 
of CC is spare and contradictory. The steroids have an important role in the earlier 
phases of wound healing
[228]
, and the role of those effects on the early phase of breast 
capsule formation are also not understood nor explored. In study 5, breast implants with 
triamcinolone were introduced in the rabbit model. 
 
1.7.1 Tissucol/Tisseel® 
Fibrin glue consists of two components, a fibrinogen solution and a thrombin 
solution rich in calcium. Fibrin serves as a binding reservoir for several growth factors 
such as vascular endothelial growth factor (VEGF) 
[229]
, transforming growth factor-β1 
[230]
 and basic fibroblastic growth factor (bFGF)
[231]
. Fibrin glue has been studied for 
decades for its use surgically as a hemostatic and sealant agent. It is routinely used in: 
gastrointestinal anastomosis, breast surgery, face-lifts, abdominoplasty, nerve repairs, 
graft securing, neurosurgery and ophthalmology 
[232],[233],[234],[235],[236],[237],[238],[239],[240],[241],[242]
. More recently it has also gained attention 
as a possible means to deliver drug therapies
[243]
. For example, in a study by Zhibo and 
Miabo
[244]
, release of lidocaine from fibrin glue for pain reduction was tested in humans 
after breast augmentation. Patients who received fibrin glue with lidocaine in the 
subpectoral pocket experienced less pain than those who received the same amount of 
lidocaine or fibrin glue alone. 
 To study the implications of wound healing in development of capsular 
contracture, the instillation of fibrin (Tissucol/Tisseel®) in the implant pocket, to induce 
hemostasis and as a tissue glue to bind the tissues together (adhesive properties), was 
performed (Studies 2 and 3); numerous reports have demonstrated that fibrin glue 
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application is an effective adhesive that is associated with improved parameters of 
wound healing
[245],[246],[247],[248]
. In Adams and Marisa et al.
[84]
 (Publication I), we have 
demonstrated exactly the opposite; in this study, one experimental group has been 
instilled with 5 cc of fibrin glue [fibrin glue is prepared with 4 ml of rabbit cryo (Pel-
Freez; Pel-Freez Biologicals, Rogers, Ark.), 500_l of 10% CaCl (Sigma- Tau 
Pharmaceuticals, Gaithersburg, Md.), 1000 units of thrombin (Monarch 
Pharmaceuticals, Bristol, Tenn.) in 1 ml of 50 mM TrisCl (Sigma), pH 7.4] into the 
implant pocket as a contracture inducing agent. Even if there was a non–statistically 
significant increase in capsular thickness in the Fibrin group, the degree of fibrosis was 
greater in the 8-week rabbit fibrin capsules and human contracture than in their 
counterparts (the 8-week rabbit control and human capsules, respectively). The purpose 
of this study is to clarify the impact of fibrin in contracture development. Incidentally, 
studies 1 and 2 were performed with fibrin (Tissucol/Tisseel®), to induce hemostasis 
and as a tissue glue to bind the tissues together (adhesive properties), which is different 
from the one used in publication I. As indicated by Sead et al.
[249], 
fibrin sealant 
prepared from Tisseel kit without aprotinin has the ability to reduce extracellular matrix 
and TGF-β1 mRNA levels, especially from adhesion fibroblasts, which may indicate a 
role in reduction of postoperative adhesion development. As it has been demonstrated, 
TGF-β is a mediator in scar formation and in multiple fibrotic disorders. It has also been 
demonstrated that connective tissue growth factor (CTGF) is a downstream mediator of 
TGF-β and acts to stimulate wound contraction and fibrosis. It has been observed that 
local treatment with antagonists/anti-sense-oligonuceotides of TGF-β and CTGF at the 
time of surgery reduced CTGF levels in tissue and correlated with reduced capsular 
formation in a rat model. The study by Cole et al.
[250]
 supports the use of fibrin to 
deliver MALP-2 and possibly other peptides, in an active form that might enhance 
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wound healing. In the increase understanding of the wound healing process, it becomes 
clear to Brissett et al.
[251]
, that cellular recruitment and release of growth factors are 
paramount for normal healing to occur; a delay in this process can result in a chronic 
wound or excessive scar. Although the use of these preparatins (Tisseel and Vi-Guard) 
allows the closure of dead-space and approximation of the skin flaps, it is argued that 
these tissue adhesives produce such a dense architecture that angiogenesis and vascular 
ingrowth are inhibited; in addition, because these tissue adhesive do not possess growth 
factors or cytokines to actively recruit cells that are essential for wound healing, they 
are considered bioactively inert. The study by Petter-Puchner et al.
[252]
 was designed to 
assess the impact of fibrin sealing with Tissucol/Tisseel® on adhesion formation to 
condensed polytetrafluoroethylene meshes as well as on tissue integration of these 
implants in experimental intra-abdominal peritoneal on lay mesh repair in rats. The 
authors concluded that Tissucol/Tisseel® improves the tissue integration and reduces 
early adhesion.  
 
1.7.2 FloSeal® 
FloSeal® does not contain any fibrinogen (different from the above fibrin 
sealant); it requires blood as a source for fibrinogen, for clot activation and is ineffective 
in the absence of any bleeding. FloSeal® is a combination of a gelatin-based matrix 
from bovine collagen containing microgranules, cross-linked with glutaraldehyde and 
human thrombin solution
[253]
. Upon contact with blood the gelatin particles swell and 
induce a tamponade-like effect. This characteristic allows it to be effective in 
controlling moderate arterial bleeding. Numerous reports have demonstrated that 
FloSeal® successfully reduces bleeding in cardiac surgery
[254]
, urologic 
procedures
[255],[256],[257]
, gynecology
[258],[259]
 and neurosurgery
[260]
. Dogulu et al. 
[261]
, in a 
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pre-clinical model, concluded that the application of FloSeal® at a laminectomy site 
may be useful to decrease adhesion at the interface between the dura mater and epidural 
fibrosis. 
 
1.7.3 Triamcinolone acetonide 
The data available in the literature regarding the effect of steroids in the 
prevention and treatment of CC is spare and contradictory. Perrin
[262]
 reported less than 
5 percent of significant capsule formation on patients submitted to augmentation 
mammaplasty with inflatable breast prostheses filled with saline and a cortisone 
derivative, with no evidence of wound complications attributable to the steroid. This 
results were reinforced by  Ksander
[263]
  in a  pre-clinical model with rats, where it was 
reported that saline implants filed with saline solution were harder and surrounded by a 
thicker capsular membrane than those filed with metilprednisolone sodium succinate, at 
60 and 120 days.  Caffee et al.
[264]
  reported in a preclinical study, that triamcinolone in 
the pocket during surgery was ineffective for prevention of capsular contracture, but if 
injected 4 and 8 weeks postoperatively, the drug was able to completely eliminate 
contracture. Caffee et al.
[264]
 assume that triamcinolone in the pocket was not effective 
because its effect does not last long enough, and the objection to this method has been 
the fact that the drug was given at the time of operation and was therefore most effective 
in the early phases of wound healing and less active in the latter stages when contracture 
is more likely to begin. However, betadine
[62]
 and antibiotic breast irrigation
[64],[87]  
were 
clinically associated with a low incidence of CC and more effective in the early phases 
of wound healing and less active in the latter stages.  The majority of patients 
undergoing breast augmentation will never experience contracture, and therefore, it did 
not seem reasonable to apply an experimental invasive method to such a group only a 
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minority of patients who would potentially benefit. Caffee et al.
[264]
 conclusions were 
based on indantation and applanation tanometry. There have been no further reports 
confirming that triamcinolone in the pocket during surgery was ineffective. Morover, 
Caffee et al. in 2002
[265]
, and Sconfienza et al. in 2011
[266]
, reported clinical success 
treating patients with CC with the injection of triamcinolone-acetonide between the 
capsule and the implant. Derendorf et al.
[267]
 reported a plasma half-life after venous 
injection of 2h. Recently, Yilmaz et al.
[268]
 performed an extensive review of human and 
experimental studies published on the pharmacokinetics of TA for the treatment of 
macular edema. The authors concluded that the pharmacokinetic profile of TA is 
unpredictable and the agent has a time-limited therapeutic action due to its relatively 
short half-life. This has led to the need for repeated injections to treat contracture or 
macular edema. The answer to the clinical efficiency of triamcinolone-acetonide with 
various doses is not known.   
 
1.8. Chitosan and Chitooligosaccharides 
  Chitin, the polymer D-glucosamine in β (1,4) linkage, is the major component 
of exoskeleton of crustaceous and cell wall fungi
[269]
. Chitosan (CS) is the deacetylated 
product of chitin. Chitooligosaccharides (COS) are degraded products of chitosan, or 
the deacetylated and degraded products of chitin, by chemical and enzymatic 
hydrolysis.  In the literature, the term chitosan is used to describe chitosan polymers 
with different molecular weight (50-2000 kDa), viscosity and degree of deacetilation 
(40-98%)
[270]
. Material with lower levels of deacetylation degrades more 
rapidly
[271],[272],[273]
.  Chitosan has been the better researched version of the biopolymer 
because of its ready solubility in dilute acids rendering it more accessible for utilization 
and chemical reactions
[274]
.  
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Chitosan and related chitooligosaccharides have intrinsic antibacterial and 
antifungal activities
[217],[218],[219],[220]
, which permit the study of the infectious hypothesis.  
On other hand, its ability to bind to growth factors
[221],[275]
, the hemostatic action
[276]
, the 
ability to activate macrophages and cause cytokine stimulation
[276] 
and to increase the 
production of TGF-β[277] allows the study of the hypertrophic scar hypothesis. 
 Chitosan can be processed in a variety of different shapes. These attributes make 
chitosan a promising biopolymer for tissue engineering due to its excellent 
biocompatibility. Chitosan applications include use in wound healing (full thickness 
skin defect, dermal burns)
[218],[221],[278],[279]
, in target delivery of low molecular drugs
[280]
, 
in orthopaedics (cartilage, anterior cruciate ligament, intervertebral disc, bone, 
osteomyelitis )
[220],[281]
, in otologic diseases (tympanoplasty)
[279]
 and in breast capsular 
contracture
[282]
. The combination of chitosan with materials is common in various 
reports
[274]
. The results published by Khor et al.
[274]
, from cell line culture and animal 
model studies, indicated that chitin and chitosan materials were non-cytotoxic and 
suggest that these materials would provide tissue engineered implants that are 
biocompatible and viable. Baldrick et al.
[276]
 observed that chitosan has local biological 
activity in the form of hemostatic action and, together with its ability to activate 
macrophages and cause cytokine stimulation (which has resulted in interest in medical 
device and wound healing applications), may result in a more careful assessment of its 
safety as a parenteral excipient. 
Literature data reporting general toxicity testing for chitosan is limited
[276]
. An 
investigation of intestinal absorption of chitosan in rats showed that the material 
underwent digestion into low molecular weight substances within the gastrointestinal 
tract, and that they are distributed extensively in tissues
[283]
. Apparent toxicity was seen 
with 653-720 mg/Kg/day of COS in rats with side effects in skin and fur and decrease 
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bodyweight
[284]
; it is further suggested that increased platelet count, lymphocyte count 
and differential neutrophils count may be related to dermal inflammation. High dose 
effects were also seen in rabbits following intravenous dosing of chitosan, with deaths 
at 50 mg/Kg/day (but no effect at 4.5 mg/Kg/day)
[285]
; it was suggested that the finding 
was probably due to cell aggregation. Studies in dogs
[286]
 showed evidence of toxicity 
following subcutaneous dosing with clinical signs (anorexia) from 30 mg/Kg/day, 
chemistry changes (especially neutrophilia) from 50 mg/Kg/day, and severe dyspneia 
and deaths from 150 mg/Kg/day; pathological examination showed severe pneumonia 
in the latter animal and it was suggested that this finding was possibly induced by 
immunological reaction and cytokine activation. Cytotoxicity was demonstrated with an 
inhibitory concentration (IC50) of 0.2 mg/ml for chitosan hydrochlorid with release of 
haemoglobin, damage of the erythrocyte membrane, cell aggregation and complete 
lysis
[285]
. Intratumoral injection of chitosan on tumor bearing mice, increases the rate of 
tumor growth, metastasis and the number of capillaries formed
[287]
. There were no 
reports in rabbits related with impregnated chitosan breast implants or with toxicity 
after chitosan implantation. 
 
1.9 The New Zealand white rabbit  
 Adams and Marques et al.
[84]
 (Publication I) reported a model to study capsule: 
the New Zealand white rabbit. The New Zealand white rabbit has the capability to 
support tissue expanders and breast implants, which is impossible in mice; porcine had 
limited reports. 
 This thesis is an extension of Adams and Marques et al.
[84]
 study (Publication I). 
In this study New Zealand white rabbits (n = 32) were subdivided into experimental (n 
= 16) and control groups (n = 16). Each subgroup underwent placement of smooth 
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saline mini implants (30 cc). The experimental group underwent instillation of fibrin 
glue into the implant pocket as a capsular contracture-inducing agent. Rabbits were 
euthanized from 2 to 8 weeks after the procedure. Before the animals were euthanized, 
each implant was serially inflated with saline and a pressure-volume curve was 
developed using a Stryker® device to assess the degree of contracture. Representative 
capsule samples were collected and histologically examined. Normal and contracted 
human capsular tissue samples were also collected from patients undergoing breast 
implant revision and replacement procedures. Tissue samples were assessed 
histologically. Pressure-volume curves demonstrated a statistically significant increase 
in intracapsular pressure in the Fibrin group compared with the Control group. The 
Fibrin group had thicker, less transparent capsules than the Control group. Histological 
evaluation of the rabbit capsule was similar to that of the human capsule/contracture for 
the Control and the Fibrin groups. The authors concluded that pathological capsular 
contracture can be reliably induced in the rabbit. This animal model provides the 
framework for future investigations testing the effects of various systemic or local 
agents on reduction of capsular contracture. 
In the discussion of this paper (Publication I) performed by Burkhardt
[84]
, the 
author believe that if a rabbit model must be used for research, a more appropriate 
model is that reported by Shah et al.
[288],[77]
, who used bacterial contamination to 
produce contracture. In opposite to our belief that the cause of contracture is 
multifactorial, to include hematoma, granuloma, foreign body reaction, hereditary 
factors and subclinical infection as any one of these factors may theoretically stimulate 
an internal hypertrophic scar response that then becomes a contracted capsule, 
Burkhardt believes that presumed cause is limited to infection or bacterial 
contamination. 
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The end result is that the histological analysis of the rabbit fibrin model was 
similar to human contracture but the limitation of this study was the inability to provide 
a clinical translation of this contracture model, as no rabbit developed a Baker II, III or 
IV. Moreover, this was a pilot study, and the fibrin modeling response in capsule 
formation deserves further studies. 
This thesis is an extension of the Adams and Marques et al.
[84]
 study (Publication I) 
to clarify the etiology of capsular contracture, based on this animal model, and with the 
hope of developing a clinical capsular contracture model. 
 
1.10 The pig and the mice models  
 Two recent studies introduced a pre-clinical CC model; 1) Tamboto et al.
[206] 
developed a pig model of CC with submammary pockets inoculated with S. epidermidis 
before miniature gel-filled implants introduction; 2) Katzel et al.
[289] 
developed a mice 
model implanted with silicone gel implants then received a 10-Gy directed radiation 
dose from a slit-beam cesium source. These models brought to the science the 
possibility of further promissory studies. 
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2. Aims of the thesis  
 Retrospective study in aesthetic and reconstructive groups of Portuguese women 
who received silicone textured breast implants within 1998 to 2004. Report the 
occurrence and severity of postoperative complications focused on capsular 
contracture. Analyse the impact of the follow up period, the Baker grade II subjects 
and factors that might contribute to the development of capsular contracture rates, 
namely estrogens and menopausal status (STUDY 1) 
 Identify bacteria and fungi from operation air, rabbit’s skin, tissue expanders, breast 
implants  and removed capsules (STUDIES 2, 3, 4 and 5) 
 Histological analysis of the capsule (STUDIES 2, 3, 4 and 5) 
 Monitor the levels of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in 
capsule extracellular fluid by microdialysis (STUDY 4 and 5) 
 Identify the impact of hematoma  in capsular contracture (STUDY 2)  
 Identify the impact of coagulase-negative Staphylococci in capsular contracture 
(STUDY 3) 
 Identify the impact of thrombin (FloSeal®) in capsular contracture (STUDY 2) 
 Identify the impact of fibrin (Tissucol/Tisseel®) in capsular contracture (STUDIES 
2 and 3) 
 Identify the impact of chitosan in capsular contracture (STUDY 4) 
 Identify the impact of triamcinolone acetonide in capsular contracture (STUDY 5) 
 Clarify the etiology of capsular contracture (STUDIES 2, 3 and 4) 
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3. Material and methods 
STUDY 1 
Subjects and data collection 
Existing medical records of women who had undergone breast implantation with 
customized textured silicone breast implants (Allergan, Santa Barbara, California, USA) 
between 1998 and 2004 in the Hospital of S. João (Oporto, Portugal) were examined. A 
total of 224 women were identified with 104 women who underwent cosmetic breast 
augmentation (Cosmetic group) and 120 women who underwent postmastectomy 
reconstruction of the breast (Reconstructive group). 
The following data were collected from medical records: patient demographics, 
alcohol and medication habits, medical history, surgical procedures, incision location, 
implant device placement
[290]
 and postoperative acute complications (hematoma, 
infection, and seroma). Postoperative chronic complication data (capsular contracture, 
folds, wrinkles, breast pain, and change of tactile sense) were not gathered from medical 
records. Self-reported complications related to satisfaction with implantation surgery 
were collected using a self-administered questionnaire. Women who answered the 
questionnaire were asked to attend a consultation to be further evaluated by two trained 
plastic surgeons in order to decrease subjectivity of this evaluation. The degree of late 
capsular contracture was assigned by the plastic surgeons according to Baker’s 
classification
[25]
.  
Women from the initial group (157 of 224) completed the self-questionnaire and 
attended the consultation. The remaining 67 were then excluded (n = 35 women, 
Cosmetic group; n = 32, Reconstructive group) to remove any potential bias that might 
result from patients with incomplete data. Women were excluded due to loss of contact 
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as they moved out of Oporto or if no current mailing address or phone numbers were 
available at the time of the study. The Reconstructive group was comprised of 88 
patients with 115 breast implants with 27 patients having received bilateral breast 
implants. The Cosmetic group had 69 patients with 136 breast implants from which 2 
had a tuberous breast deformity, 1 had a unilateral aplasia and 1 had a Poland’s 
syndrome. All cosmetic patients younger than 18 years old (n = 4) received implants 
following medical indication, namely severe asymmetry, aplasia of breast tissue or 
congenital malformation. 
 
Statistical analysis 
Postoperative local complications were analyzed independently for the entire 
study group and individual clinical treatment groups and reported per woman and per 
implantation operation (SPSS, Statistical Package for Social Sciences).  Possible 
associations among recorded data sets of patients characteristics, surgical procedures 
and complications were evaluated using Pearson 2 testing and logistic regression 
modeling
[291]
.  Trend analysis was performed using Chisquared Automatic Interaction 
Detection (CHAID) method (SPSS, Statistical Package for Social Sciences, Chicago, 
IL)
[292]
, using the likelihood ratio chi-square statistic as growing criteria, along with the 
Bonferroni 0.05 adjustment of probabilities, and setting the minimum size for parent 
and child nodes at 10 and 5, respectively. Relative risks (RR) and 95 percent confidence 
intervals (CI) were calculated for identified characteristics of interest to examine 
strength and precision of statistical associations.  
CHAID has not been widely applied to trend analyses in plastic surgery 
investigations, but CHAID is one of the oldest tree-classification methods originally 
proposed by Kass
[292]
. In brief, CHAID is an exploratory method to examine 
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relationships between a dependent variable (e.g. capsular contracture) and a series of 
predictor variables (e.g.: type of cohort, age at surgery, follow up period, etc.) and their 
interactions. The CHAID algorithm creates adjustment cells by splitting a data set 
progressively via a classification tree structure where the most important predictor 
variables are chosen that to maximize a chi-square criterion. The most significant 
predictors defined the first split or the first branching of the tree. Progressive splits from 
the initial variables resulted in smaller and smaller branches. The result at the end of the 
tree building process is a series of groups that are different from one another on the 
dependent variable. Classification trees lend themselves to be displayed graphically and 
are far easier to interpret than numerical interpretation from tables. 
 
STUDY 2 
 Eighteen (n = 18) New Zealand white female rabbits (3-4 kg) were implanted  in 
an approved institutional animal care protocol, with textured saline tissue expanders (20 
ml, Allergan, Santa Barbara, California, USA) with intact connecting tube and port. 
Prior to surgery the rabbit´s skin was washed with Betadine® Surgical Scrub containing 
7.5% povidone-iodine, followed by Betadine® Solution containing 10% povidone-
iodine (Purdue Products, Stamford, USA). The surgical procedure was performed in an 
animal operating theatre following aseptic rules. Penicillin G 40.000 u/Kg IM was 
administered just intraoperatively. Talc-free gloves were used at all times during the 
procedure. Pockets were developed in the sub-panniculus carnosis along the back 
region, with atraumatic dissection. Particular attention was given to hemostasis, under 
direct vision avoiding blunt instrumentation and there was no obvious bleeding.   A new 
pair of talc-free gloves was used before tissue expanders insertion with minimal skin 
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contact.  Each tissue expander was placed and filled up to 20 mls volume. Four 
expanders were placed per rabbit. 
 In each rabbit, 1 control and 3 experimental tissue expanders were placed. The 
experimental groups were: 1) sprayed with 1 ml of fibrin glue (Tisseel/Tissucol®; 
Baxter Healthcare Corporation, Vienna, Austria, Europe);  2)  instillation of 2 ml of 
rabbit´s blood into the expander pocket to simulate a hematoma; 3) instillation of 5 ml 
of thrombin sealant (FloSeal®; Baxter Healthcare Corporation, Vienna, Austria, 
Europe) into the expander pocket.  
 A pressure measure device (Stryker® instruments, Michigan, USA) was 
connected to the tissue expander port and intra-expander pre-surgical pressure was 
recorded directly. Pressures were recorded after each 5 ml increments until tissue 
expanders were overfilled.  
 Rabbits were sacrificed at 2 or 4 weeks. Prior to sacrifice, each animal was 
anesthetized and the dorsal back area shaved. The pressure measure device was 
connected to the tissue expander port and intracapsular pressures were recorded 5 ml 
increments previously to any incision in the capsule. Capsule samples were submitted 
for histological and microbiological evaluation. 
 
Microbiological  Assessments 
 Air 
Operating room air samples (n = 36) were collected during all surgical procedures 
using the MAS 100-Eco® air sampler 00109227.0001 / 26299 at a flow rate of 100 
L/min. Identification of bacterial and fungal isolates followed standard microbiological 
procedures. Gram positive cocci were characterized by biochemical methods. Catalase-
positive and coagulase-positive isolates were reported as Staphylococcus aureus; 
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catalase-positive and coagulase-negative isolates were reported as coagulase-negative 
Staphylococci. Gram negative bacilli were characterized using the Vitek Two® with 
version VT2-R04.02 software. Fungi were characterized according to the macroscopic 
appearance and microscopic morphology.  
 Rabbit skin 
A total of 54 contact plates (18 brain-heart agar, 18 mannitol salt agar and 18 
Sabouraud agar contact plates) were pressed to the shaved dorsal skin surfaces. Brain-
heart and mannitol salt agar plates were incubated for 3 days at 28ºC; Sabouraud contact 
plates were incubated for 7 days at 28ºC. The identification of the bacteria and fungi 
followed the procedures reported above. 
 Capsules and tissue expanders 
Excised implants and representative capsule samples were incubated at 37ºC for 3 
days in brain-heart broth and examined daily; changes in turbidity of the broth media 
were considered positive and were subcultured in solid agar media. Characterization of 
microbial isolates followed the above described procedures.  
 
Histological Assessment 
Capsule specimens were fixed with 10% buffered formalin and embedded in 
paraffin. Sections were stained with hematoxylin and eosin and evaluated histologically 
for tissue inflammation and capsular thickness. The type of inflammatory cells was 
grouped into 3 categories: 1) mononuclear (lymphocytes, plasmocytes and histiocytes); 
2) mixed (mononuclear cells and eosinophils); and 3) polymorph (eosinophils and 
heterophils/neutrophils). Inflammatory infiltrate intensity was categorized according to 
the following criteria: absent (-); mild (+); moderate (++); and severe 
(+++)[125]
. 
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Samples were stained with Masson`s trichrome
[293],[294]
 to characterize the 
connective tissue (loose or dense), organization of the collagen fibers (arranged in a 
parallel array or haphazard), angiogenesis (absent, mild, moderate or high) and fusiform 
cells density (mild, moderate or high) were observed. The dense connective tissue was 
semiquantitative analysed: a) dense ≤ 25%, thick collagen bundles less than 25%; b) 
dense 25-50%; c) dense 50-75%; e) dense >75%. 
 
Statistical analysis 
 Data was grouped according to the type of product applied to the tissue 
expander, as none (Control), blood (Blood), Tissucol/Tisseel® (Fibrin) and FloSeal® 
(Thrombin), and analyzed separately for rabbits sacrificed at 2 or 4 weeks after surgery 
as well as for all 18 sacrificed rabbits. One-way analysis of variance was used to 
compare the intra-expander pressure prior to insertion. A two-tailed paired t-test and the 
nonparametric alternative Wilcoxon signed rank test were used to determine if 
continuous variables (intracapsular pressure and histological measured thickness) were 
significantly different between Control and experimental groups. Categorical variables 
were evaluated by Chisquare statistics and by Phi, Cramer’s V and Contingency 
coefficients. Statistical significance was presumed at p  0.05. Major trends within each 
group were further examined by the Chisquared Automatic Interaction Detection 
(CHAID) method
[292]
, using the likelihood ratio Chi-square statistic as growing criteria 
along with a Bonferroni 0.05 adjustment of probabilities. All analyses were carried out 
with the SPSS, Statistical Package for Social Sciences (SPSS, Version 16, Chicago, IL). 
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STUDY 3 
 Thirty-one (n = 31)  New Zealand white female rabbits (3-4 kg) were implanted 
in an approved institutional animal care protocol with 1 textured tissue expander (non-
filled with 20 ml, Allergan, Santa Barbara, CA) and 2 textured breast implants (90 ml, 
Allergan, Santa Barbara, CA). Prior to surgery the rabbit skin was washed with 
Betadine® Surgical Scrub contains 7.5% povidone-iodine, followed by Betadine® 
Solution containing 10% povidone-iodine (Purdue Products, Stamford, USA). The 
surgical procedure was performed in an animal operating theatre following aseptic rules. 
Penicillin G 40.000 u/Kg IM was administered just intraoperatively. Talc-free gloves 
were used at all times during the procedure. Pockets were developed in the sub-
panniculus carnosis along the back region, with atraumatic dissection. Particular 
attention was given to hemostasis, under direct vision avoiding blunt instrumentation 
and there was no obvious bleeding. A sterile Op-site dressing was placed over the skin 
around the incision before the tissue expander and the implants insertion to eliminate 
contact with the skin
[295]
.  A new pair of talc-free gloves was used to perform the tissue 
expander and the implants insertion. 
 The rabbits groups were: 1) untreated implants and expander (Control; n = 10); 
2) implants sprayed each one with 2 ml of fibrin (Tisseel/Tissucol®; Baxter Healthcare 
Corporation, Vienna, Austria, Europe) and  expander sprayed with 0.5 ml of fibrin and 
(Fibrin;  n = 11); 3) implants each one inoculated with 100 microlitres of a suspension 
of coagulase-negative Staphylococci (10
8 
CFU/ml - 0.5 density in McFarland scale) and 
expander with 2.5 x 10
7 
CFU/ml (CoNS; n = 10). 
 Rabbits were sacrificed at 4 weeks. Prior to sacrifice, each animal was 
anesthetized and the dorsal back area shaved. A pressure measure device (Stryker® 
instruments, Michigan, USA) was connected to the tissue expander port and 
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intracapsular pressures were recorded at each 5 ml increments previously to any incision 
in the capsule. All capsule samples were submitted for histological and microbiological 
evaluation. All implants and expander devices were also submitted for microbiological 
evaluation. 
  
Microbiological  Assessments 
 As performed in STUDY 2.  
 Air : air samples (n = 36)  
 Rabbit skin: 93 contact plates (31 brain-heart agar, 31 mannitol salt agar and 31 
Sabouraud agar contact plates)  
 
Histological Assessment 
 As performed in STUDY 2.  
 
Statistical analysis 
 Data were grouped according to the type of product applied to the breast 
implants, namely none (Control; n = 20), Tisseel/Tissucol® (Fibrin; n = 22) and 
coagulase-negative Staphylococci (CoNS; n = 20).  One-way analyze of variance either 
parametric or nonparametric (Kruskal-Wallis H test) were performed to determine if 
continuous variables (intracapsular pressure and histological measured thickness) were 
equal, followed by post-hoc range tests to identify homogeneous subsets across groups. 
Two-tailed independent pair t-tests and the nonparametric alternative Mann-Whitney U 
tests were used. Categorical variables were evaluated by Chisquare statistics and by 
Phi, Cramer’s V and Contingency coefficients. Statistical significance was presumed at 
p  0.05. Major trends within each group were further examined by the Chisquared 
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Automatic Interaction Detection (CHAID) method 
[292]
, using the likelihood ratio Chi-
square statistic as growing criteria along with a Bonferroni 0.05 adjustment of 
probabilities. All analyses were carried out with the Statistical Package for Social 
Sciences (SPSS, Version 16, Chicago, IL). 
 
STUDY 4  
 Eleven (n = 11) New Zealand white female rabbits (3-4 kg) were implanted 
according an approved institutional animal care protocol; each rabbit received 3 
different textured breast implants (90 ml, Allergan, Santa Barbara, CA). Prior to surgery 
the rabbit skin was washed with Betadine® Surgical Scrub containing 7.5% povidone-
iodine, followed by Betadine® Solution containing 10% povidone-iodine (Purdue 
Products, Stamford, USA). The surgical procedure was performed in an animal 
operating theatre following aseptic rules. Penicillin G 40.000 u/Kg IM was administered 
just intraoperatively. Talc-free gloves were used at all times during the procedure. 
Pockets were developed in the sub-panniculus carnosis along the back region, with 
atraumatic dissection. Particular attention was given to hemostasis, under direct vision 
avoiding blunt instrumentation and there was no obvious bleeding. A sterile Op-site 
dressing was placed over the skin around the incision before the implants insertion to 
eliminate contact with the skin
[295]
.  A new pair of talc-free gloves was used to perform 
the implants insertion. 
 Each implant was placed beneath panniculus carnosis along the back (Figure 
1A). The implant groups were: an untreated implant (Control); an implant impregnated 
with COS (MW 1.4 kDa, Nicechem, Shanghai, China); and an implant impregnated 
with LMWC (MW 107 kDa, Sigma-Aldrich, Sintra, Portugal). Both chitosan mixtures 
possessed deacetylation degree in the range of 80−85%. Implants were prepared by 
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immersion in either COS (20.0 mg/mL) or LMWC (10.0 mg/mL) solutions with pH 
adjusted to 5.8-5.9 for 2 hours. Implants were incubated at 37ºC in a flow chamber for 2 
days, packed and sterilized by ethylene oxide.  
Rabbits were sacrificed at 4 weeks. Prior to sacrifice, each animal was 
anesthetized and a 5 mm incision was made directly over the implant through skin, 
panniculus carnosis and capsule. A 100,000 molecular weight cutoff microdialysis 
probe (CMA Microdialysis, Stockholm, Sweden) was placed by the capsule implant 
interface and microdialysates were collected using sterile, normal saline solution (6 
µl/min) for 1 hour.  Whole blood was obtained by venipuncture and serum was 
collected after centrifugation (2000 gmin
-1
, 4
0
C). Capsule samples were submitted to 
histological and microbiological evaluations. 
 
Microbiological  Assessments 
As performed in STUDIES 2 and 3. 
 Air : air samples (n = 20)  
 Rabbit skin: 33 contact plates (11 brain-heart agar, 11 mannitol salt agar and 11 
Sabouraud agar contact plates) 
 
Histological Assessment 
As performed in STUDIES 2 and 3. 
 
Microdialysis  Assessment 
The Invitrogen® Hu TNF-α US kit (Invitrogen®, Hu TNF-α Cat# KHC3014:1) 
is a solid phase sandwich Enzyme-Linked-Immuno-Sorbent-Assay (ELISA). An 
antibody specific for Hu TNF-α has been coated into wells of the microtiter strips 
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provided. The microdialysis fluid was pipetted into wells. During the first incubation, 
the Hu TNF-α antigen binds to the immobilized (capture) antibody on one site, and to 
the solution phase biotinylated antibody on a second site. After removal of excess 
second antibody, Strepavidin-Peroxidase (enzyme) was added which binds to the 
biotinylated antibody to complete the four-member sandwich. After a second incubation 
and washing to remove the unbound enzyme, a substrate solution was added, which was 
acted upon by the bound enzyme to produce color. The intensity of this colored product 
was directly proportional to the concentration of Hu TNF-α presented in the original 
specimen. 
The protocol was repeated with the BioSource® Hu IL-8 US kit (BioSource®, 
Hu IL-8 Cat# KHC0083/KHC0084). 
 
Statistical analysis 
 Data were grouped according to the type of product applied to the implant, 
namely none (Control), chitooligosaccharide mixture (COS) and low-molecular-weight-
chitosan (Chitosan) and analyzed separately for the 11 sacrificed rabbits at 4 weeks after 
surgery. Two-tailed paired t-test and the nonparametric alternative Wilcoxon signed 
rank test were used to determine whether continuous variables (histologic measured 
thickness and dialysate levels of IL-8 and TNF-α) were likely to show differences 
between Control and experimental groups. Categorical variables were evaluated by 
Chisquare statistics and by Phi, Cramer’s V and Contingency coefficients. Statistical 
significance was presumed at p  0.05. Major trends within each group were further 
examined by the Chisquared Automatic Interaction Detection (CHAID) method [292], 
using the likelihood ratio Chi-square statistic as growing criteria along with a 
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Bonferroni 0.05 adjustment of probabilities. All analyses were carried out with the 
SPSS, Statistical Package for Social Sciences (SPSS, Version 17, Chicago, IL). 
 
 
STUDY 5 
 Nineteen (n = 19) New Zealand white female rabbits were implanted in an 
approved institutional animal care protocol with 1 textured tissue expander (non-filled 
with 20 ml, Allergan, Inc., Santa Barbara, CA) and 2 textured breast implants (90 ml, 
Allergan, Inc., Santa Barbara, CA). Prior to surgery, rabbit skin was washed with 
Betadine® Surgical Scrub contains 7.5% povidone-iodine, followed by Betadine® 
Solution containing 10% povidone-iodine (Purdue Pharma LP, Stamford, Connecticut). 
The surgical procedure was performed in an animal operating theatre following aseptic 
rules. Penicillin G 40.000 U/Kg was administered intramuscularly was administered just 
intraoperatively. Talk-free gloves were used at all times during the procedure. Two 5 
cm incisions and one 2,5 cm incision were made directly over the skin and sub-
panniculus carnosus to introduce the implants and the expander, respectively. Pockets 
were developed in the sub-panniculus carnosis along the back region, with atraumatic 
dissection. Particular attention was paid to hemostasis, under direct vision avoiding 
blunt instrumentation and there was no obvious bleeding. A sterile Op-site dressing was 
placed over the skin around the incision before the tissue expander and the implants 
insertion to eliminate contact with the skin.  A new pair of talc-free gloves was used to 
perform the tissue expander and the implants insertion. Then, the implants and the tissue 
expander with intact connecting tube and port were introduced. In the experimental 
group, the introduction of triamcinolone-acetonide (Trigon® depot; Bristol-Myers 
Squibb) into the implant and expander pocket was performed. All wounds were closed 
with two planes of interrupted suture. 
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 The rabbits groups were: 1) untreated implants and expander (Control; n = 10); 
2) introduction of 1 ml (40 mg) of triamcinolone-acetonide into each implant pocket and 
0.25 ml (10 mg) of triamcinolone-acetonide into each expander pocket (Triamcinolone; 
n = 9).  No fluid suction was performed in order to retain the prevent dilution of the 
triamcinolone-acetonide (Trigon® depot; Bristol-Myers Squibb) in the surgical pocket. 
 Rabbits were sacrificed at 4 weeks. Prior to sacrifice, each animal was 
anesthetized and the dorsal back area shaved. A pressure measure device (Stryker 
Instruments, Kalamazoo, Michigan) was connected to the tissue expander port and 
intracapsular pressures were recorded at each 5 ml increments previously to any incision 
in the capsule. Then, a 5 mm incision was made directly over the implant through skin, 
panniculus carnosus and capsule. A 100,000 molecular weight cutoff microdialysis 
probe (CMA Microdialysis, Stockholm, Sweden) was placed by the capsule implant 
interface and microdialysates were collected using sterile, normal saline solution (6 
µl/min) for 1 hour.  Whole blood was obtained by venipuncture and serum was 
collected after centrifugation (2000 gmin-1, 40C). All capsule samples were submitted 
for histological and microbiological evaluation. All implants and expander devices were 
also submitted for microbiological evaluation. 
   
Microbiological  Assessments 
As performed in STUDIES 2, 3 and 4. 
 Air : air samples (n = 24)  
 Rabbit skin: 57 contact plates (19 brain-heart agar, 19 mannitol salt agar and 19 
Sabouraud agar contact plates)  
 
58 
 
Histological Assessment 
As performed in STUDIES 2, 3 and 4. 
 
Microdialysis  Assessment 
As performed in STUDY 4. 
 
Statistical analysis 
 Data were analyzed by groups: Control (n = 20) and Triamcinolone (n = 18). 
One-way analysis of variance (parametric or nonparametric) was performed to check if 
the several means of continuous variables (histologic measured thickness and dialysate 
levels of IL-8 and TNF-α) were equal, followed by post-hoc range tests to identify 
homogeneous subsets across groups. A two-tailed independent pair t-test and the 
nonparametric alternative Mann-Whitney U test were used to determine whether such 
continuous variables were likely to show differences between control and experimental 
group. Categorical variables were evaluated by Chisquare statistics and by Phi, 
Cramer’s V and Contingency coefficients. Statistical significance was presumed at p  
0.05 and all analyses were carried out with the SPSS program. 
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4. Results 
STUDY 1 
Baseline descriptive information for the Cosmetic and Reconstructive patient 
groups were presented in Tables IV and V, respectively.  
 
Table IV. Baseline characteristics for the Cosmetic group. 
Variable No % 
Women with implants (breast implants) 
69 (136)  
Age at surgery in years, mean (range) 31.0 (1551)  
Follow-up period in months, mean (range) 35.4 (1280)  
Implant placement   
 Subpectoral 9 13.0 
 Subglandular 58 84.1 
 Dual plane Tebbets 2 2.9 
Incision placement   
 Inferior periareolar 7 10.1 
 Axillary 21 30.4 
 Inframammary 41 59.5 
Contraceptive drugs   
 No 30 43.5 
 Yes 39 56.5 
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Table V. Baseline characteristics for the Reconstructive group. 
Variable No % 
Women with implants (breast implants) 88 (115)  
Age at surgery in years, mean (range) 48.6 (2573)  
Follow-up period in months, mean (range) 48.5 (1296)  
Symmetrizing breast   
 No 28 31.8 
 Breast implant (with or not mastopexy) 22 25 
 Breast reduction 33 37.5 
 Bilateral breast reconstruction 5 5.7 
Hormone therapy
a
   
 No 85 96.6 
 Yes 3 3.4 
a 
Including contraceptive drugs or hormone replacement therapy  
 
Cosmetic patients were younger at the time of surgery when compared with 
reconstructive patients (31.0 vs. 48.6 years). The average follow-up period was 35.6 
months in the Cosmetic group when compared with 48.5 months in the Reconstructive 
group.  Cosmetic patients reported contraceptive use (56.5%) while only 3.4% of 
reconstructive patients reported contraceptive use or hormone replacement therapy. 
Cosmetic patients also reported decrease use of psychotropic drugs (antidepressants, 
antianxiety and hypnotics drugs) compared with reconstructive patients (23.2% .vs. 
52.3%, respectively). One woman from each group (n = 2) had a connective tissue 
disease (rheumatoid arthritis). 
Among women in the Cosmetic group, the majority of silicone gel implants were 
placed subglandularly (84.1%) and the surgical approach was through the 
inframammary fold (58.0%). The majority of reconstructive patients had not received 
radiotherapy (85.2%) or tamoxifen (67.1%); chemotherapy was administered in 51.1%; 
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the reconstructed breast was on the left side in 52.3% of the patients and 68.2% were 
submitted to breast size symmetrization. 
 
Clinical adverse events: acute 
 Acute complications were recorded in 20 reconstructive patients (8%) during the 
follow-up period, with complications recorded as seroma (8.0%), hematoma (4.5%) and 
perforation of the skin (3.2%).  
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Clinical adverse events: chronic 
Chronic complication events were recorded and tabulated in Table VI.   
 
Table VI. Chronic complications for both groups. 
Chronic complications Cosmetic group 
(N = 69) 
Reconstructive 
group (N = 88) 
 No % No % 
Capsular contracture     
 No 57 82.6 46 52.3 
 Unilateral 9 13.0 41 46.5 
 Bilateral 3 4.4 1 1.2 
Palpable implant folds     
 No 40 58.0 27 30.7 
 Unilateral 12 17.4 48 54.5 
 Bilateral 17 24.6 13 14.8 
Visible skin wrinkles     
 No 59 85.5 72 81.8 
 Unilateral 7 10.1 14 15.9 
 Bilateral 3 4.4 2 2.3 
Prolonged pain in the breast     
 No 59 85.5 78 88.7 
 Unilateral 4 5.8 9 10.2 
 Bilateral 6 8.7 1 1.1 
Change of tactile sense     
 No 61 88.4 9 10.2 
 Unilateral 4 5.8 67 76.1 
 Bilateral 4 5.8 12 13.7 
 
Overall, 81% (n = 127) of all women had 1 or more postoperative chronic 
events, ranging from less severe effects (e.g.: change in tactile sense) to complications 
requiring additional surgical interventions, such as severe capsular contracture. The 
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distribution of chronic complication frequency among women was: a) 23% of the 
patients had one complication; b) 31% of the patients had two complications; c) 27% of 
the patients had three 3 or more complications. From a temporal view of the clinical 
onset of chronic complications, 3% of the patients were diagnosed from 0-12 months 
postoperatively; 31% of the patients were diagnosed from 13-24 months; and 72% of 
the patients were diagnosed from 0-60 months.  
The most frequent chronic adverse effect was palpable implant folds (47.8% of 
all cases), occurring in 42.0% of women from the Cosmetic group and in 69.3% from 
the Reconstructive group. Change of tactile sense also had a high incidence (41.0% of 
all cases) with 89.8% reporting changes in the Reconstructive group, not due to 
reconstruction but mastectomy. For this reason, capsular contracture was the second 
most common chronic complication, occurring in 34.4% of all women and in 23.1% of 
all implantations. Capsular contracture incidence rates were significantly different 
between the Cosmetic group (17.4% of women or 11.0% of implantations) and the 
Reconstructive group (47.7% of women or 37.4% of implantations; p < 0.05). Other 
chronic complications occurred less frequently (< 10% of all patients). 
Furthermore, the occurrence of postoperative complications had a marked 
influence upon satisfaction index, e.g., women without contracture were 1.6 times more 
likely to consider the outcome either good or very good compared to women with 
capsular contracture (RR = 1.6; 95% CI, 1.2, 2.2).  
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Capsular contracture characteristics 
Baker capsular contracture grades for the cosmetic and reconstructive groups 
were presented in Table VII.  
 
Table VII. Capsular Contracture per implant for both groups. 
Grade 
Cosmetic group Reconstructive group 
I 121 (89.0%) 72 (62.6%) 
II 5 (3.7%) 9 (7.8%) 
III 2 (1.4%) 12 (10.4%) 
IV 8 (5.9%) 22 (19.1%) 
Total 136 (100%) 115 (100%) 
 
As a percent of patients, Reconstructive group had 7.4 and 3.2 fold great 
incidences of Baker III and IV grade capsular contractures compared to the Cosmetic 
group. When examined as a function of clinical time when Baker grades were assigned, 
44 women (76%) of the 58 total patients were diagnosed 2 years after surgery.  In detail, 
5 (7%) women from the Cosmetic group and 28 (32%) from the Reconstructive group 
developed capsular contracture grade III/IV after the initial 2 years subsequent to 
implantation. Overall, the rate of grade III/IV capsular contracture per woman during 
the 8-year period of follow-up was 10.1% for patients undergoing cosmetic surgery, and 
37.5% for breast reconstruction patients.  
 The occurrence of capsular contracture was associated with the duration of 
follow-up period and age at time of surgery (Table VIII).  
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Table VIII. Identified variables related to capsular contracture for the entire group  
(n = 157). 
 
Variable 
Capsular contracture (% of women) p value 
No Yes  
Follow-up period   < 0.001 
  42 months 40.1 10.8 
 > 42 months 25.5 23.6 
Age at Surgery 
 
 < 0.001 
  54 years 60.5 24.8 
 > 54 years 5.1 9.6 
Hormone therapy
a
   0.014 
 No 21.7 29.3 
 Yes 43.9 5.1 
Type of group   < 0.001 
 Reconstructive 29.3 26.8 
 Cosmetic 36.3 7.6 
a 
Including contraceptive drugs or  hormone replacement therapy 
 
 Women with a follow-up period longer than 42-months (RR = 1.8; 95% CI, 1.3 
to 2.4) or older women (RR = 3.6; 95% CI, 1.6 to 7.9 for an age of 54+ versus < 54 
years) had increased incidences of capsular contracture (p < 0.001 for both 
comparisons). Moreover, an increased capsular contracture was detected in the 
Reconstruction group when compared to the Cosmetic group (RR = 1.7; 95% CI, 1.4 to 
2.3; p < 0.001). No associations between capsular contracture cases and surgical 
procedures or other personal characteristics were observed. 
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 Using the CHAID decision tree (Figure 3), the type of group was identified as 
the determining factor to develop capsular contracture. The first-level split produced 
two initial branches: Cosmetic (no capsular contracture; percentage = 82.6%) and 
Reconstructive (positive capsular contracture; percentage = 47.7%). The next splits 
indicated the best predictor variables for the Reconstructive group, as the follow-up 
period followed up by the age at surgery. Within that group, a follow-up period of 42 
months or less was the best predictor for no capsular contracture (unadjusted percentage 
= 74.3%) while a follow-up of more than 42 months was predictive for positive capsular 
contracture (unadjusted percentage = 62.3%). For women with a follow-up of 42 
months or less, capsular contracture was reported among 67.7% of women older than 54 
years old compared to younger women (11.5%). The overall risk estimate according to 
the classification tree was 0.240 (standard error of risk estimate 0.034), indicating that 
75.8% of the cases will be classified correctly using the decision algorithm based upon 
the current tree. The CHAID algorithm resulted in larger predictive values for 
occurrence of capsular contracture (72.2%) than LR (57.4%). 
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Figure 3. Prediction tree of capsular contracture by Chi-squared Automatic Interaction 
Detection algorithm. 
 
 
 
 
 
 A second CHAID decision tree analysis was performed with grade II subjects 
placed in the no capsular contracture group – similar to other reports – versus grade III 
and IV subjects. The first-level split produced two initial branches: Cosmetic (no 
capsular contracture or grade II; percentage = 89.9%) and Reconstructive (capsular 
contracture grade III or IV; percentage = 37.5%). The next split indicated the best 
predictor variable for the Reconstructive group, as the follow-up period. Within that 
group, a follow-up period of 64 months or less was the best predictor for no capsular 
contracture or grade II (unadjusted percentage = 73.4%) while a follow-up of more than 
64 months was predictive for capsular contracture grade III or IV (unadjusted 
percentage = 66.7%). The overall risk estimate according to the classification tree was 
0.255 (standard error of risk estimate 0.035), indicating that 79.6% of the cases will be 
classified correctly using the decision algorithm based upon the current tree.  
CAPSULAR CONTRACTURE 
NO 103 (65.6%) 
YES 54 (34.4%) 
COSMETIC GROUP 
NO 57 (82.6%) 
YES 12 (17.4) 
RECONSTRUCTIVE GROUP 
NO 46 (52.3%) 
YES 42 (47.7%) 
FOLLOW UP ≤ 42 months 
NO 26 (74.3%) 
YES 9 (25.7%) 
YES 9 25.7 
FOLLOW UP > 42 months 
NO 20 (37.7%) 
YES 33 (62.3%) 
AGE AT SURGERY ≤ 54 years 
NO 23 (88.5%) 
YES 3 (11.5%) 
AGE AT SURGERY > 54 years 
NO 3 (33.3%) 
YES 6 (66.7%) 
TYPE OF GROUP p < 0.045  
FOLLOW UP p < 0.036 
AGE AT SURGERY p < 0.026 
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 Exogenous hormone use was reported in 56.5% of cosmetic patients (n = 39) 
with one subject in menopause that used hormone replacement therapy; of the 
remaining 68 women, 38 used contraceptives (Figure 4). Only 3.4% of reconstructive 
patients (n = 3) used hormone therapy. Seventy-three patients were in menopause with 2 
subjects using hormone replacement therapy. Fifteen women were premenopausal with 
one using contraceptives.  
 
Figure 4. Graphic of patients with or without menopause per type of group. 
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Subjects who were premenopausal or postmenopausal using hormone therapy 
replacement, were grouped and analyzed as “estrogen protected” (Figure 5).   
 
Figure 5. Graphic of patients protected or not by estrogen per type of group. 
 
To clarify the relationships between menopause or women protected by estrogen 
with capsular contracture rates per type of group, 2 cross-tabulations were performed 
(Tables IX and X). No associations between capsular contracture and menopause or 
estrogen status were observed.  
 
Table IX. Cross-tabulation between capsular contracture and menopause per type of 
group. 
Type of group Menopause Capsular 
contracture 
Total 
Yes No 
Cosmetic Menopause Yes 0 1 1 
No 12 56 68 
Total 12 57 69 
Reconstructive Menopause Yes 36 37 73 
No 6 9 15 
Total 42 46 88 
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Table X. Cross-tabulation between capsular contracture and being protected or not by 
estrogen per type of group. 
Type of group Protected by estrogen
a
 Capsular 
contracture 
Total 
Yes No 
Cosmetic Protected by 
estrogen  
Yes 12 57 69 
Total 12 57 69 
Reconstructive Protected by 
estrogen 
Yes 35 36 71 
No 7 10 17 
Total 42 46 88 
a 
Including all women before menopause or  in menopause with hormone replacement therapy. 
 
 
STUDY 2 
Intracapsular pressure 
 No significant differences were observed regarding the pressure-volume curves 
between the Control and the experimental groups at baseline (tissue expander 
introduction) or at 2 weeks. At 4 weeks, rupture of 6 capsules in the Control group, 5 
capsules in the Blood group and 1 capsule in Thrombin group, during pressure 
measurement were observed; no capsule ruptures in the Fibrin group were noted. To 
avoid too less sampling, the ruptured capsules were not excluded from statistical 
analyses but was stated that the pressure levels measured before capsule rupture were 
maintained after further additional saline was added. At 4 weeks, significant decreased 
intracapsular pressures were registered in the Fibrin (p  0.0006) and Thrombin (p  
0.003) groups (Figure 6). 
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Figure 6. The pressure-volume curves at 4 weeks; there was a significant difference in 
intracapsular pressure in the Thrombin (FloSeal®) and Fibrin (Tissucol/Tisseel®) 
experimental groups. 
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Histology 
The average capsular thicknesses were similar among all groups at 2 and 4 
weeks (Table XI). At 2 weeks, mixed type of inflammatory cells was predominantly 
observed in rabbit capsules and no statistically differences were found (Table XII). At 4 
weeks, mononuclear type of inflammatory cells was predominant in the Control, Blood 
and Thrombin groups; in the Fibrin group mixed type of inflammatory cells was 
predominant but no statistically significant differences were observed (Table XII).  Both 
at 2 and 4 weeks trends of intensity of inflammation showed no significant difference 
(Table XIII). 
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Table XI. Average capsular thickness of Control versus experimental groups. 
Group 2 weeks (mm) 4 weeks (mm) 
Control 0.83 ± 0.085 0.64 ± 0.078 
Blood 1.02 ± 0.207 0.78 ± 0.572 
Fibrin 
(Tissucol/Tisseel®) 
0.89 ± 0.082 0.72 ± 0.083 
Thrombin 
(FloSeal®) 
0.90 ± 0.064 0.71 ± 0.105 
 
 
Table XII. Outcomes for type of inflammatory cells of Control versus experimental 
groups. 
Group Type of inflammatory cells 2 weeks (%) 4 weeks (%) 
Control Mononuclear  22.2 55.6 
Polymorph  0 0 
Mixed  77.8 44.4 
Blood Mononuclear  33.3 55.6 
Polymorph  0 0 
Mixed  66.7 44.4 
Fibrin 
(Tissucol/Tisseel®) 
Mononuclear  11.1 22.2 
Polymorph  0 0 
Mixed  88.9 77.8 
Thrombin 
(FloSeal®) 
Mononuclear  22.2 77.8 
Polymorph  0 0 
Mixed  77.8 22.2 
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Table XIII. Outcomes for intensity of inflammation of Control versus experimental 
groups. 
Group Intensity 2 weeks (%) 4 weeks (%) 
Control Mild 11.1 55.6 
Moderate 77.8 44.4 
High 11.1 0 
Blood Mild 33.3 33.3 
Moderate 66.7 66.7 
High 0 0 
Fibrin 
(Tissucol/Tisseel®) 
Mild 0 22.2 
Moderate 66.7 33.3 
High 33.3 44.4 
Thrombin 
(FloSeal®) 
Mild 11.1 66.7 
Moderate 77.8 33.3 
High 11.1 0 
 
Fibrosis was developed in all capsules at 2 and 4 weeks and no significant 
differences were observed regarding the organization of the collagen fibers between the 
Control and the experimental groups. At 2 weeks, dense >25% connective tissue in the 
Control group and loose or dense 25% connective tissue in the Blood group were 
observed (p = 0.023). Both at 2 and 4 weeks, increased angiogenesis was observed in 
the Control group (moderate or high) versus the Blood group (negative or mild) (p = 
0.018). At 4 weeks, significant differences in the fusiform cells density were observed 
between the Control and the Blood groups (p = 0.047), with mild in the Control group 
and moderate in the Blood group. 
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Microbiology 
Bacteria were isolated in 53% (38 of 72) of the capsules at 2 and 4 weeks, and in 
47% (34 of 72) of tissue expanders. The isolates included: coagulase-negative 
Staphylococci (41%), Escherichia coli (10%), Staphylococcus aureus (8%), 
Pseudomonas spp. (0.7%), and other gram-negative bacilli (0.7%). In capsules, the 
predominant isolates were coagulase-negative Staphylococci detected in 53% (19 of 36) 
at 2 weeks and in 33% (12 of 36) at 4 weeks. In tissue expanders, coagulase-negative 
Staphylococci were found in 44% (16 of 36) at 2 weeks and in 22% (8 of 36) at 4 
weeks. Capsules yielded a single isolate in 43% (31) of cases and more than one in 10% 
(7) of cases; tissue expanders yielded a single isolate in 32% (23) of cases and more 
than one in 15% (15) of cases. No fungi were recovered from the removed capsules or 
tissue expanders of all rabbits. 
Similar bacterial isolates were cultured from the rabbit’s skin. The predominant 
isolates were coagulase-negative Staphylococci, found in 16 of all 18 sacrificed rabbits 
(89%).  Bacterial isolates from rabbit’s skin were similar to those found in capsules and 
tissue expanders. Coagulase-negative Staphylococci were also isolated from all air 
samples. Other common airborne isolates included gram-positive bacilli and 
Staphylococcus aureus; less frequently Penicillium spp., Aspergillus niger and 
zygomicetes were recovered from the operation room air. 
Statistical analyses revealed no significant differences in the frequency of 
culture positivity and the type of bacterial isolates among all the groups; also, no 
significant correlation between the microbiological and the histological data were 
found.  
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CHAID modeling associations 
At 4 weeks statistical analysis with CHAID modeling showed association of 
intracapsular pressure measured at 20 ml, for the Control and the Fibrin groups. The 
determining factor for intracapsular pressure at 4 weeks was the type of inflammatory 
cells (Figure 7 a/b). The CHAID analysis showed in both trees that mixed type of 
inflammatory cells was correlated with decreased intracapsular pressure and 
mononuclear type of inflammatory cells was correlated with increased intracapsular 
pressure. In the Control tree, in the capsules with mononuclear type of inflammatory 
cells, the moderate inflammation was correlated with decreased pressure while capsules 
with mild inflammation had increased pressure. 
CHAID classification analyses using intracapsular pressure measured at 20 ml, 
for the Fibrin and the Thrombin groups showed that the determining factor for 
intracapsular pressure at 4 weeks was the kind of bacteria isolated from tissue expanders 
(Figure 8 a/b). Escherichia coli, Pseudomonas spp. and negative cultures (other than 
Staphylococcus and no contaminated) were correlated with decreased intracapsular 
pressures. Coagulase-negative Staphylococci and Staphylococcus aureus 
(Staphylococcus) were correlated with increased intracapsular pressures. 
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Figure 7. Decision tree by CHAID algorithm for histological data at 4 weeks. (a) 
Control group; (b) experimental Fibrin (Tissucol/Tisseel®) group. 
 
Figure 7 – (a) 
 
 
 
 
 
Figure 5 – (b) 
Figure 7 – (b) 
 
 
 
PRESSURE 
< 70: 6 (66.7%) 
≥70: 3 (33.3%) 
MIXED 
< 70: 6 (85.7%) 
≥70: 1 (14.3%) 
 
MONONUCLEAR 
< 70: 0 (0%) 
≥70: 2 (100%) 
 
TYPE OF INFLAMMATORY CELLS  p < 0.017  
PRESSURE 
≤ 81: 5 (55.6%) 
>81: 4 (44.4%) 
MIXED 
≤ 81: 4 (100%) 
>81: 0 (0%) 
 
MONONUCLEAR 
≤ 81: 1 (20%) 
>81: 4 (80%) 
MILD 
≤ 81: 0 (0%) 
>81: 4 (100%) 
MODERATE 
≤ 81: 1 (100%) 
>81: 0 (0%) 
 
TYPE OF INFLAMMATORY CELLS  p < 0.0007  
INTENSITY p < 0.025 
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Figure 8. Classification tree by CHAID algorithm for microbiological data at 4 weeks. 
(a) experimental Fibrin (Tissucol/Tisseel®) group; (b) experimental Thrombin 
(FloSeal®) group. NO: other than Staphylococci and no contaminated includes 
Escherichia coli, Pseudomonas spp. and negative cultures; S: Staphylococci includes 
coagulase-negative Staphylococci and Staphylococcus aureus. 
 
Figure 8 – (a) 
 
 
 
 
Figure 8 – (b) 
 
 
 
PRESSURE 
< 64: 5 (55.6%) 
≥64: 4 (44.4%) 
NO (no Staphylococci) 
< 64: 5 (83.3%) 
≥64: 1 (16.7%) 
 
S (Staphylococci) 
< 64: 0 (0%) 
≥64: 3 (100%) 
 
MICROBIOLOGY   p < 0.001  
PRESSURE 
< 70: 6 (66.7%) 
≥70: 3 (33.3%) 
NO (no staphylococci) 
< 70: 6 (100%) 
≥70: 0 (0%) 
 
S (Staphylococci) 
< 70: 0 (0%) 
≥70: 3 (100%) 
 
MICROBIOLOGY   p < 0.001  
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STUDY 3 
 
Statistical analyses revealed no significant differences in histological and 
microbiological results between breast implants and tissue expanders (data not shown). 
 
Intracapsular pressure 
During pressure measurements, 5 (50%) capsules ruptured in the Control group 
and 5 (50%) capsules ruptured in the CoNS group. To avoid too less sampling, the 
ruptured capsules were not excluded from statistical analyses but, in such cases, the 
pressure value measured before rupturing was maintained after further additional ml 
saline added. Significant decreased intracapsular pressures were registered for the Fibrin 
group compared with the Control and the CoNS groups (p  0.001; p  0.05) (Figure 9).  
Statistical analyses revealed no significant differences between the CoNS and the 
Control groups (Figure 9). 
 
Figure 9. The pressure-volume curves; there was a significant difference in 
intracapsular pressure in the Fibrin (Tissucol/Tisseel®) experimental group. 
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Histology 
Average capsular thicknesses were 0.81 ± 0.21 mm, 0.47 ± 0.13 mm and 1.06 ± 
0.29 mm in the Control, Fibrin and CoNS groups. Capsular thickness was not 
statistically homogeneous across the 3 groups (p  0.001). Then, three subsets of similar 
means were found out by applying pos-hoc range tests, namely a first one comprising 
the Fibrin group (with the thinnest capsule), a second comprising the Control group, and 
a third one with the CoNS group (with the thickest  capsule). 
CHAID statistical modeling showed correlation between intracapsular pressure 
measured at 20 ml and thickness for the Control and the Fibrin groups (Figure 10 a/b); 
decreased intracapsular pressure was associated with thinner capsule for both groups, 
and the opposite was also true. 
 
Figure 10. Decision tree by CHAID algorithm for thickness. (a) Control group; (b) 
experimental Fibrin (Tissucol/Tisseel®) group. 
 
 
Figure 10- (a) 
PRESSURE 
≤ 173: 12 (60%) 
>173: 8 (40%) 
≤0.8 mm 
≤ 173: 12 (80%) 
>173: 3 (20%) 
 
>0.8 mm 
≤ 173: 0 (0%) 
>173: 5 (100%) 
 
THICNESS   p < 0.002  
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Figure 10- (b) 
 
A mixed type of inflammatory cells was the most common finding in the Control 
and the Fibrin groups, but in the CoNS group, the polymorph type became predominant 
(Table XIV). Significant differences were observed between the Control and the CoNS 
groups (CoNS: p = 0.0001), between the CoNS and the Fibrin groups (p = 0.0009), but 
not between the Control and the Fibrin groups. 
Intensity of inflammation was moderate in the Control and the Fibrin groups and 
mild in the CoNS group (Table XIV). Significant differences were found between the 
Control and the CoNS groups (p = 0.011), between the CoNS and the Fibrin groups (p = 
0.0058) but not between the Control and the Fibrin groups. Significant correlations 
between the intensity of inflammation and the type of inflammatory cells for the Control 
(p = 0.005) and the Fibrin (p = 0.006) groups were observed. 
 
 
PRESSURE 
≥140: 14 (63.6%) 
<140: 8 (36.4%) 
≤0.5 mm 
≥140: 12 (85.7%) 
<140: 2 (14.3%) 
 
>0.5 mm 
≥140: 2 (25%) 
<140: 6 (75%) 
 
THICNESS   p < 0.004  
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Table XIV. Outcomes for capsule inflammation of Control versus experimental groups. 
Group Type of inflammatory 
cells 
 (%) Intensity  (%) 
Control Mononuclear  25.0 Mild 30.0 
Polymorph  0 Moderate 70.0 
Mixed  75.0 High 0 
Fibrin 
(Tissucol/Tisseel®) 
Mononuclear  13.6 Mild 31.8 
Polymorph  13.6 Moderate 59.1 
Mixed  72.8 High 9.1 
CoNS 
 
Mononuclear  35.0 Mild 70.0 
Polymorph  50.0 Moderate 30.0 
Mixed  15.0 High 0 
 
Fibrosis was detected in all capsules; no significant differences regarding the 
fusiform cells density among all groups were observed. Significant differences in the 
connective tissue were found between the Control and the Fibrin groups (p = 0.005), 
and between the CoNS and the Fibrin groups (p = 0.0007), with dense >25% connective 
tissue in the Control and the CoNS groups and loose or dense 25% connective tissue in 
the Fibrin group.  
Significant differences in the organization of the collagen fibers were observed 
between the Control and the Fibrin groups (p = 0.019), and between the CoNS and the 
Fibrin groups (p = 0.0039), with haphazard collagen fibers in the Control and the CoNS 
groups and fibers arrayed parallel in the Fibrin group.  
Significant differences in the angiogenesis were found between the Control and 
the Fibrin groups (p = 0.003), and between the CoNS and the Fibrin groups (p = 0.016), 
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with moderate or high in the Control and the CoNS groups and negative or mild in the 
Fibrin group.  
 
Microbiology 
Bacteria were isolated in 31% (19 of 62) of removed capsules, and in 84% (56 of 
62) of the removed implants (Table XV). The predominant isolates were coagulase-
negative Staphylococci, which were found in 16% (10 of 62) of all culture positive 
capsules, and in 60% (37 of 62) of culture positive implants. Overall, 97% and 90% of, 
respectively, culture positive capsules and implants yielded a single isolate, while 3% 
and 10% yielded two. No bacteria were detected on 69% of the removed capsules and 
on 16% of the removed implants. No fungi were recovered from the removed capsules 
or implants among all groups.  
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Table XV. Bacterial isolates from capsules and implants removed from the sacrificed 
rabbits
a
. 
Bacteria Group
b
 Number of positive 
cultures 
Capsules Implants 
Coagulase-negative Staphylococci  Control 2 (10%) 13 (65%) 
 Fibrin 2 (9%) 9 (41%) 
 CoNS 6 (30%) 15 (75%) 
Staphylococcus aureus Control 2 (10%) 2 (10%) 
 Fibrin 1 (5%) 7 (32%) 
 CoNS 0 (0%) 2 (10%) 
Gram-positive bacilli Control 1 (15%) 1 (5%) 
 Fibrin 3 (14%) 4 (18%) 
 CoNS 0 (0%) 2 (10%) 
Micrococcus spp. Control 0 (0%) 0 (0%) 
 Fibrin 0 (0%) 0 (0%) 
 CoNS 2 (10%) 1 (5%) 
a
 62 capsules and 62 implants were obtained from 31 rabbits 
b
 Data collected from groups Control (10 rabbits; 20 capsules and 20 implants), Fibrin 
(11 rabbits; 22 capsules and 22 implants) and CoNS (10 rabbits; 20 capsules and 20 
implants) 
 
Statistical analysis revealed no significant differences in the type of bacteria and 
in the frequency of culture positivity among the study groups. Also, there was no 
significant association between microbiological and histological data. 
Similar bacteria were isolated from the rabbit’s skin. The predominant isolates 
were coagulase-negative Staphylococci, which was found in 37 of all 45 sacrificed 
rabbits (82%), followed by gram-positive bacilli (60%), Staphylococcus aureus (33%) 
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and Micrococcus spp. (9%). Other isolates found were Enterococcus hermanii, S. 
harmolyticum and Proteus mirabilis, though much less frequently. No skin sample was 
culture-negative while thirty-five samples yielded more than one isolate. The bacterial 
isolates from rabbit’s skin were similar to those from the removed capsules and 
implants. Finally, coagulase-negative Staphylococci were also cultured from all the air 
samples; other airborne isolates were gram-positive and negative bacilli, such as 
Micrococcus spp., Cryptococcus laurentii, Acinetobacter lwofii and Enterococcus 
agglomurans. Fungal species, such as Penicillium spp., Aspergillus niger, A. flavus and 
A. fumigatus were recovered from the operation room air, Penicillium being the most 
common fungal isolate one. 
In the CoNS group one animal developed a clinical contracture Baker grade IV, 
in one breast implant (Figure 11). The capsular thickness measured 1.70 mm and was 
the largest one among all capsules.  The type of inflammatory cells was polymorph with 
moderate intensity. Histological evaluation of fibrosis revealed dense 25-50% 
connective tissue, haphazard collagen fibers, moderate fusiform cells density and 
moderate angiogenesis. Capsule and breast implant, were both infected with 
Micrococcus spp.; no other bacteria or fungi were detected.  
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Figure 11. Rabbit 31 from the CoNS group with a clinical contracture grade IV in the B 
implant. 
 
 
 
 
STUDY 4  
Clinical 
In the Control group, 1 of the 11 implants was ulcerated and none had developed 
clinical capsular contracture.  In the COS group, 3 of the 11 implants were ulcerated and 
no implant had an observation of clinical capsular contracture. The Chitosan group had 
1 ulcerated implant and all 11 implants had grade III/IV capsular contracture (Figure 
12B). All Chitosan group capsules were extremely thick, opaque, stiff and resistant to 
cutting (Figure 12C); the implants were constricted and surface folding was observed.  
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Figure 12.  
A) Rabbit with control implant, COS implant and Chitosan implant (contracture 
grade IV) 
B) Chitosan implant- contracture grade IV  
C) Chitosan implant - extremely thick, dense and opacity capsule 
D) Chitosan implant - hematoxylin-eosin stain magnification 100x with apoptotic 
cells (cells have hiperchromatic and fragmented nuclei) 
 
Histology 
The average capsular thickness was 0.418 ± 0.160 mm in the Control group, 
0.6364 ± 0.216 mm in the COS group, and 2.746 ± 0.817 mm in the Chitosan group. 
Capsular thicknesses were found to be statistically different among the 3 groups; 
capsular thicknesses from the Control group, were different from the COS group (p = 
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0.035) and from the Chitosan group (p= 0.003); capsular thicknesses were different 
between COS and Chitosan groups (p = 0.003). 
No significant differences were observed regarding the type of inflammatory 
cells and intensity of capsule inflammation among the groups (Table XVI). 
 
Table XVI.  Outcomes for type and intensity of inflammatory cells of Control versus 
experimental groups. 
Groups Type of inflammatory cells (%) Intensity (%) 
Control Mononuclear  
Polymorph  
Mixed  
 9.1 
36.4 
54.5 
Mild 
Moderate 
High 
72.7 
27.3 
0.0 
COS Mononuclear  
Polymorph  
Mixed  
9.1 
27.3 
63.6 
Mild 
Moderate 
High 
54.5 
45.5 
0.0 
Chitosan Mononuclear  
Polymorph  
Mixed  
0.0 
45.5 
54.5 
Mild 
Moderate 
High 
36.4 
63.6 
0.0 
 
Apoptotic cells and necrosis (Figure 12D) were observed strongly in Chitosan 
group.  Fibrosis was a component of all capsules and no significant difference was 
found regarding the organization of the collagen fibers (mainly arrayed in parallel in all 
groups), fusiform cells density and angiogenesis among all the groups. Regarding the 
characteristics of connective tissue (either loose or dense), significant differences were 
found between the Control and the Chitosan groups (p = 0.001); Control group had 
loose or dense 25% connective tissue and Chitosan group dense >25% connective 
tissue (mainly dense 25-50%). 
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Microbiology 
Bacteria were isolated from 36.4% (12 of 33) capsules, and from 78.8% (26 of 
33) implants. The organisms cultured (Table XVII) included coagulase-negative 
Staphylococci, Staphylococcus aureus, gram-negative bacilli and Enterococcus spp.. 
Among all the capsules that yielded bacteria, 11 of 12 capsules harboured coagulase-
negative Staphylococci (91.7%) and Enterococci were associated with 1 capsule (8.3%). 
The same trend was observed in excised implants. In 20 of 26 implants that yielded 
bacteria, coagulase-negative Staphylococci were cultured from 76.9% and Enterococcus 
spp. was associated with 1 capsule (3.8%). In contrast to capsules, 4 of 26 bacterial 
contaminated implants harboured gram-negative bacilli (15.4%) and 1 of 26 
Staphylococcus aureus (3.8%). 
 
Table XVII. Bacterial isolates from capsules and implants samples removed from 
sacrificed rabbits. 
 
 
Bacteria 
 
 
 
Number of Positive Cultures 
Capsules Implants 
Coagulase-negative 
Staphylococci 
 
Control 
COS 
Chitosan 
4 (36.4%) 
5 (45.5%) 
2 (18.2%) 
9 (81.8%) 
8 (72.7%) 
3 (27.3%) 
Staphylococcus aureus Control 
COS 
Chitosan 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
1 (9.1%) 
0 (0%) 
Gram-negative bacilli Control 
COS 
Chitosan 
0 (%) 
0 (%) 
0 (0%) 
2 (18.2%) 
1 (9.1%) 
1 (9.1%) 
Enterococcus spp. Control 
COS 
Chitosan 
0 (0%) 
1 (9.1%) 
0 (10%) 
1 (9.1%) 
0 (%) 
0 (%) 
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Overall, 39.4% (13 of 33) and 63.6% (21 of 33) of respectively culture positive 
capsules and implants yielded a single isolate, while 0% (0 of 33) and 9.1% (3 of 33) 
yielded more than one. No fungi were recovered from either capsules or implants. 
No significant differences in the frequency of culture positivity and type of 
bacterial isolates were observed among all the study groups. No significant association 
between microbiological and histological data were also observed. 
Considering rabbit’s skin isolates, the predominant isolate was again coagulase-
negative Staphylococci, which was formed in all rabbits. Bacterial isolates from skin 
were similar to those from capsules and implants. Coagulase-negative Staphylococci 
and gram-positive bacilli were isolated from all the air samples of the operation room, 
along with Penicillium spp. and Aspergillus spp.. 
 
Immunology 
Interstitial fluid of IL-8 levels decreased from 89.4 ± 26.7 mg/ml in the Control 
group to 78.3 ± 32.7 mg/ml in the COS group, and to 66.8 ± 17.9 mg/ml in the Chitosan 
group. Significant differences were observed in IL-8 levels between the Control and the 
Chitosan groups (p = 0.028). 
Levels of TNF-α decreased from 143.9 ± 123.8 mg/ml in the Control group to 
96.8 ± 38.5 mg/ml in the COS group, and to 81.5 ± 31.8 mg/ml in the Chitosan group. 
Statistical analysis revealed no significant differences in the dialysate levels of TNF-α 
among all the groups.  There was correlation between IL-8 and TNF-α in the Control 
group (p < 0.001), but it was not found in the COS (p = 0.073) and the Chitosan groups 
(p = 0.099). 
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STUDY 5 
Statistical analyses revealed no significant differences in histological and 
microbiological results between breast implants and tissue expanders (data not shown). 
The expanders were included in the protocol to determine the pressure-volume curves. 
 
Clinical 
In the Triamcinolone group (Figure 13) the capsule was thinner and more 
transparent than those of the Control group. 
 
Figure 13. Capsule in the Triamcinolone experimental group. 
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Intracapsular pressure 
During pressure measurements, 5 (50%) capsules ruptured in the Control group. 
To avoid too less sampling, the ruptured capsules were not excluded from statistical 
analyses but, in such cases, the pressure value measured before rupturing was 
maintained after further additional mls saline added. Pressure-volume curves were 
generated for all rabbits sacrificed. Statistical analyses revealed no significant 
differences between the Triamcinolone and the Control groups (Figure 14). 
 
Figure 14. The pressure-volume curves. 
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Histology 
Significant decreased capsular thickness was registered for the Triamcinolone 
group compared with the Control group (p  0.001) (Table XVIII).  
A mixed type of cells was the most common finding in the Control and the type 
mononuclear of cells was the most common finding in the Triamcinolone group (Table 
XVIII). Significant differences were found between the Control group and the 
Triamcinolone group ( p = 0.0003).  
Regarding the intensity of inflammation, a significant difference was observed 
between the Triamcinolone and Control groups (p =0.009), with mild in the 
Triamcinolone group and moderate in the Control group (Table XVIII). 
No significant differences regarding the fusiform cells density, connective tissue, 
organization of the collagen fibers, between the Control and Triamcinolone groups were 
observed. Significant differences were found in angiogenesis between the Control group 
where it is basically moderate or high and the Triamcinolone (p = 0.007) group, where it 
was negative or mild. 
 
Table XVIII. Outcomes for capsular thickness and inflammation of Control versus 
Triamcinolone Groups. 
Group Capsular 
thickness (mm) 
Type of 
inflammatory cells 
(%) Intensity (%) 
Control 0.81 ± 
0.209 
Mononuclear 
Polymorph  
Mixed  
25.0 
0 
75.0 
Mild 
Moderate 
High 
30.0 
70.0 
0 
Triamcinolone 0.53 ± 
0.136 
Mononuclear 
Polymorph  
Mixed  
83.3 
0 
16.7 
Mild 
Moderate 
High 
72.2 
27.8 
0 
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Microbiology 
Statistical analysis revealed no significant difference in the type of bacteria and 
in the frequency of culture positivity bacteria between the Control and Triamcinolone 
groups regarding either implants or capsules. Also, there was no significant association 
between microbial presence and histological data. The predominant isolate was 
undoubtedly coagulase-negative staphylococci, which was identified predominantly in 
the removed implants (Table XIX).  
Isolated bacteria from rabbits’ skin and from the room air were statistically 
similar to those from the removed capsules and implants, being coagulase-negative 
staphylococci the prevailing one. 
No fungi were recovered from the removed capsules or implants or skin samples 
of all rabbits. Fungal species, such as Penicillium spp. and Aspergillus were recovered 
from the operation room air.  
 
Table XIX. Bacteria isolated from Capsule and Implant samples removed from all 
sacrificed Rabbits
a
. 
 
 
Bacteria 
 
 
Group 
Number of Positive Cultures 
Capsules Implants 
Coagulase-negative staphylococci  
 
Control 
Triamcinolone 
 
2 (10%) 
6 (33%) 
 
13 (65%) 
14 (78%) 
 
Staphylococcus Aureus Control 
Triamcinolone 
 
2 (10%) 
2 (11%) 
 
2 (10%) 
2 (11%) 
 
Bacillus gram-positive Control 
Triamcinolone 
 
1 (15%) 
2 (11%) 
 
1 (5%) 
2 (11%) 
 
a
 Data collected from groups Control (10 rabbits; 20 capsules and 20 
implants),and Triamcinolone (9 rabbits; 18 capsules and 18 implants) . 
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Immunology 
The dialisate levels of IL-8 decreased from 115.56 ± 128.03 mg/ml in the 
Control group, to 54,41 ± 31.21 mg/ml in the Triamcinolone group. Statistical analysis 
revealed no significant difference in the dialisate levels of IL-8 between the Control and 
the Triamcinolone groups. 
The dialisate levels of TNF-α decreased from 328.62 ± 307.55 mg/ml in the 
Control group to 148.9177 ± 211.92273 mg/ml in the Triamcinolone group. Statistical 
analysis revealed no significant difference in the dialisate levels of TNF-α between the 
Control and the Triamcinolone group. 
There is correlation between IL-8 and TNF- α in the Control group (p < 0.001) 
and in the Triamcinolone group (p = 0.036)  
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5. Discussion 
STUDY 1 
Capsular contracture in a Portuguese population 
In our report, the occurrence of local complications, the frequency, severity and 
long-term sequela were in the reported range as described in other 
studies
[12],[13],[14],[15],[16],[17],[18],[19]
. 
TableIII
[12],[13],[14],[18],[19],[57] ,[85],[86],[87],[88],[89],[90],[91],[92],[93],[94]
 demonstrates that 
reported capsular contracture rates vary widely due to authors’ reporting various Baker 
classification rates and follow-up time periods. These data showed incidence 
complications were elevated in reconstruction patients compared to cosmetic 
patients
[95],[13]
. No acute complications occurred in the Cosmetic group and all chronic 
complications were less prevalent in this group. In our study, women with breast 
implants due to cosmetic reasons had a lower body mass index than women with breast 
reconstruction, similarly to previous study which compared breast augmentation with 
breast reduction and general population
[9]
. 
 In this study, 16% of capsular contracture (Baker III to IV) was diagnosed after 
a 1.6-year period following initial breast implantation. There were no significant 
associations between surgical route or implant placement, and any postoperative 
complication. Like Henriksen et al.
[58]
, no significant associations were observed 
between body index mass, smoking habits, alcohol consumption, hormone therapy and 
capsular contracture in our study groups. 
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Capsular contracture, type of cohort, Baker II subjects and follow-up period 
 Capsular contracture may be apparent within the first year after 
implantation
[13],[14],[20],[58]
.  However, in our study, about 76% of cases of capsular 
contracture (Baker II to IV) appeared just following 2 years; 10.1% and 37.5% of severe 
capsular contracture (Baker III to IV) occurred in the Cosmetic and Reconstructive 
groups, respectively, during the 8 years period of follow-up.  Breiting et al. 
[9]
 reported 
18% of severe breast pain, indicative of severe capsular contracture and, in a previous 
study, involving a subgroup of this population they had diagnosed 45% of capsular 
contracture (Baker II to IV) after a 5 years period following breast implantation
[96]
. 
Capsular contracture may also be symptomatic several years after surgery
[9],[20],[58],[59]
. 
  Using the CHAID decision tree, the determining factor for capsular contracture 
was the type of group; the next splits indicated the best predictor variables for the 
Reconstructive group, as being the follow-up period; once considered no capsular 
contracture versus capsular contracture the follow-up period should be longer than 3 
years and 6 months. However, if considering no capsular contracture including grade II 
subjects versus grade III or IV subjects, a longer follow up period of 5 years and 4 
months was determined. It is interesting that both CHAID tree decision analyses had the 
same qualitative splits but with longer follow up time periods in grade III or IV 
subjects. This is expected as breast capsule formation is thought to develop from grade 
II to grade III, and grade III to grade IV. These results underscore the importance of 
considering grade II as an important clinical observation that should be included in the 
capsular contracture analyses. Thus, we believe that a follow-up period longer than 42 
months from grade II and reconstructive patients should be considered when studying 
local complications among women receiving breast implants. 
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Estrogens, menopause and capsular contracture 
 It is well known the protective role of estrogens in the progression of liver 
fibrosis
[97],[98]
 and the fact that estrogen deprivation was being associated with declining 
dermal collagen content and impaired wound healing
[99]
, nevertheless there are no 
reports concerned with menopause nor estrogens versus capsular contracture. The 
authors for the first time report no association between capsular contracture and 
menopause or estrogen status. Therefore, the pathophysiology of capsule formation and 
subsequent contracture developing metabolic pathways are not estrogen derived. 
 
Limitation and strength of the study 
 The main limitation of this study was the relatively small sample size and thus 
limited statistical power to observe relationships with rare outcomes, especially in the 
Cosmetic group. 
One strength of this study was the statistical analyses of these data among the 2 
groups using the CHAID method, a sophisticated algorithm used in many other 
disciplines, adjusting the probability of a single variable among multiple variables.   
 
STUDY 2 
The major findings of our study were observed on capsules and tissue expanders 
in the rabbits sacrificed at 4 weeks. Compared to the Control group, in the Fibrin and 
the Thrombin groups significantly decreased intracapsular pressures were measured. 
The Fibrin group was the only group without capsule ruptures during the pressure 
measurement. For both the Control and the Fibrin groups, mixed type of inflammatory 
cells was correlated with decreased intracapsular pressures while mononuclear type of 
inflammatory cells was correlated with increased intracapsular pressures. For both the 
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Fibrin and the Thrombin groups, other bacteria than Staphylococci or negative cultures 
were correlated with decreased intracapsular pressures and Staphylococci were 
correlated with increased intracapsular pressures. In the Blood group increased fusiform 
cells density were observed compared to the Control group. Increased angiogenesis was 
observed in the Control group compared to the Blood group. Average capsular 
thicknesses, type and intensity of the inflammatory cells, connective tissue and 
organization of the collagen fibers were similar among all groups. Also the bacterial 
isolates from capsules, tissue expanders and rabbit skin were similar among the four 
groups. In capsules, tissue expanders and rabbit skin the predominant isolates were 
coagulase-negative Staphylococci, which were also isolated from all air samples. No 
fungi were recovered from capsules, tissue expanders or rabbit’s skin, although being 
isolated from all air samples. 
It should be addressed that this study was performed with tissue expanders to 
measure the capsule pressure directly, o achieve more accurate results
[144]
. Similar 
capsules and increased pressure levels were observed in both the Control and Blood 
groups. Based on wound healing principles we may conclude that increased pressure 
levels and capsule rupture rates were correlated with contracture
[145]
. The fact that 
increased angiogenesis is related with fibrosis was demonstrated, supporting the major 
trends observed in the capsule contracture development in the Control group of this 
study
[129],[144],[296]
. 
FloSeal® requires blood for activity; with the Thrombin group results we may 
conclude that an active hemostasis is indispensable to prevent capsular contracture, 
although unnecessary with a hemostatic commercial product.  
On the other hand, the Fibrin group had mixed type of inflammatory cells 
correlated with decreased intracapsular pressures compared with the Control group, 
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which is consistent with other reports observing that the activation of fibrosis in the 
early implant period may be the major mechanism for capsular contracture 
development
[125]
. In our study, type of inflammatory cells was not significantly 
correlated with capsular thickness which is consistent with Siggelkow et al.
[125]
 results. 
Sead et al.
[249]
 studied fibrin sealant prepared from Tisseel kit without aprotinin and 
observed the ability to reduce extracellular matrix and TGF-β1, especially from 
adhesion fibroblasts, which may indicate a role in reduction of postoperative adhesion 
development. It is well known that fibrosis is associated with excessive collagen 
extracellular matrix (ECM) formation and cells proliferation and activation of 
myofibroblasts. In this context, macrophages and mast cells have been implicated as 
important participants in the inflammatory process involving fibrosis
[124]
. Macrophages 
contribute to this process by the production of TGF-β1 and IL-6[162]. In the study by 
Ruiz-de-Erenchun et al.
[297]
, TGF-β1 inhibitor peptide applied in a matrix with 
tetraglycerol dipalmitate was significantly effective in achieving a reduction in 
periprosthetic fibrosis after placement of silicone implants. Interestingly, in the Fibrin 
group, mixed type of inflammatory cells was correlated with decreased intracapsular 
pressures, however if infected by Staphylococcus the intracapsular pressures increased. 
Our results suggest the role of fibrin in preventing capsular contracture; and that the 
bacterial colonization of mammary implants may be partially responsible for capsule 
contracture, and coagulase-negative Staphylococci may play a relevant role 
[71],[72],[130],[131],[132],[133],[134],[135],[136],[137],[138],[139],[140],[141],[142]
. It is reported in literature 
that infection of implanted medical devices was commonly mediated by formation of 
bacterial biofilms
[298],[299],[300],[301]
. However, Pajkos
[74]
 reported that biofilm was 
demonstrated with scanning electron microscopy in a single culture-negative sample. 
Interestingly was the fact that extensive amorphous biological deposits were observed 
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with scanning electron microscopy, even in the absence of bacterial structures. 
Moreover, because of the low pathogenicity of coagulase-negative Staphylococci and 
the existence of microorganisms in a dormant phase within the biofilm around the 
implant, capsular contracture does not usually clinically manifest until some remote 
time after placement of mammary implants
[74],[298],[299],[300],[301]
. For all these reasons, in 
a pre-clinical study, the authors did not consider the biofilm investigation. All the 
methods to biofilm investigation are very expensive, are not routinely used and the 
follow-up period should be really longer. 
We sacrificed the rabbits at 2 and 4 weeks to study the capsule formation and try 
to understand how it is possible to model wound healing formation
[145]
. Our study 
demonstrated very similar wound healing results at 2 weeks among all the groups, 
consistent with Adams and Marques et al.
[84]
 report (Publication I). Our results differed 
from Adams and Marques et al.
[84] 
study where intracapsular pressures were increased 
with fibrin glue application while in our results intracapsular pressure decreased. This 
may be explained in part as our data were collected at 4 weeks while Adams and 
Marques et al. 
[84]
 data examined more mature capsules at 8 weeks. On other hand, in 
this previous study Adams and Marques et al.
[84]
 applied an autologous fibrin glue of 
unknown fibrin concentration into the implant pocket while in this experimental design 
we sprayed a commercial fibrin product widely studied and used in clinical practice 
(Tisseel/Tissucol®) in Europe and USA to reduce polypropylene meshes 
adhesions
[252],[302]
. To the best of our knowledge, this is the first report examining 
capsular formation with a commercial available fibrin product (Tissucol/Tisseel®). In 
addition, this is the first study with investigation of bacterial contamination from 
rabbit’s skin and operation room air.  
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The authors performed the study on a New Zealand white rabbit animal model, 
an extension of Adams et al.
[84]
 study, with the capacity to support four tissue 
expanders, which is impossible in mice. There are limited reports with the use of 
porcine.  
One limitation of this study was the use of tissue expanders to measure the 
pressure directly using ports, instead of commercial silicone breast implants with ports, 
not available in this size. One strength of this study was the statistical analyses of these 
data among the 4 groups using the CHAID method, modeling a single variable among 
multiple variables.   
Other parameters considered to be addressed in future studies: longer follow-up 
time period; breast implants sprayed with fibrin (Tissucol/Tisseel®); focus on fibrosis 
that may influence or modulate capsule contracture. 
 
STUDY 3 
Significant results were demonstrated in each of the experimental groups. In the 
Fibrin group the data showed significantly decreased intracapsular pressures and 
capsular thicknesses without any capsule rupture, compared to the Control and the 
CoNS groups. For the Fibrin and the Control groups, decreased intracapsular pressures 
were correlated with thinner capsules. A mixed type of inflammatory cells was the most 
common finding for both Fibrin and Control groups.  In the Fibrin group, loose or dense 
≤ 25% connective tissue was observed compared to the Control and the CoNS groups 
that had dense >25% connective tissue. In the Fibrin group, negative or mild 
angiogenesis was observed compared with the Control and the CoNS groups with 
moderate or high angiogenesis. No significant differences regarding fusiform cells 
density were observed between the Fibrin and Control groups.  
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In the CoNS group, increased capsular thickness was measured compared to the 
Control group. A polymorph type of inflammatory cells was the most common 
observation in the CoNS group, significantly different from the Control group. 
Regarding fusiform cells density, connective tissue, organization of the collagen fibers 
and angiogenesis, similar results were observed for both CoNS and Control groups.  
Similar bacterial isolates were observed among all the study groups, regarding 
either implants or capsules.  Implants were 2.7 times more frequently infected than 
capsules. The predominant isolates were coagulase-negative Staphylococci, which were 
present 3.8 times more in implants compared to capsules. There was no significant 
association between microbiological and histological data. Bacteria isolates from 
rabbit´s skin were similar to those isolated from capsules and implants. As expected, the 
predominant isolate in rabbit´s skin, as in implants and capsules, were coagulase-
negative Staphylococci. Unexpectedly, Micrococcus spp. were isolated from rabbit´s 
skin specimens, operating room air samples and from one rabbit; in this specific rabbit, 
Micrococcus spp. were detected on the capsule, but not on the implant surface, and this 
capsule did not develop capsular contracture. Interestingly, on the contrallateral implant 
in the same rabbit, a Micrococcus spp. isolate was detected on both implant surface and 
capsule which was associated with clinical Baker grade IV capsule contracture 
development (Figure 11). To the best of our knowledge, this is the first report that 
shows a direct association between the presence of Micrococcus spp. and clinical 
capsule contracture, in a rabbit model.  Fungi were isolated from the operation room air 
samples but not from the rabbit´s skin, capsules or implants. Even with similar bacteria 
types observed among all the groups, regarding implants or capsules, fibrin still 
modulates the capsule formation.  
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 Our results support the probable role of fibrin as an agent that may modify 
capsule formation and subsequent capsule contracture, with decreased capsule 
thicknesses and pressures, loose or dense ≤ 25% connective tissue and negative or mild 
angiogenesis. The decrease of intracapsular pressure correlating with thinner capsules 
was also consistent with other clinical contracture reports
[125],[126],[144],[303]
. In addition to 
these results, the dense connective tissue and increased angiogenesis related with 
capsular contracture has already been demonstrated  in other reports as achieved in our  
Control and CoNS groups
[126],[129],[296]
. The organization of the collagen fibers (parallel 
or haphazard) in capsular contracture is controversy; our results are similar to the study 
of Karaçal et al.
[144]
.   
The cytokine transforming growth factor beta 1 (TGF-β1) is a central mediator 
of fibrosis
[304],[305],[306]
. Some reports focused on fibrin properties for enhanced wound 
healing by the reduction of collagen extracellular matrix and decreased TGF-
β1[157],[162],[249],[250].  TGF-β1 inhibitor peptide was significantly effective in achieving a 
reduction in fibrosis in silicone breast implants
[297]
. The use of fibrin-containing 
preparations (Tisseel® and Vi-Guard®) allow the closure of dead-space and 
approximation of the skin flaps, and it is argued that fibrin-containing tissue adhesives 
produced such a dense architecture that angiogenesis and vascular ingrowth were 
inhibited
[251]
.To the best of our knowledge, this is the first pre-clinical study with a 
commercial fibrin compound (Tissucol/Tisseel®), sprayed to a textured silicone breast 
implant.   
According to our results, bacterial infection of breast implants was more 
common than capsules infection and the predominant isolates were coagulase-negative 
Staphylococci. This is consistent with the fact that coagulase-negative Staphylococci, a 
commensal bacteria of the skin, are the predominant cause of biomaterial-associated 
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infection, commonly mediated by the formation of biofilms
[298],[299],[300],[301],[307],[308]
. The 
major pathogenicity is related to extensive biofilm formation on solid surfaces, which is 
extremely difficult to treat with antibiotics, thereby necessitating invasive procedures to 
remove the infected tissue or devices
[309],[310],[311]
. A strong correlation between the 
presence of biofilm (particularly by S. epidermidis) and the presence of significant 
capsular contracture were also reported
[74]
. They assumed that biofilm on the outer 
surface of the implant, once established, acts as a focus of irritation and chronic 
inflammation, leading to accelerated capsular contracture
[74]
. However, our results are 
contradictory to this report
[74]
. In the study by Pajkos et al.
[74]
, the rate of recovery 
bacteria from the implant surface was lower than the rate of recovery from the capsule 
surface, but the authors explain that there was a greater sensitivity in detecting bacterial 
growth on capsules.  
The clinical contracture Baker grade IV developed in one implant had the 
thickest capsule (Figure 11) among all capsules studied and was unusual as the 
contracture developed quickly with an acute inflammation.  Histological evaluation of 
fibrosis in this capsule contracture revealed dense 25-50% connective tissue, haphazard 
collagen fibers and moderate angiogenesis. Unexpectedly, both the capsule and implant 
were infected only with Micrococcus spp., a low pathogenic agent. As far as we know, 
there are few reports concluding that Micrococcus spp. may have a true etiologic role in 
infection
[312]
 and mediated by formation of bacterial biofilms
[313],[314].  
Our fibrin results are contradictory to our previous report
[84]
 (Publication I), but 
consistent with another pre-clinical study
[315]
 (Study 2; Publication III). This may be 
explained as in this previous published study
[84] 
(Publication I), where we applied an 
autologous fibrin glue of unknown fibrin concentration into the implant pocket while in 
this experimental design we sprayed a commercial fibrin product widely study and used 
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in clinical practice (Tisseel/Tissucol®) in Europe and USA to reduce polypropylene 
meshes adhesions
[252],[302]
, to reduce the incidence of posterior spinal epidural adhesion 
formation
[236]
, and to reduce the recurrence rate of pterygium after surgery
[242]
. Another 
explanation was the application mechanism (manual with a syringe versus sprayed). A 
previous study found that a thin layer of glue is preferable to a thick one
[316]
; a thin layer 
of fibrin glue may support the healing process, whereas a thick layer of adhesive 
inhibits skin graft healing
[317]
. Moreover was the fact that in this study capsule pressure 
was measured directly in tissue expanders, to achieve more accurate results 
[144]
. The 
fibrin glue is used by its properties as a hemostatic agent
[318]
;  for enhanced wound 
healing by the reduction of collagen extracellular matrix and decreased TGF-β1 
(mediator of fibrosis)
[157],[162],[249],[250]
; to prevent adhesions
[252],[302]
;  widely use in 
ophthalmology
[237],[238],[239],[240],[241],[319]
;  used as a drug delivery system such as 
antibiotic
[320]
; and our preclinical animal model results, make fibrin glue a promissing 
agent to prevent capsular contracture. Furthermore, fibrin glue was already used in a 
clinical model after breast augmentation as a drug delivery system
[244]
. 
The limitation of this study was the use of one tissue expander per rabbit just to 
measure the pressure directly using port. To correlate intracapsular pressure from tissue 
expanders with histological and microbiological results from breast implants, we 
performed statistical analyses that revealed no significant differences in histological and 
microbiological results between breast implants and tissue expanders. However, silicone 
breast implants with ports 90 ml size would be better to achieve more accurate results 
but are not commercially available. One strength of this study was the statistical 
analyses of these data among the 3 groups using the CHAID method, a sophisticated 
algorithm used in many other disciplines, adjusting the probability of a single variable 
among multiple variables.   
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Possible future studies would include: 1) a prospective clinical study comparing 
a women control group with a experimental group with Tissucol/Tisseel® sprayed to a 
silicone breast implants/pocket, with a follow-up period longer than 42 
months
[321]
(Study1; Publication II); and 2) analyze S. epidermidis and Micrococcus spp. 
biofilm development in a pre-clinical study with silicone breast implants with ports 
sprayed with Tissucol/Tisseel® and infected with bacteria 
 
STUDY 4 
 In this study, we report the development of capsular contracture in a rabbit 
model associated with chitosan. All Chitosan group implants had clinical Baker grade 
III/IV breast contractures with significantly thicker capsules than non-treated implants. 
Chitosan exposed capsules were opaque, stiff and resistant to cutting and considerable 
shrinkage, and folding of the implant surfaces were observed that may indicate the 
constricting nature of fibrous implant capsules. Control group had thin capsule and 
loose or dense ≤ 25% connective tissue compared to the dense > 25% connective tissue 
observed in the Chitosan group. This is consistent with the fact that the major 
component of chitosan, glucosamine, forms cartilage tissue and is also present in 
tendons and ligaments
[146]
. Collagenous layer of granulation tissue is increased by 
chitosan applications; according to this finding, chitosan may stimulate fibroblast 
proliferation and extracellular matrix production
[287]
. Chitosan induced an accelerated 
wound healing process which increased TGF-β1 responsible for several 
proinflammatory regulatory influences, including cell migration, granulation tissue 
formation and increased collagen production
[277]
 and, recognized as a central mediator 
of fibrosis
[155]
. 
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A mixed or polymorph type of inflammatory cells was the most common finding 
in all rabbit capsules and inflammation intensity was moderate or mild in all capsules 
which was expected as chitosan is chemoattractant for neutrophils
[220],[322]
. Chitosan 
enhances the function of inflammatory cells such us polymorphonuclear leukocytes 
(PMN), macrophages, fibroblasts (production of IL-8), angioendothelial cells
[287] 
and 
LMWC has a systemic effect
[283]
. Apoptotic cells and necrosis were observed strongly 
in Chitosan capsules which were consistent with other reports
[323],[324]
. 
Statistical analyses revealed no significant differences in the frequency of 
culture positivity and types of bacteria among all the groups. Interestingly, no 
significant associations between microbiological and histological data were observed in 
any group. Similar bacterial isolates were cultured from rabbits’ skin and air samples 
and the predominant isolates were coagulase-negative Staphylococci. The antimicrobial 
activity of chitosan and its derivatives against several bacterial species has been 
recognized and considered as one of the most important properties linked directly to 
their possible biological applications
[217],[218],[219],[220]
; however, the new interest on 
chitosan as a drug deliverer such us antibiotics questioned the high efficacy of chitosan 
alone as an antibacterial agent
[325],[326],[327],[328]
.  This study supports that capsular 
contracture formation was not the result of bacterial infection alone, in contrast to the 
infectious hypothesis which has been championed and consistently supported by 
Burkhardt
[61],[63],[84]
. 
To gain insight into the inflammatory process, the major biomarkers, TNF-α and 
of IL-8, were measured.  This is the first report examining extracellular levels of IL-8 
and TNF-α in a breast capsule implant environment. Microdialysate levels of IL-8 were 
decreased (p< 0.05) in the Chitosan group compared to the Control group. No 
significant differences in the microdialysate levels of TNF-α were observed among the 
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groups. In the Control group, a correlation between IL-8 and TNF-α was observed; no 
significant correlation between IL-8 and TNFα levels were observed in the experimental 
groups.  
 We originally hypothesized that serum concentrations of the inflammatory 
mediators would be significantly increased in the Chitosan group due to the expected 
greater inflammatory response with Chitosan as this molecule promotes the production 
of IL-8
[287]
. These data did not support the hypothesis but were consistent with Tilg et 
al.
[329]
 study which reported increased IL-8 and TNF-α levels in bacterial infection and 
decreased  IL-8 and TNF-α levels in acute rejection. Interestingly, we now report 
clinical Baker grade III/IV breast capsule contractures in all rabbits exposed to chitosan 
associated with polymorph and mixed inflammation and not due to a bacterial infection. 
Not all Chitosan implants were infected and IL-8 and TNF-α were decreased in the 
Chitosan group. Molecular regulation of IL-8 production has been studied in vitro and 
TNF-α has proven to be a major regulatory molecule. It is not surprising that in vivo IL-
8 and TNF-α serum levels were also significantly correlated in the Control group. 
Correlation between IL-8 and TNF-α was well established in the case of bacterial 
infection, less pronounced in cytomegalovirus hepatitis and not apparent in acute 
cellular liver rejection episodes. Lack of correlation in acute rejection was also 
associated with low levels of IL-8
[329]
. This suggests that in contrast to bacterial 
infection, countering cytokines may be active in capsular contracture (at least promoted 
by chitosan), and down-regulating IL-8 transcription and/or translation. So far, no 
reports exist on production and regulation of IL-8 in capsular contracture. Recent 
studies have additionally demonstrated that COS displayed anti-inflammatory properties 
in immunocytes including the inhibition of nitricoxide, the down-regulation of IL-6 and 
TNF-α and the increase of cell viability of neutrophils[330],[331]. Additionally, IL-8 was 
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induced by a wide range of stimuli, including lipopolysaccharide (LPS), a component of 
the outer membrane of Gram-negative bacteria and TNF-α.  The study by Lund et 
al.
[190]
 concluded that LPS induced IL-8 release in monocytes, while TNF-α was a good 
inductor of IL-8 in PMN. In the chitosan contracture model, we had decreased levels of 
IL-8 and it was possible to conclude that there was no Gram-negative bacteria infection 
to induce IL-8. On the other hand, chitosan increased the production of TGF-β1[277], a 
central mediator of fibrosis; the degree of capsular contracture is directly related to an 
increased level of TGF-β[125]. Even with contradictory studies about the role of TNF-α, 
Moritomo et al.
[332] 
concluded that TNF-α played a pivot role in the maintenance of 
hemostasis and tissue repair by inhibiting TGF-β1. 
Our data support the theory that chitosan initiates capsular contracture response 
due to a toxic local effect that resulted in an impaired wound healing response. An 
earlier series of pilot studies were performed with much higher levels of chitosan (data 
not shown). Using similar experimental protocol in the rabbit model, implants exposed 
to 25.0 mg/mL levels were used. The majority of animals expired within a short time 
period; surviving animals had decreased weight (15-25.8%) compared to baseline body 
weights with leucocitosis and decreased hemoglobin. At autopsy, fat biopsies were 
atrophied and liver specimens had lymphoid infiltration in portal spaces. We report 
toxicity with 25.0 mg/mL of implanted LMWC per rabbit. The study design was 
modified to test decreased chitosan levels that were not systemically toxic to the 
animals. In the reported data, all animals were clinically healthy.  Literature data 
reporting general toxicity testing for chitosan is limited
[276] 
and our results are consistent 
with the few papers about chitosan toxicity
[283],[284],[285],[286],[287]
. 
In several important studies
[73],[77]
 the same rabbit had different implants. 
Darouich et al.
[73]
 with the objective to examine in vivo the antimicrobial efficacy of 
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minocycline/rifanpin-impreganated saline-filled silicone implants, used the same rabbit 
to place 4 implants (2 antimicrobe-impregnated and 2 control implants were placed in 
each rabbit). In the study by Shah et al.
[77]
, with the objective to examine in vivo the 
infectious hypothesis, each rabbit underwent a Staphylococcus epidermidis 
contaminated implant and a control implant. However, due to the systemic influence of 
chitosan, the use of 3 different implants in the same rabbit, in our study, obviously may 
confounded the results. To clarify this issue, a Control limb study was performed (data 
not shown) and compared with the Control group of this study. Using similar 
experimental protocol, 10 rabbits were implanted with 2 textured breast implants. 
Interestingly, on the Control group from this study the capsular thickness was lower 
than in the Control limb group (0.81 ± 0.21 mm) (p = 0.001). No significant differences 
were observed regarding the intensity of inflammation, characteristics of connective 
tissue (either loose or dense), fusiform cells density and angiogenesis between the 
groups;  significant differences were observed with respect to the type of inflammatory 
cells, with mixed type of inflammatory cells in 54.5% of the Control group of this study 
and  mononuclear type of inflammatory cells in 55.6% of the Control limb group  (p = 
0.017); significant differences were observed in the organization of the collagen fibers, 
which were arrayed in sequence in the Control group of this study and haphazard in the 
Control limb group (p = 0.007). Statistical analysis revealed no significant differences 
in the type of bacteria and frequencies between the control group of this study and the 
control limb group. A decreased levels of IL-8 (p = 0.016) and TNF-α (p = 0.001), were 
observed in the Control group of this study when compared with the Control limb 
group, which prove the systemic influence of chitosan.  
In the discussion of our previous paper
[84]
 (Publication I), Burkhard considered 
that if a rabbit model must be used for research, a more appropriate model was that 
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reported by Shah et al.
[77],[288]
 who used bacterial contamination to produce contracture. 
In that study
[77]
, 16 New Zealand white rabbits underwent each one, a Staphylococcus 
epidermidis contaminated implant and a control implant. The capsules were dissected at 
2, 4, 6 and 8 weeks. Capsules on the contaminated side were 2 to 3 times thicker than 
those on the control side, and did not change thickness with time. Capsules on the 
contaminated side consisted of densely packed longitudinally oriented thick bundles of 
collagen fibers; there was a large cellular infiltration with leukocytes and macrophages. 
In contrast, the capsules on the control side were thinner and consisted of loosely 
organized connective-tissue fibers predominantly parallel to the prosthesis surface. 
Bacteriologic cultures on the contaminated side consistently isolated Staphylococcus 
epidermidis with occasional diphtheroides, while the control side showed no bacterial 
growth. As Prantl et al.
[333]
 we believe that subclinical infection with chronic 
inflammation represents one of the possible important reasons for the development of 
capsular contracture. We also hypothesize that all possible causes of fibrosis result in 
the common key factor of pathological response with the development of chronic 
inflammation. Prantl et al.
[333]
 included only those implants with high gel cohesiveness 
(third-generation implants); in these implants, the silicone filler presumably does not 
leak from the shell into the tissue in case of implant rupture; surprising, in 67% of their 
specimens, they detected vacuolated macrophages with microcystic structures 
containing silicone, and in 54% of the specimens, the capsular tissue contained empty 
spaces of varying sizes of silicone particles. It remains unclear whether these silicone 
structures represented friction particules from the surface of the implant or particules in 
the implant filler. Heppleston and Styles
[334]
 study  performed in vitro experiments 
demonstrating that silica damages macrophages, which subsequently produces TGF-β1 
which stimulates fibroblast to produce collagen. However, since the study by Shah et 
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al.
[77]
, and as far as we know, even with many publications with infected implants, there 
was no translation of the Baker classification in a pre-clinical model.  
An infection-induced contracture limb study was performed (data not shown) 
and compared with the Chitosan group of this study. Using similar experimental 
protocol, 10 rabbits were implanted with 2 textured breast implants, each one with a 
suspension of 100 microlitres of coagulase-negative Staphylococci (10
8 
CFU/ml - 0.5 
density in McFarland scale). Histologically, the average capsular thickness was 1.065 ± 
0.287 mm in the infection-induced contracture limb group (CoNS group) and 2.746 ± 
0.817 mm in the Chitosan group. Capsular thicknesses were found to be statistically 
different among the two groups (p = 0.00003). A significant difference was also 
observed regarding the type of inflammatory cells among the two groups (p = 0.021), 
with a polymorph type predominant in the CoNS group, and mixed type predominant in 
the Chitosan group. No significant differences were found between the two groups 
regarding the intensity of capsule inflammation. Significant differences in the 
angiogenesis were found between the CoNS and Chitosan groups (p = 0.004), with 
equally absent/mild and moderate/high in the CoNS group but only high in the Chitosan 
group, as well as in the synovial metaplasia (p = 0.043) which was always absent in the 
Chitosan group but present in some cases of the CoNS group. However, no significant 
differences were found between the two groups regarding the characteristics of the 
connective tissue, organization of the collagen fibers (parallel or haphazard) and 
fusiform cells density. Histologically, this type of capsular contracture induced by 
chitosan is different than those induced by infection, in some aspects: 1) the capsule was 
thicker; 2) the mixed type of inflammatory cells was predominant; 3) the angiogenesis 
was high; 4) the synovial metaplasia was absent. This study reported to science a pre-
clinical non-infectious model of capsular contracture and further studies are necessary. 
113 
 
We sacrificed rabbits at 4 weeks to study early capsule formation and to 
understand how it is possible to model wound healing formation
[145]
. The point is well 
taken for longer time periods and is currently planned for future experiments. However, 
long term differences in capsule structures under these experimental challenges do 
result from different wound healing trajectories from day 0. Our strategy was to 
examine these early differences with methods that were sensitive to detect histological 
or biomarker changes. There is no answer how long enough is necessary in a pre-
clinical model. In a clinical model the authors propose a follow-up period longer than 
42 months
[321]
 (Study 1; Publication II). However, it might be expected that the finding 
of a dense collagenous capsule would increase with time, reflecting a continued 
stimulus toward a fibroplasia and ultimately collagen remodelling
[335],[336],[337]
. 
The weakness of this study was the relatively small size and the lack of capsule 
immunohistochemestry detection of IL-8 and TNF-α in tissue specimens. Nevertheless, 
the release of IL-8 and TNF-α into the circulation represented a “spillage” of factors 
rather than a direct signal driving inflammation and leukocyte recruitment; the use of 
microdialysis was appropriate for determining tissue concentration of cytokines such us 
IL-8 and TNF-α. Because of the proximity of the sampling site to the source of the 
cytokine, microdialysis may provide a means of sensitively detecting relative changes 
of inflammatory mediators’ concentration with experimental treatments.  
Possible future studies would include: 1) silicone breast implants with ports (to 
measure the capsule pressure directly) impregnated with low molecular weight chitosan 
(LMWC) implanted per rabbit; detection of IL-8, TNF-α, TGF-β1 and  determination of 
fibrosis index; 2) With the same protocol analyze silicone breast implants with ports 
impregnated with low molecular weight chitosan (LMWC) and sprayed with 
Tissucol/Tisseel®
[315],[338]
 . In summary, a capsular contracture animal model was 
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observed when implants were impregnated with chitosan and not due to a bacterial 
infection. This report suggests a new approach of studying capsular contracture using a 
pre-clinical animal model.  
 
STUDY 5 
The capsule is composed by a layer of fibrous dense connective tissue
[339]
, and is 
an integrant part of the wound healing process. To understand the formation of this late 
complication, and the potential therapeutic roles of both pharmacological and non 
pharmacological approaches, it is crucial to know the physiological mechanisms that are 
behind this process. 
Wound healing has been divided into three distinct phases: inflammation, 
proliferation and maturation
[340]
. The first phase of wound healing, which courses 
immediately upon injury through day 4 to 6, is characterized firstly by hemostasis, an 
important event that serves as the initiating step for the healing process; and an 
inflammatory response.  The second phase of wound healing (proliferative phase) is 
characterized by epithelization, angiogenisis and provisional matrix formation, and 
courses from day 4 through 14, overlapping the phase 1 and 3. Fibroblasts and 
endothelial cells are the predominant cells proliferating during this phase. Maturation 
and remodeling (phase 3), occurring from day 8 through 1 year, is characterized by the 
deposition of collagen in an organized and well-mannered network
[145]
.  
As seen before, corticosteroids are known to have an important role on 
modelling wound healing, as they can stop the growth of granulation completely, the 
proliferation of fibroblasts, diminish the new outgrowths of endothelial buds from blood 
vessels and stop the maturation of the fibroblasts already present in connective 
tissue
[227]
.  Also when administered early
 
after injury, corticosteroid delay the 
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appearance
 
of inflammatory cells, fibroblasts, the deposition of ground
 
substance, 
collagen, regenerating capillaries, contraction
 
and epithelial migration
[228]
. As so, 
steroids can have an important role in CC formation, in both early and late phases of 
fibrous phase formation.  
The efficacy of triamcinolone on treating and preventing CC in women has been 
reported
[265], [266]
. However, this still represents an off-label practice and further studies 
are required to validate the efficacy of this approach. Both works have limitations: are 
non-randomised, with no control group, with a limited follow-up period
[265],[266]
 and 
none of them have, as an objective, to comprove which is the mechanism of action of 
this compound in capsular contracture formation. 
A comprehensive understanding on the effects of this compound on the 
mechanisms of capsular formation; a knowledge on the systemic side effects and 
potential adverse events are, in the authors opinion, crucial for the improvement of TA 
in clinical activity. 
This study arises as the first one analyzing the impact of TA in early capsule 
formation. The authors examined the effects of TA on pressure, histological, 
microbiological and immunological characteristics of capsules, in an animal model, in 
order to understand the role of this steroid in early capsule formation, and the possible 
role in the prevention of CC.   
In our study, TA was found to decrease capsular thickness both on macroscopic 
and microscopic examination, when compared to the Control group. These findings 
were also associated with decreased inflammation and angiogenesis, as it was expected 
as steroids are anti-inflammatory drugs, capable of delaying the appearance
 
of 
inflammatory cells and diminish the proliferation of endothelium from blood vessels
[227]
 
and regeneration of capillaries
[228]
. Although no significance was found in the 
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intracapsular pressure between groups, it was observed a tendency to lower pressures 
(and no capsule rupture during the pressure measurement) in the Triamcinolone group 
when compared to the Control group (Figure 14). Also both cytokine markers (IL-8 and 
TNF-α) were lower in the Triamcinolone group, even without statistic significance. No 
significant differences were observed in fusiform cells densities, connective tissue and 
organization of the collagen fibers. Taken together, these results suggest that washing 
the pocket intraoperatively with TA has a role on capsule formation, and might prevent 
CC.  
As Caffee et al.
[264]
, we were not able to observe a significant decreased capsular 
pressure in the group treated with triamcinolone in the time of implant placement. 
However in our study we go further and we analyzed not only the pressure, an 
unquestionable indicator of capsular contracture, but also other characteristics that are 
related with the formation of this pathology, as a continuous process. The breast capsule 
begins being formed after implant placement, however, in the clinical practice, the 
contracture is a late complication, and a follow-up as longer as 42 months (Study 1; 
Publication II)
[321]
, is required to the diagnostic of this entity. In preclinical models, 
there is no consensus on the timing for sacrifice and timing for representative stages for 
capsule formation.We were not able to observe significant differences on pressure 
between the groups, probably because we sacrificed animals too early to the complete 
development of this complication. However, we were able to observe the early 
alterations that are not characteristic of CC as thinner and more transparent capsules on 
macroscopic and microscopic evaluation, and decreased inflammation and angiogenesis. 
It might be expected and is reasonable to assume that a more dense collagenous capsule 
with increased thickness would be present with longer incubation times, reflecting a 
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continued stimulus toward a fibroplasia and ultimately collagen 
remodelling
[336],[335],[337]
.   
Caffee et al. reported in both preclinical
[264]
 and clinical
[265]
 studies that 
triamcinolone injected postoperatively was able to eliminate CC and prevent the 
recurrence of this condition.  Those findings are confirmed by Sconfienza et al.
[266]
, that 
was able to demonstrate that US-guided injection of triamcinolone acetonide in the peri-
implant pouch of women with augmented or reconstructed breast affected by Baker 
grade IV CC is effective in reducing capsular contraction. Both authors concluded that 
triamcinolone was effective in the late stages of capsule formation. With our study we 
were able to observe that triamcinolone is probably not only effective when injected 
postoperative, but it also as a role in the early phases of the development of capsular 
contracture. 
In a previous report (Study 3; Publication 4)
[338] 
using the same protocol, the 
authors were also able to find another compound, fibrin (Tissucol/Tisseel), that was 
associated with a lower incidence of CC when sprayed in the pocket/implant during 
surgery  and more effective in the early phases of wound healing than in later phases. It 
was found that fibrin
[338] 
, was able to decrease intracapsular pressures when compared 
to Control (p  0.001 - data not shown), and the capsular thickness were decreased (0.47 
± 0.129 mm) (p  0.001) as in Triamcinolone group. 
TNF-α plays an important role in the wound healing process: it is produced by 
activated macrophages, platelets, keratinocytes, and other tissues and it stimulates 
mesenchymal, epithelial, and endothelial cell growth and endothelial cell 
chemotaxis
[341],[342]
. During the inflammatory phase, it is one of the main responsible for 
neutrophils drawn into the injured area
[343]
, macrophages generation of NO
[344] 
and 
damaged extracellular matrix digestion by matrix metalloproteinase
[345]
. During the 
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second phase TNF-α upregulates KGF gene expression in fibroblasts, upregulate 
integrins, a matrix component that serves to anchor cells to the provisional matrix, 
stimulates epithelial proliferation
[341] 
and is also a potent promoter of angiogenesis. 
TNF-α is known to be a growth factor for normal human fibroblast, and promotes the 
synthesis of collagen and prostaglandin E2. IL-8, enhances neutrophil adherence, 
chemotaxis, and granule release; and enhances epithelization during wound 
healing
[341],[346]
.  TNF-α levels were reported to be markedly elevated in fibrotic diseases 
as liver fibrosis, and is considered a mediator of fibrosis such as TGF-β1[346]. Moritomo 
et al.
[332]
 concluded that TNF-α played a pivot role in the maintenance of hemostasis 
and tissue repair by inhibiting TGF-β1. We were not able to find significant differences 
in IL-8 and TNF-α levels, although decreased levels were observed in the group treated 
with triamcinolone, possibly reflecting a role of this drug in modulation of wound 
healing process and fibrotic response in the presence of the implant. More studies, with 
longer follow-up and increasing doses of the compound are needed to confirm this data.  
 On the other hand, a significant correlation was also found between IL-8 and 
TNF-α in both groups. This was not unexpected as correlations between IL-8 and TNF-
α with bacterial infections have been reported[329]. We did not find any differences in the 
microbiology cultures between groups but further studies are necessary to clarify if 
triamcinolone increases the risk of infection.  
With fibrin it was observed a significant decreased on TNF-α (140.9 ± 165.9 
mg/ml) and IL-8 (23.9 ± 43.4 mg/ml) levels (p = 0.003; p = 0.048) supporting the 
possible role of this compound in the early capsule formation and in the reduction of 
collagen extracellular matrix. No correlation between IL-8 and TNF- α was observed in 
the Fibrin group which suggests a possible antibacterial role of fibrin
[338]
. 
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The main limitations of this study are: 1) inappropriate dosage in this model 
system; rabbits have much faster basal metabolic rates than human, and as such, it is 
presumed that rabbits have shorter drug half-lives
[268]
; 2) unknown pharmacokinetics of 
triamcinolone in the capsule pocket and subsequent metabolism, although triamcinolone 
modelling may be based on systemic steroid modelling
[347]
; 3) short follow-up, as 
capsular contracture usually takes more than four weeks on developing; and 4) the use 
of one tissue expander per rabbit to directly measure internal expander pressures using 
the port. Silicone breast implants with ports with a 90 ml volume capacity would be 
optimal to achieve more accurate results but are not commercially available. In addition, 
the preclinical model would not support the use of multiple large expanders or implants 
over long time periods.  
Our data support future studies examining triamcinolone as a potential agent on 
preventing CC. 
Possible future studies may include: 1) pre-clinical study with silicone breast 
implants with ports (to measure the capsule pressure directly) with introduction of  1.5 
ml (60 mg) of triamcinolone-acetonide into each implant pocket and sacrifice the 
animals at a much longer time point with detection of IL-8, TNF-α, TGF-β1 and  
determination of fibrosis index; and  2) with the same protocol, assess the effects of  of 
saline or other vehicles of triamcinolone-acetonide on pressure/volume curves.  We 
believe that a pre-clinical study higher dose of triamcinolone-acetonide introduced into 
the implant pocket and a longer follow-up time period will support the growing body of 
evidence that triamcinolone-acetonide mitigates capsular contracture. 
In summary, our results suggest that triamcinolone has a role in early capsule 
formation, and it may have a role in the prophylactic management of this complication. 
Obviously, it role is centred on the management of the factors related to wound 
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healing
[124]
, and it is important to exclude a deleterious role in the factors related to 
infection that are also known to increase CC
[62],[64],[79],[21],[206]
. The clinical use of 
triamcinolone-acetonide may prove to be a reliable and safe intraoperative method to 
prevent capsular contracture in women undergoing breast implants. The ultimate goal is 
to translate these preclinical results to the clinic as these finding may help not only 
patients with breast implants, but to all patients with any device in which capsule 
contracture around that device may lead to an adverse clinical event. 
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6. Conclusions 
 
 The authors for the first time report no association between capsular contracture 
and menopause or estrogen status. (Study 1; Publication II) 
 Our data suggest that grade II subjects should be included in a capsule contracture 
analyses and a follow-up period longer than 42 months (3 years and 6 months) should 
be considered. (Study 1; Publication II) 
 The authors document a pre-clinical capsular contracture with thicker capsule, 
mixed or polymorph inflammatory cells, dense >25% connective tissue, haphazard 
collagen fibers or arrayed in sequence, moderate or high angiogenesis. (Studies 3 and 4; 
Publications IV and V ) 
 It is not appropriate to sacrifice the animals at 2 weeks. (Study 2; Publication III) 
 Bacteria from rabbit´s skin and operation air were similar to those from removed 
capsules, tissue expanders and breast implants, but, the fungi were just isolated in the air 
samples. (Studies 2, 3, 4 and 5; Publications III, IV, V and VI) 
 Interestingly, in the Fibrin (Tissucol/Tisseel®) group mixed type of inflammatory 
cells were correlated with decreased intracapsular pressures, however if infected by 
Staphylococcus the intracapsular pressures increased. Our results suggest the role of 
fibrin (Tissucol/Tisseel®) in preventing capsular contracture; and that the bacterial 
colonization of mammary implants may be partially responsible for capsule contracture, 
and coagulase-negative Staphylococci may play a large role. (Studies 2 and 3; 
Publications III and IV) 
 The role of Micrococcus spp.  in the pathogenesis of capsular contracture deserves 
further study. (Study 3; Publication IV) 
 Based on the Blood and the Thrombin (FloSeal®) groups results we may conclude 
122 
 
that an active hemostasis is indispensable to prevent capsular contracture, although 
unnecessary with a hemostatic commercial product. (Study 2; Publication III) 
 The fibrin (Tissucol/Tisseel®) benefits enhance wound healing reducing capsular 
contracture and the minor adverse events observed make this drug an attractive 
alternative for use in women undergoing breast implantation. (Studies 2 and 3; 
Publications III and IV) 
 A capsular contracture animal model related with chitosan and not due to an 
infection. (Study 4; Publication V) 
 The use of microdialysis is appropriate for determining the concentration of 
cytokines such us IL-8 and TNF-α and could provide a means of sensitively detecting 
relative changes of inflammatory mediators’ concentration with experimental 
treatments. (Study 4 and 5; Publication V and VI) 
 Our data support the theory that chitosan initiates capsular contracture response 
due to a toxic local effect that resulted in an impaired wound healing response. (Study 
4; Publication V) 
 Triamcinolone-acetonide during breast implantation influences the early capsule 
formation and may reduce capsular contracture. (Study 5; Publication VI) 
 Capsular contracture is multifactorial including any bias which promotes a 
subclinical toxic effect. (Studies 2, 3 and 4; Publications III, IV and V) 
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far) the Big Boss in Plastic Surgery! It wasn’t the interview that I had anticipated but 
instead an engaging and interesting conversation. During 1 hour, Professor José 
Amarante outlined all of the Plastic Surgery themes, the opportunities and challenges as 
well as the duties, hard work, academic expectations, his demands from a resident, and 
as a result, he removed all my fears. When I questioned him about the possibility of a 
foreign fellowship (it was the key of my decision), he answered: “You have to; at least 
six months!”. He made my day; he “decided” my professional life! Since that day, 
Professor José Amarante has held those same high standards! For me, he is a pushing 
mentor... pushing me up and more and more, all the time! I express my gratitude with 
all my heart!  Sometimes, it seems that our lives are in the form of a circle ... this day 
was reiterated. In 2002, I decided to travel for three months to do a microsurgery 
fellowship in Taiwan with Professor Fu-Chen Wei. Regarding the remaining 6 months, 
it would be hard to achieve because I wanted to experience both clinical research with 
basic science and facial aesthetic surgery. The Department of Plastic Surgery at 
University of Texas Southwestern Medical School at Dallas, Texas, USA has some of 
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the best Aesthetic Facial Surgeons and is famous for resident’s mentorship, scientific 
publications and has their own research lab - the Nancy L. & Perry Bass Advanced 
Wound Healing Laboratory. I forwarded my Curriculum Vitae and a letter to Research 
Professor Spencer Brown, and also a letter to Dr. Rod Rohrich. One week later, I was in 
the operating room, in the middle of 2 surgeries, and I received a phone call from 
Professor Spencer Brown, the Director of the Research Department of Plastic Surgery at 
UT Southwestern Medical School in Dallas! He was so friendly with such 
encouragement during this phone call (without knowing me at all!) which was, to me, 
unbelievable! Once again, I was so afraid to disappoint, but accepted and started my 
research projects with Professor Spencer Brown in 2003. His far-reaching vision, not 
only in science, but also in life, has been a true inspiration to me.  
            After returning from Dallas in 2004, Professor Amarante introduced me in the 
Faculty of Medicine, University of Oporto. I was and I´m so proud! Last year, 2010, in 
the Times Higher Education World University Ranking, the University of Oporto was 
classified in the 250
th
 position of the best university in the world and the 106
th
 in 
Europe. I completed my Plastic Surgery Residency in February 2005. The next day, 
Professor Amarante asked me to start a PhD thesis. I confess: I was exhausted! He 
introduced me to Professor Acácio Gonçalves Rodrigues, the Director of the 
Department of Microbiology. The microbiology study was crucial in this thesis. In the 
first meeting with Professor Acácio Gonçalves Rodrigues, among a multitude of 
students in the 3
rd
 Exhibition of Science, Education and Innovation of University of 
Oporto, he outlined this project and encouraged me strongly to go ahead! During this 
entire project, the Department of Microbiology and Professor Acácio Gonçalves 
Rodrigues provided faithful support. During our scientific discussions, he would 
suggest new fantastic ideas. I presented them to Professor Spencer Brown who has 
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taken ownership of these studies as a true mentor. He is indeed an extraordinary teacher, 
and his passion towards life and science are contagious. He is the most altruist person I 
have ever met, but he firmly expects that others do their best as he does himself.  
Without his guidance and continuous support, it would have never been possible to 
make a bridge between Oporto and Dallas, which was the most grateful thing that has 
happened to me! For our weekly meetings by phone, almost all my holidays working 
with him in Dallas (since 5 in the morning!), being received in his home as a family 
member, for meeting his wonderful wife Roxane and his daughter Keersten, for his 
brightness in science, for his sense of humor, for the economic support… my deepest 
gratitude and friendship! What such good memories I have of Dallas! It is now my 
second home, difficult to survive without being there twice a year! It was an honor and 
a privilege to learn not only about science from a great scientist, a master in 
grantsmanship for economically supporting his research and team, but also about life, 
family, sense of community and humanity! I am so blessed to be a part of such an 
amazing family! 
            I present my gratitude to: Master Pedro Rodrigues Pereira for his tremendous 
dedication and efficient work in the histological analysis of the samples; Professor João 
Fernandes from the Biotechnology School, due to the impregnation of the breast 
implants with chitooligosaccharide mixture and low molecular weight chitosan and his 
expertise on this issue, and for whom I am grateful for teaching me so much; and Dr. 
Luis Cobrado for his collaboration in the microbiology section.  
           I also present my gratitude to Professor Natália Cordeiro for her tremendous 
effort in the statistical analysis. Professor Natália has been my friend for 20 years, and is 
a professional at the highest level and dedication! However during this project, she was 
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operated on twice by neurosurgery. I will never forget that in the days following each 
surgery, she wanted to discuss the statistical results and was concerned not to delay my 
thesis! For the thousands of hours in her house (sometimes working all night), for her 
incredible perseverance, brilliant mind, knowledge dependency and friendship, I express 
my profound gratitude! Furthermore, I thank her for the friendship and care she offered 
to me, particularly when I most needed, despite of her numerous tasks! This project 
wouldn´t be the same without her. I also forward my thanks to Professor Aliuska 
Helguera-Morales who also performed the statistical analysis and assisted me a great 
deal and always reminded me of her mother land- Cuba! She has a precise and rational 
mind, a high capacity of organization and her simplicity and lovely heart was always 
available to help me and was an example of generosity!      
            I have a special gratitude to the veterinary surgeon, Fernando Carvalho, for his 
incredible dedication to this project. The New Zealand white rabbits are very sensitive. 
In study 2, he brought from his private clinic the anesthesia equipment. During the 
entire research program, he was available and changed his schedules all of the time in 
order to support this project. I would like to say thank you to the other members of the 
Department of Experimental Surgery for assisting me in the care of my rabbits: Maria 
José Neto; Pedro Leitão; Luis Bastos; and Maria José. The same gratitude goes to Nuno 
Rego, who raised these special rabbits… for an instance I was afraid that I would have 
to import them! To the Department of Microbiology, I would like to thank Anabela 
Silvestre, Isabel Santos, Cristina Moura and Elisabete Ricardo. Related with the 
implants devices and commercial products, I would like to thank them for their 
tremendous help: Tom Powell, Luis Sogalho, Pedro Lopes and Luis Lopes.  
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            At UT Southwestern Medical School at Dallas, my extreme gratitude to them for 
their support: Dr. Rod Rohrich and Dr. Jeffrey Kenkel for the strong encouragement 
during all these years. To Dr. William Adams, for the knowledge about this issue and 
giving me the privilege of being a part of his team. To Dr. Jeffrey Kenkel, Dr. Michel 
Saint-Cyr and Dr. James Richardson for their scientific experience, guidance and 
revision of the papers. To Jiying Huang, Debby Noble, Donna Henderson for their 
excellent assistance. 
            To the medical students who helped me in organizing much of this work: Lara 
Queirós (current specialist in Ophthalmology), Rui Freitas (current resident in Urology), 
André Santos Luís (current specialist in Stomatology), Mário Mendanha (current 
resident in Plastic Surgery), and Nuno Lima (current specialist in General and Family 
Medicine). 
            To the Plastic Surgery team I work with, for the encouragement and professional 
help, with a special gratitude to my friend and current Director, Dr. Álvaro Silva and 
my resident, Dr.ª Inês Correia Sá. 
            To my special friends and my godson Miguel for their emotional support, strong 
encouragement and for understanding my absence time. I have the best friends in the 
world!!!  
            I´m extremely grateful to my family: my mother for her kindness and freedom 
love and to my father for his rationality and strong behavior, during my entire life; my 
two brothers for the strong friendship and care between us; to my sisters-in-law, my 
niece and goddaughter Inês, and my nephew Diogo that brought more happiness to my 
family. 
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Finally, I would like to thank Maria de Lurdes for taking care of my son as he 
belongs to her! She took care of my home and gave to Gustavo such love and peace, 
and worked with him the rules he needs to grow up with respect and self confidence! 
Moreover, she was available at any time of the day or night to come to my home to help 
me! There is not enough money to pay for that! This serenity allowed me to work hard, 
especially when it was outside of my home! 
Last, but most important: my lovely son Gustavo. I am sorry when I was 
working at night, or during the week-ends, or I was in Dallas, or I was so exhausted! I 
know that he is only 3 years old and that it is impossible to explain to him so many 
things, but so far I have concealed the worries and he has translated that in a funny 
smile to my eyes! What a miracle power he has over me! There are no words in any 
language to explain this huge feeling full of love and responsibility… in his little hand 
he handles my heart!  I have grown up listening to my parents saying that the best and 
most difficult thesis in one’s life is the education of their sons, and, at least, they had to 
be a step above the parents! They did an excellent job! This thesis is dedicated to 
Gustavo! I had to work hard in all senses to give to him the best opportunities and be an 
example! I will do my best… just his future will give me the big answer. 
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Background: Capsular contracture remains one of the most common compli-
cations involving aesthetic and reconstructive breast surgery; however, its cause,
prevention, and treatment remain to be fully elucidated. Presently, there is no
accurate and reproducible pathologic in vitro or in vivo model examining
capsular contracture. The purpose of this study was to establish an effective
pathologic capsular contracture animal model that mimics the formation of
capsular contracture response in humans.
Methods: New Zealand White rabbits (n  32) were subdivided into experi-
mental (n  16) and control groups (n  16). Each subgroup underwent
placement of smooth saline mini implants (30 cc) beneath the panniculus
carnosus in the dorsal region of the back. In addition, the experimental group
underwent instillation of fibrin glue into the implant pocket as a capsular
contracture–inducing agent. Rabbits were euthanized from 2 to 8 weeks after
the procedure. Before the animals were euthanized, each implant was serially
inflated with saline and a pressure-volume curve was developed using a Stryker
device to assess the degree of contracture. Representative capsule samples were
collected and histologically examined. Normal and contracted human capsular
tissue samples were also collected from patients undergoing breast implant
revision and replacement procedures. Tissue samples were assessed histologi-
cally.
Results: Pressure-volume curves demonstrated a statistically significantly in-
creased intracapsular pressure in the experimental group compared with the
control group. The experimental subgroup had thicker, less transparent cap-
sules than the control group. Histologic evaluation of the rabbit capsule was
similar to that of the human capsule for the control and experimental sub-
groups.
Conclusions: The authors conclude that pathologic capsular contracture can be
reliably induced in the rabbit. This animal model provides the framework for
future investigations testing the effects of various systemic or local agents on
reduction of capsular contracture. (Plast. Reconstr. Surg. 117: 1214, 2006.)
Breast implant capsular contracture remainsone of the most common complicationsfor both aesthetic and reconstructive
breast surgery. Despite the importance of this
problem, the cause and treatment have re-
mained unresolved for the past 40 years. Further
complicating this problem is that there are cur-
rently no reliable in vitro or in vivo models pro-
ducing capsular contracture. Various animal
models have been reported in previous studies;
however, most lack the ability to produce the
pathologic state of contracture and, thus, corre-
lation of proposed treatments for clinical capsu-
lar contracture are invalid in this setting.
Histologically, the human breast capsular
tissue is composed of an inner layer of fibro-
cytes and histiocytes, which is surrounded by a
thicker layer of collagen bundles arranged in a
parallel array.1,2 The outer layer is more vascu-
lar and is composed of loose connective tissue.
Although intuitively and clinically most would
consider the degree of capsule thickness to be
commensurate with the severity of capsular
contracture, this has never been definitively
proven, and some reports have found no cor-
relation among contamination, thickness, and
clinical contracture.3
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The literature is replete with earlier studies
that attempted to detect differences in capsule
characteristics between those formed around
smooth versus textured implants. Both gross an-
dhistologic sections revealed a thicker capsule,
with increased cellularity surrounding the tex-
tured implants4,5; however, other reports have
produced contradictory results.6,7 Equally per-
plexing is the incongruity between studies with
animal models compared with human clinical
studies.4,5,8 Current data have yet to determine
the exact cause for contracture and thus no
completely effective prophylaxis or therapy has
been developed.5–9 Compounding the problem
is the use of various animal models for analysis of
capsular contracture when the animals them-
selves do not produce a pathologic capsular
state.6,10,11
Furthermore, a large body of conflicting data
exist on the mechanisms and various cell types
involved with the formation of the host capsular
contracture tissue response. As with any condi-
tion where the cause is unknown, there exists a
multitude of treatment modalities offered based
on anecdotal or clinically based experience. The
bulk of the literature on this subject is retrospec-
tive, unblinded, uncontrolled, and rarely uses
elegant scientific methodology.
The purpose of this study was to develop a
pathologic, reproducible, and reliable animal
model for capsular contracture that is similar to
human breast capsular contracture tissue. This
information can be used to help systematically
determine the cause of this problem and to allow
options for prevention and potential treatment
of capsular contracture.
MATERIALS AND METHODS
Thirty-two New Zealand White rabbits under-
went implantation with customized smooth saline
mini implants (30 cc; McGhanMedical, Santa Bar-
bara, Calif.) under an approved institutional an-
imal care protocol. Each implant was placed in the
subpanniculus carnosus plane in the dorsal back
region and filled to the manufacturer’s recom-
mended 30-cc fill volume. One implant was placed
per rabbit, using sterile surgical technique.
The rabbits were divided into an experimental
(n  16) and control subgroups (n  16). The
experimental subgroup also underwent instilla-
tion of 5 cc of fibrin glue [fibrin glue is prepared
with 4 ml of rabbit cryo (Pel-Freez; Pel-Freez Bio-
logicals, Rogers, Ark.), 500l of 10%CaCl (Sigma-
Tau Pharmaceuticals, Gaithersburg, Md.), 1000
units of thrombin (Monarch Pharmaceuticals,
Bristol, Tenn.) in 1 ml of 50 mM TrisCl (Sigma),
pH 7.4] into the implant pocket as a contracture-
inducing agent. The incision was closed in two
layers with subdermal 4-0 Vicryl (Ethicon, Inc.,
Somerville, N.J.) and 4-0 interrupted nylon suture.
Rabbits were killed at 2 or 8 weeks. Before the
animals were killed, each animal was anesthetized
and the dorsal back area was shaved. A small in-
cision was made directly over the implant fill valve
through skin, panniculus carnosus, and capsule.
The incision traversing the capsule was sufficiently
small (3 mm) to not impede the accurate as-
sessment of intracapsular pressure. The Stryker
device was connected to the valve and opening
intracapsular pressure was recorded (Fig. 1). Sub-
sequent pressures at 2-cc increments were re-
corded after equilibration as the implants were
overfilled. Representative capsule samples were
Fig. 1. (Above) Stryker pressure monitor setup next to the im-
planted mini implant. (Below) Stryker pressure monitor con-
nected to the mini implant through a small capsular window.
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submitted in formalin for histologic evaluation for
tissue architecture and capsular thickness.
Human breast capsular tissue samples from
clinically normal breasts (implantation time, 6
months) and pathologically contracted capsule
(Baker III/IV; implantation time, 5 to 6 months)
were collected and processed using standard he-
matoxylin and eosin staining. The histologic sec-
tions were reviewed by a blinded pathologist and
themorphologic characteristics of the human cap-
sule samples were characterized.
Statistics comparing the intracapsular pres-
sures were performed using the two-tailed t test
demonstrating a significant difference between
the experimental and control groups. Statistical
significance is defined as p  0.05.
RESULTS
The pressure-volume curve was generated at 2
and 8 weeks (Fig. 2). There was no significant
difference between the experimental and control
groups at 2 weeks; however, at 8 weeks there was
a significant increase in intracapsular pressure in
the experimental group. On gross examination of
the capsules, the control group capsule appeared
more transparent and had less vessel predomi-
nance on the capsular surface (Fig. 3, above). The
experimental group (Fig. 3, below) had a more
opacified capsule and in many cases appeared
thicker. The average capsular thickness (histolog-
ically measured) was 0.6 mm in the rabbit control
group, 1.0 mm in the rabbit experimental group
and in human capsules, and 2.5 mm in human
capsule contractures. There was a non–statistically
significant increase in capsular thickness in the
experimental group.
Histology
Hematoxylin and eosin sections of rabbit con-
trol capsules at 8 weeks, rabbit contractures at 8
weeks, human capsules, and human contractures
were compared. Synovial-like reaction of fibrohis-
tiocytic cells (synovial metaplasia) was most pro-
nounced in the rabbit control capsule at 8 weeks,
focal in the rabbit contracture at 8 weeks, and
absent in the human contractures and control
capsules (which is not unexpected, as synovial
metaplasia is reported to be present in only 50
percent of cases).12
Inflammation (consisting of lymphocytes, his-
tiocytes, and eosinophils) was moderate in the
8-week rabbit control capsule and mild in the
8-week rabbit contracture. The human capsule
demonstratedminimal inflammation, whereas the
human contracture showed mild inflammation.
The degree of fibrosis was greater in the 8-week
rabbit contracture and human contracture (Fig.
4) than in their counterparts (the 8-week rabbit
control and human capsules, respectively).
DISCUSSION
Capsular contracture is the most common
complication involving aesthetic and reconstruc-
tive breast surgery, with a reported incidence rang-
Fig. 2. The pressure-volume curve at 8 weeks; there was a significant in-
crease in intracapsular pressure in the experimental group.
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ing from 0.6 to 50 percent.13,14 An incidence of 8
to 15 percent15–17 may be cited as a more scientific
appraisal. Clinically, capsular contracture mani-
fests on a continuum with varying degrees of se-
verity, and is typically measured subjectively by
means of the Baker classification. Furthermore,
contracture may become clinically evident from
weeks to years after implantation.
Capsular contracture is the formation of fi-
brous scar tissue investing a foreign body or sur-
gically implanted device. Artificial joints or heart
valves, central venous catheter ports, breast im-
plants, and a multitude of additional surgical de-
vices have been involved in the development of
capsule formation and its adverse consequences.
Capsule formation presumably plays a vital role in
the host’s response to a foreign body. Neverthe-
less, the results of this process may pose potential
serious health risks or adverse aesthetic sequelae.
The true cause of capsular contracture re-
mains elusive.18 Two prevailing theories have
emerged: the infectious hypothesis and the hypertro-
phic scar hypothesis. The infectious hypothesis,
which has been championed by Burkhardt and
supported by others,19–23 implicates subclinical in-
fection in the development of capsular contrac-
ture. Staphylococcus epidermidis, which is the most
common organism isolated from nipple secre-
tions, is the most common organism cultured
from capsules excised during open capsulotomies.
Furthermore, acceleration of capsule formation
around silicone implants by addition of Staphylo-
coccus aureus as an independent variable has been
reported.24
The hypertrophic scar hypothesis attempts to
implicate noninfectious stimuli, namely, hemato-
Fig. 3. (Above) Rabbit capsule at 8weeks (control; the capsule is
transparent and has less vessel predominance on the capsular
surface). (Below) Rabbit capsule at 8 weeks (with fibrin glue); the
capsule is more opacified and thicker.
Fig. 4. (Above) Experimental group rabbit contracture at 8
weeks (original magnification, 40) showing areas of more
dense fibrous deposition in the mildly cellular mid zone; fibro-
blasts are widely separated by spindled fibroblasts. (Below) Hu-
man capsule contracture (original magnification,40) showing
hypocellularfibrousmidzone;centralareashowsdensecollagen
without any fibroblasts; fibroblasts at periphery are widely sep-
arated by thick, dense bands of collagen fibers.
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mas, granulomas, or hereditary factors, which con-
fer a foreign body reaction and resultant forma-
tion of a hypertrophic scar around an implanted
device. The underlying mechanism behind this
process involves the activation of the myofibro-
blast cells within the capsule, which supposed con-
tractile elements exert the force necessary to pro-
duce capsular contracture.Myofibroblasts contain
the contractile elements actin and myosin and
have been identified inconsistently within the cap-
sules of implanted devices; however, they have
proven difficult to culture and study in detail and,
when found in the capsule, are found in exceed-
ingly small quantities, are located sporadically
throughout the capsule, and are not found to
attach to each other. This scenario poses an in-
consistent model for the development of contrac-
tile forces necessary to produce contracture.
The purpose of this study was to consider a
novel pathologic animal model for capsular con-
tracture. The fibrin glue inducing agent was dis-
covered serendipitously in our laboratory; how-
ever, this places ample amounts of fibrinogen
around the implant, and the critical role of fibrin-
ogen in capsule formation has been scientifically
established independent of our work.25 This agent
merely reliably produces conditions that are likely
to result in a contracted capsule.
Many different animal models for contracture
studies have been reported6,8,10,19,24–28; however,
the majority consider the effect of a given therapy
on normal capsule formation.6,10,11,19,29,30 This min-
imizes and likely invalidates the significance/con-
clusions of many of these previous studies, as ther-
apy needs to be directed at a pathologic capsule.
Other reports have used bacteria to stimulate the
formation of pathologic capsules; however, the
reproducibility and control of this model have not
been validated.19 It is our opinion that the cause
of contracture is multifactorial. In humans, there
exist capsular contracture–inciting agents that, for
known or unknown reasons, result in a contrac-
ture (i.e., hematoma, infection). The fibrin glue
inducing agent is no different. This agent simply
facilitates conditions that already are known to
produce capsule formation in a predictable fash-
ion.
Furthermore, the correlation between animal
contracture and that of humans has not been sub-
stantiated. In fact, several studies using the rabbit
model have found contradictory results from our
clinical observation in humans.7,8 Most of these
studies have reportedmore pathologic capsules in
rabbits using textured implants,4,5 when it is gen-
erally accepted that textured implants produce
less contracture in humans. The reason for this is
largely unknown; however, the use of a nonpatho-
logic animal model is likely a major issue.
The histologic findings demonstrate a similar
increase in fibrosis in rabbit and human con-
tracted capsule compared with respective con-
trols. The differences in synovial metaplasia in the
specimens constitute a histologic detail that car-
ries no clinicopathologic significance; however,
they were reported for the sake of completeness.
The end result is that the histologic analysis of the
rabbit contracture model is similar to human con-
tracture.
We report for the first time, to the best of our
knowledge, a breast capsular contracture animal
model that mimics the histologic characteristics of
human breast capsular tissue. The degree of in-
flammation and fibrosis over time in the rabbit
contracture appears to correlate with those of the
human contracture, suggesting that the rabbit
capsule may be an optimal animal model for the
changes seen in human contractures. Despite
these findings, we acknowledge that the ultimate
model for the study of capsular contracture is the
human model, and all animal models, including
this one, will need to ultimately reconcile this fact.
CONCLUSIONS
Our model does produce pathologic and non-
pathologic capsules histologically similar to the
human pathologic and nonpathologic capsule. In-
terestingly, our contracture-inducing agent (fi-
brin) has been implicated as a key player in the
formation of capsule formation in prior studies.28
Plastic surgeons have endured 40 years of darkness
in their true understanding of capsular contrac-
ture. We hope this model may not only provide a
platform for future investigation but allow us all to
see the “light” and provide insight into the true
cause of breast implant capsular contracture.
William P. Adams, Jr., M.D.
University of Texas Southwestern Medical Center at
Dallas
Southwestern Medical School
Department of Plastic Surgery
5323 Harry Hines Boulevard
Dallas, Texas 75390-9132
william.adams@utsouthwestern.edu
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DISCUSSION
A Rabbit Model for Capsular Contracture: Development and
Clinical Implications
Boyd R. Burkhardt, M.D.
Tucson, Ariz.
I have admired the work that Dr. Adams and histeam have published previously, and compli-
ment them once again on their carefully con-
trolled methodology and their nicely presented
results. Well-meaning colleagues often have con-
structive disagreements, however, and I do have
some with Dr. Adams. Readers will have to de-
cide.
An accurate, reliable, and reproducible ani-
mal model for capsular contracture is indeed
needed. The authors do report an apparently
reliable and reproducible method for producing
measurable contracture around saline mini im-
plants in rabbits. Whether the model is accurate
is discussed below. The experiment included a
control group, the measurement of contracture
was objective and reproducible, and the histol-
ogy of the capsules was consistent with capsules
from around implants in humans. It is good
work, and the authors should be congratulated.
I do not believe, however, that this is an accu-
rate model of the contracture process that oc-
curs around breast implants in humans. For this
reason, I question the usefulness of this and
other similar animal research models in advanc-
ing our understanding and (it is hoped) prevent-
ing human contracture. This is a fundamental
dissent, and requires further explanation.
The authors note correctly that capsule forma-
tion is a normal physiologic response and that
our focus should be on capsular contracture
rather than on the capsule formation itself, a
distinction that has sometimes been ignored in
our literature and deserves emphasis. Although
acknowledging infection as one probable cause,
however, they believe the cause of contracture is
“multifactorial,” to include hematoma, granu-
loma, foreign body reaction, and hereditary fac-
tors, any one of which may theoretically stimu-
late an internal hypertrophic scar response that
then becomes a contracted capsule. This as-
sumption is central to the potential usefulness of
their rabbit model: if contracture is just the final
common pathway for expression of a whole mar-
ket basket of presumed nonbacterial causes, us-
ing fibrin glue to produce contracture in rabbits
and then developing treatments that modify this
tissue response is a rational approach. If the
presumed cause is limited to infection or bacte-
rial contamination, however (and I confess some
personal bias here), I do not believe that work-
ing with glue-induced contracture in rabbits will
lead to remedies that are transferable to hu-
mans. If we examine published evidence, the
burden of proof falls clearly on those who as-
sume that the cause is multifactorial and there-
fore reasonably duplicated by this rabbit re-
sponse to fibrin glue.
Evidence for a bacterial etiology for human
contracture is abundant. Bacteria (mainly Staph-
ylococcus epidermidis) have been cultured from 671
to 95 percent2 of contractures, 97 percent of
human breast milk samples,3 50 percent of intra-
operative cultures of retromammary implant
pockets,4 and 50 percent of cultures of biopsy
specimens from uninfected breasts.5 Peripros-
thetic lactoceles, demonstrating a clear connec-
tion between the periprosthetic space and the
ductal system of the breast, are well documented
in our literature.6,7 To this I would add a per-
sonal observation that contractures in my own
practice often occur long after the initial sur-
gery, following pregnancy and lactation. Bacte-
rial contamination of mini inflatable implants
with S. epidermidis causes contracture in rabbits
that is reduced by intraluminal antibiotics.8,9
What is the evidence for other causes? An
“inherent” or genetic tendency is clearly incon-
sistent with a preponderance of unilateral con-
tracture (do the right and left breasts really have
different genes or different tissue responses?).
Although previous authors have implicated inad-
equate initial dissection,10 foreign body
reaction,11 hematoma,12 and the myofibroblast,13
the relevance of these studies, using the advan-
tage of today’s knowledge, is quite thin.
If we are in fact dealing with a tissue response
to a securely buried, contaminated foreign body,
we must be especially cautious about attempts to
modify that tissue response. Intraluminal
steroids14 were a notable disaster that few of us
veterans would care to revisit. I do not pretend to
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have the answer, but I believe that if a rabbit
model must be used for research, a more appro-
priate model is that reported by Shah et al.,8,9
who used bacterial contamination to produce
contracture. I do question whether such studies
as the one at hand can lead to progress in the
prevention of human contracture, which I be-
lieve is the result of contamination from a
uniquely human environment of open, epitheli-
um-lined, bacteria-filled breast ducts that simply
cannot (as yet) be duplicated on the backs of
rabbits.
Boyd R. Burkhardt, M.D.
4445 East Saranac Drive
Tucson, Ariz. 85718
bob@themanitou.com
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Long-Term Follow-Up of Breast Capsule
Contracture Rates in Cosmetic and
Reconstructive Cases
Marisa Marques, M.D.
Spencer A. Brown, Ph.D.
Isabel Oliveira, M.D.
M. Nata´lia D. S. Cordeiro,
Ph.D.
Aliuska Morales-Helguera,
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Aca´cio Rodrigues, M.D.,
Ph.D.
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Porto, Portugal; and Dallas, Texas
Background: Silicone gel breast implants are associated with long-term adverse
events, including capsular contracture, with reported incidence rates as high as
50 percent. However, it is not clear how long the follow-up period should be and
whether there is any association with estrogen ormenopausal status. In addition,
the placement of Baker grade II subjects in the majority of reports has been in
data sets of controls instead of capsular contracture.
Methods: A retrospective medical study (1998 to 2004) was performed in
women (n  157) who received textured silicone breast implants for aesthetic
or reconstructive procedures at the Hospital of S. Joa˜o (Portugal). Medical data
were collected that included the following: patient demographics, history, life-
style factors, surgical procedures, and postoperative complications. Statistical
analyses included Pearson chi-square testing, logistic regression modeling, and
chi-squared automatic interaction detection (CHAID) methods.
Results: The reconstructive cohort had a great incidence of capsular contrac-
ture compared with the cosmetic cohort. If one considered no capsular con-
tracture versus capsular contracture, the follow-up period should be longer than
42 months. However, if considering no capsular contracture and grade II sub-
jects versus grade III or IV subjects, a longer follow-up period of 64 months was
determined. There was no association between capsular contracture and meno-
pause/estrogen status.
Conclusions: Increased frequencies of capsular contracture were recorded in
breast reconstruction that were not attributable to estrogen or menopausal
status. On the basis of these results, the authors propose a follow-up period
longer than 42 months and the inclusion of Baker grade II subjects. (Plast.
Reconstr. Surg. 126: 769, 2010.)
Silicone gel breast implants for cosmetic aug-mentation and breast reconstruction havebeen implanted worldwide since 1962.1 Multi-
ple investigations have to date been alert for the po-
tential adverse health effects of silicone breast
implants.2–12 Additional reports have focused on post-
operative local complications and patient safety issues
in women receiving silicone breast implants.13–20
Capsular contracture is themost common and
severe complication associated with silicone breast
implants,13–20 despite innovations in shell surface
textures, implant shapes, inner gel composition,
surgical implantation techniques, and pocket
irrigation.21–41 In cosmetic and reconstructive
breast surgery reports, the incidence of capsular
contracture ranged widely from 0 to 50 percent of
implantations.13–20,24,33,42–46
The Baker classification system defines stages
of breast capsule clinical presentation into distinct
grades.46 Grade II is the first stage of capsular
contracture, and clinical interpretation of grade II
may be highly dependent on individual surgeons’
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opinions. Although the clinical impact of grade II
is relevant to the continuum of breast capsule
formation, nevertheless, the majority of retrospec-
tive and prospective reports do not include grade
II subjects as breast capsule cases.47–50 The exclu-
sion of grade II subjects in these reports may result
in underreporting of capsular contracture rates.
In this study, we report the occurrence and
severity of postoperative complications in a cohort
of Portuguese women who received silicone tex-
tured breast implants between 1998 and 2004.
Also, factors that might contribute to the devel-
opment of capsular contracture rates (including
grade II subjects) were considered along temporal
trends with estrogens and menopausal status.
PATIENTS AND METHODS
Subjects and Data Collection
The study was approved by the Portuguese
Institutional Review Board for Human Subjects.
Existing medical records of women who had un-
dergone breast implantation with customized tex-
tured silicone breast implants (McGhan Medical,
Santa Barbara, Calif.) between 1998 and 2004 in
the Hospital of S. Joa˜o (Porto, Portugal) were
examined. A total of 224 women were identified,
with 104 women who had undergone cosmetic
breast augmentation (cosmetic cohort) and 120
women who had undergone postmastectomy re-
construction of the breast (reconstructive cohort).
From medical records, the following data were
collected: patient demographics, alcohol and med-
ication use, medical history, surgical procedures, in-
cision location, implant device placement,51 and
postoperative acute complications (hematoma, in-
fection, or seroma). Postoperative chronic complica-
tion (capsular contracture, folds, wrinkles, breast
pain, and change of tactile sense) data were not
gathered from medical records. Self-reported com-
plications related to satisfaction with implantation
surgery were collected using a self-administered
questionnaire. Women who answered the question-
naire were asked to attend a consultation to be fur-
ther evaluated by the two trained plastic surgeons to
decrease subjectivity of this evaluation. The degree
of late capsular contracture was assigned by the plas-
tic surgeons according to the Baker classification.46
Women from the initial cohort (157 of 224)
completed the self-questionnaire and attended the
consultation. The remaining 67 were then excluded
(n  35 women, cosmetic cohort; n  32, recon-
structive cohort) to remove any potential bias that
might result from patients with incomplete data.
Womenwere excludedbecause of the loss of contact
as they moved out of Porto or because no current
mailing address or phone numbers were available at
the time of the study. The reconstructive cohort was
composed of 88 patients with 115 breast implants
and with 27 patients having received bilateral breast
implants. The cosmetic cohort had 69 patients with
136 breast implants: 62 patients with 124 breast im-
plants, two of whomhad a tuberous breast deformity
and unilateral aplasia; and seven patients with 12
breast implants, with one woman having Poland syn-
drome. All cosmetic patients younger than 18 years
old (n 4) had received implants followingmedical
indication, namely, severe asymmetry, aplasia of
breast tissue, or congenital malformation.
Statistical Analysis
Postoperative local complications were ana-
lyzed independently for the entire study cohort
and individual clinical treatment cohorts and re-
ported per woman and per implantation opera-
tion (SPSS, Inc., Chicago, Ill.). Possible associa-
tions among recorded data sets of patient
characteristics, surgical procedures, and compli-
cations were evaluated using Pearson chi-square
testing and logistic regression modeling.52 Trend
analysis was performed using the chi-squared au-
tomatic interaction detection (CHAID) method
(SPSS),53 using the likelihood ratio chi-square sta-
tistic as growing criteria, along with the Bonfer-
roni 0.05 adjustment of probabilities, and setting
theminimum size for parent and child nodes at 10
and 5, respectively. Relative risks and 95 percent
confidence intervals were calculated for identified
characteristics of interest to examine strength and
precision of statistical associations.
CHAID has not been widely applied to trend
analyses in plastic surgery investigations, but
CHAID is one of the oldest tree-classification
methods originally proposed by Biggs et al.53 In
brief, CHAID is an exploratory method to exam-
ine relationships between a dependent variable
(e.g., capsular contracture) and a series of pre-
dictor variables (e.g., type of cohort, age at sur-
gery, follow-up period) and their interactions. The
CHAID algorithm created adjustment cells by
splitting a data set progressively by means of a
classification tree structure where the most im-
portant predictor variables were chosen to maxi-
mize a chi-square criterion. The most significant
predictors defined the first split or the first branch-
ing of the tree. Progressive splits from the initial
variables resulted in smaller and smaller branches.
The result at the end of the tree-building process
is a series of groups that were different from one
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another on the dependent variable. Classification
trees lend themselves to be displayed graphically
and are far easier to interpret than numerical
interpretation from tables.
RESULTS
Baseline descriptive data for the cosmetic and
reconstructive patient cohorts are listed in Tables
1 and 2, respectively. Cosmetic patients were
younger at the time of surgery compared with
reconstructive patients (31.0 versus 48.6 years).
The average follow-up period was 35.4 months in
the cosmetic group compared with 48.5 months
in the reconstructive group. Contraceptive use was
reported by 56.5 percent of cosmetic patients,
whereas only 3.4 percent of reconstructive pa-
tients reported contraceptive use or hormone re-
placement therapy. Cosmetic patients also re-
ported decreased use of psychotropic drugs (e.g.,
antidepressants, antianxiety, and hypnotics drugs)
compared with reconstructive patients (23.2 per-
cent versus 52.3 percent, respectively). One
woman from each cohort (n 2) had a connective
tissue disease (rheumatoid arthritis).
Among women in the cosmetic cohort, the
majority of silicone gel implants were placed sub-
glandularly (84.1 percent), and the surgical ap-
proach was through the inframammary fold (59.4
percent). The majority of reconstructive patients
had not received radiotherapy (85.2 percent) or
tamoxifen (67.1 percent); chemotherapy was ad-
ministered in 51.1 percent; the reconstructed
breast was the left side in 52.3 percent of the
patients, and 68.2 percent submitted to breast size
symmetrization.
Acute Clinical Adverse Events
Acute complications were recorded in 20 recon-
structive patients (8 percent) during the follow-up
period, with complications recorded as seroma
(8.0 percent), hematoma (4.5 percent), and perfo-
ration of the skin (3.2 percent) (data not shown).
Chronic Clinical Adverse Events
Chronic complication events were recorded
and are listed in Table 3. Overall, 81 percent (n
127) of all women had one or more postoperative
chronic events, ranging from less severe effects
(e.g., change in tactile sense) to complications
requiring additional surgical interventions, such
as severe capsular contracture. The distribution of
chronic complication frequency among women
was as follows: 23 percent of the patients had one
complication; 31 percent of the patients had two
complications; and 27 percent of the patients had
three or more complications. From a temporal
view of the clinical onset of chronic complications,
3 percent of the patients were diagnosed from 0 to
12 months postoperatively; 31 percent of the pa-
tients were diagnosed from 13 to 24 months; and
72 percent of the patients were diagnosed from 24
to 60 months.
The most frequent chronic adverse effect was
palpable implant folds (47.8 percent of all cases),
occurring in 42.0 percent of women from the cos-
metic cohort and in 69.3 percent from the recon-
structive cohort. Change of tactile sense also had
a high incidence (41.0 percent of all cases), with
89.8 percent in the reconstructive cohort report-
ing changes. Capsular contracture was the second
most common chronic complication, occurring in
Table 1. Baseline Characteristics for the
Cosmetic Cohort
Variable No. %
No. of women with implants
(no. of breast implants) 69 (136)
Age at surgery, years
Mean 31.0
Range 1551
Follow-up period, months
Mean 35.4
Range 1280
Implant placement
Subpectoral 9 13.0
Subglandular 58 84.1
Dual-plane Tebbetts 2 2.9
Incision placement
Inferior periareolar 7 10.1
Axillary 21 30.4
Inframammary 41 59.4
Contraceptive drugs
No 30 43.5
Yes 39 56.5
Table 2. Baseline Characteristics for the
Reconstructive Cohort
Variable No. %
No. of women with implants
(no. of breast implants) 88 (115)
Age at surgery, years
Mean 48.6
Range 2573
Follow-up period, months
Mean 48.5
Range 1296
Symmetrizing breast
No 28 31.8
Breast implant
(with or without mastopexy) 22 25
Breast reduction 33 37.5
Bilateral breast reconstruction 5 5.7
Hormone therapy*
No 85 96.6
Yes 3 3.4
*Including contraceptive drugs or hormone replacement therapy.
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34.4 percent of all women and in 23.1 percent of
all implantations. Capsular contracture incidence
rates were significantly different between the cos-
metic cohort (17.4 percent of women or 11.0 per-
cent of implantations) and the reconstructive co-
hort (47.7 percent of women or 37.4 percent of
implantations; p  0.05). Other chronic compli-
cations occurred less frequently (10 percent of
all patients).
Furthermore, the occurrence of postoperative
complications had a marked influence on satis-
faction index; for example, women without con-
tracture were 1.6 times more likely to consider the
outcome either good or very good compared with
women with capsular contracture (relative risk,
1.6; 95 percent confidence interval, 1.2 to 2.2).
Capsular Contracture Characteristics
Baker capsular contracture grades for the cos-
metic and reconstructive cohorts are listed in Table
4. As a percentage of patients, the reconstructive
cohort had 7.4- and 3.2-fold greater incidences of
Baker grade III and IV capsular contractures com-
pared with the cosmetic cohort. When examined as
a function of clinical time when Baker grades were
assigned, 44 women (76 percent) of the 58 total
patientswerediagnosedafter 2 years after surgery. In
detail, five women (7 percent) from the cosmetic
cohort and 28 women (32 percent) from the recon-
structive cohort developed capsular contracture
grade III/IV after the initial 2 years after implanta-
tion. Overall, the rate of grade III/IV capsular con-
tracture per woman during the 8-year period of fol-
low-up was 10.1 percent for patients undergoing
aesthetic surgery and 37.5 percent for breast recon-
struction patients.
The occurrence of capsular contracture was
associated with the duration of follow-up and age
at the time of surgery (Table 5). Women with a
follow-up period longer than 42 months (relative
risk, 1.8; 95 percent confidence interval, 1.3 to 2.4)
or older women (relative risk, 3.6; 95 percent con-
fidence interval, 1.6 to 7.9 for age 54 years or older
versus younger than 54 years) had increased in-
cidences of capsular contracture (p  0.001 for
both comparisons). Moreover, increased capsular
contracture occurred in the reconstruction group
of patients compared with the cosmetic cohort.
(relative risk, 1.7; 95 percent confidence interval,
1.4 to 2.3; p  0.001). No associations between
capsular contracture cases and surgical proce-
dures or other personal characteristics were
observed.
Using the CHAID decision tree (Fig. 1), the
type of cohort was identified as the determining
Table 3. Chronic Complications for Both Cohorts
Cosmetic
Cohort
(n  69)
Reconstructive
Cohort
(n  88)
Chronic Complications No. % No. %
Capsular contracture
No 57 82.6 46 52.3
Unilateral 9 13.0 41 46.5
Bilateral 3 4.4 1 1.2
Palpable implant
folds
No 40 58.0 27 30.7
Unilateral 12 17.4 48 54.5
Bilateral 17 24.6 13 14.8
Visible skin wrinkles
No 59 85.5 72 81.8
Unilateral 7 10.1 14 15.9
Bilateral 3 4.4 2 2.3
Prolonged pain in
the breast
No 59 85.5 78 88.7
Unilateral 4 5.8 9 10.2
Bilateral 6 8.7 1 1.1
Change of tactile
sense
No 61 88.4 9 10.2
Unilateral 4 5.8 67 76.1
Bilateral 4 5.8 12 13.7
*All reported cases were unilateral.
Table 4. Capsular Contracture per Implant for
Both Cohorts
Grade* Cosmetic Cohort (%) Reconstructive Cohort (%)
I 121 (89.0) 72 (62.6)
II 5 (3.7) 9 (7.8)
III 2 (1.4) 12 (10.4)
IV 8 (5.9) 22 (19.1)
Total 136 (100) 115 (100)
*According to the Baker classification.
Table 5. Identified Variables Related to Capsular
Contracture for the Entire Cohort (n 157)
Capsular
Contracture
(% of Women)
Variable No Yes p
Follow-up period
42 months 40.1 10.8 0.001
42 months 25.5 23.6
Age at surgery
54 years 60.5 24.8 0.001
54 years 5.1 9.6
Hormone therapy*
No 21.7 29.3 0.014
Yes 43.9 5.1
Type of cohort
Reconstructive 29.3 26.8 0.001
Cosmetic 36.3 7.6
*Including contraceptive drugs or hormone replacement therapy.
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factor for developing capsular contracture. The
first-level split produced two initial branches: cos-
metic (no capsular contracture; 82.6 percent) and
reconstructive (positive capsular contracture; 47.7
percent). The next splits indicated best predictor
variables for the cohort reconstructive group, as
the follow-up period followed by age at surgery.
Within that group, a follow-up period of 42
months or less was the best predictor for no cap-
sular contracture (unadjusted, 74.3 percent) and
a follow-up of more than 42months was predictive
for positive capsular contracture (unadjusted,
62.3 percent). For women with a follow-up of 42
months or less, capsular contracture was reported
among 67.7 percent of women older than 54 years
old compared with younger women (11.5 per-
cent). The overall risk estimate according to the
classification tree was 0.240 (standard error of risk
estimate, 0.034), indicating that 75.8 percent of
the cases will be classified correctly by using the
decision algorithm based on the current tree. The
CHAID algorithm resulted in larger predictive val-
ues for occurrence of capsular contracture (72.2
percent) than logistic regression (57.4 percent).
A second CHAID decision tree analysis was
performed with grade II subjects placed in the no
capsular contracture group—similar to other re-
ports—versus grade III and IV subjects. The first-
level split produced two initial branches: cosmetic
(no capsular contracture or grade II; 89.9 per-
cent) and reconstructive (capsular contracture
grade III or IV; 37.5 percent). The next split in-
dicated the best predictor variable for the recon-
structive group, as the follow-up period. Within
that group, a follow-up period of 64months or less
was the best predictor for no capsular contracture
or grade II (unadjusted, 73.4 percent), whereas a
follow-up of more than 64 months was predictive
for capsular contracture grade III or IV (unad-
justed, 66.7 percent). The overall risk estimate
according to the classification tree was 0.255
(standard error of risk estimate, 0.035), indicat-
ing that 79.6 percent of the cases will be classi-
fied correctly by using the decision algorithm
based on the current tree.
Exogenous hormone use was reported in 56.5
percent of cosmetic patients (n  39), with one
subject in menopause that used hormone therapy
replacement; of the remaining 68 women, 38 used
contraceptives (Fig. 2). Only 3.4 percent of recon-
structive patients (n  3) used hormone therapy.
Seventy-three patients were in menopause, with
two subjects who used hormone replacement ther-
Fig. 1. Prediction tree of capsular contracture by chi-square automatic interaction detection algorithm. The first-
level split produced two initial branches: cosmetic and reconstructive. The type of cohort was identified as the
determining factor for developing capsular contracture, and the reconstructive group is predictive for positive
capsular contracture. The next splits indicated the best predictor variables for the reconstructive group, as the
follow-up period followed by the age at surgery. Within that group, a follow-up period of 42 months or less was
the best predictor for no capsular contracture and a follow-up of more than 42months was predictive for positive
capsular contracture. For womenwith a follow-up of 42months or less, capsular contracture was reported among
67.7 percent of women older than 54 years old compared with younger women (11.5 percent).
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apy. Fifteen women were premenopausal, with
one who used contraceptives.
Subjects who were premenopausal or post-
menopausal women using hormone therapy re-
placement were grouped and analyzed as
“estrogen protected” (Fig. 3). To clarify the re-
lationships between menopause or women pro-
tected by estrogen with capsular contracture
rates according to type of cohort, two cross-
tabulations were performed (Tables 6 and 7).
No associations between capsular contract-
ure and menopause or estrogen status were
observed.
DISCUSSION
Despite significant surgical efforts and pre-
cautions, capsular contracture continues to oc-
cur,23,29,31,54–56 and the true cause of capsular con-
tracture remains elusive.21,23,24,39–42,55–72 In our
report, the occurrence of local complications and
the frequency, severity, and long-term sequelae
were in the reported range as described in other
studies.13–20 Table 8 13–15,19,20,47–50,73–79 demonstrates
that reported capsular contracture rates vary
widely because of authors reporting various Baker
classification rates and follow-up time periods.
These data showed that the incidence of compli-
cations was elevated in reconstruction patients
compared with cosmetic augmentation patients.14,80
No acute complications occurred in the aesthetic
cohort, and all chronic complications were less prev-
alent in our study group. In our study, women with
breast implants for cosmetic reasons had a lower
body mass index than women who had undergone
Fig. 2. Patientswith orwithoutmenopause according to type
of cohort.
Fig. 3. Patients protected or not by estrogen according to
type of cohort.
Table 6. Cross-Tabulation between Capsular
Contracture andMenopause According to Type
of Cohort
Capsular
Contracture
Menopause Yes No Total
Cosmetic cohort
Yes 0 1 1
No 12 56 68
Total 12 57 69
Reconstructive cohort
Yes 36 37 73
No 6 9 15
Total 42 46 88
Table 7. Cross-Tabulation between Capsular
Contracture and Being Protected or Not by Estrogen
According to Type of Cohort
Capsular
Contracture
Protected by Estrogen* Yes No Total
Cosmetic cohort
Yes 12 57 69
Total 12 57 69
Reconstructive cohort
Yes 35 36 71
No 7 10 17
Total 42 46 88
*Including all women before menopause or in menopause with
hormone replacement therapy.
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breast reconstruction, similar to previous studies10
that compared breast augmentation with breast
reduction and the general population.
In this study, 16 percent of capsular contrac-
tures (Baker grade III to IV) of the breast was
diagnosed after a 1.6-year period after initial
breast implantation. In the cosmetic study group,
no significant associations were formed between
surgical route or implant placement and any post-
operative complication. LikeHenriksen et al.,81 no
significant associations were observed between
body index mass, smoking habits, alcohol con-
sumption, hormone therapy, and capsular con-
tracture in our study groups.
Capsular contracture may be apparent within
the first year after implantation.14,15,33,81 However,
in our study, approximately 76 percent of cases of
capsular contracture (Baker grade II to IV) ap-
Table 8. Average Follow-Up versus Capsular Contracture
Study
Type of
Study No. of Patients
Average
Follow-Up Capsular Contracture
Spear et al., 200374 Prospective 85 cosmetic revisions 11.5 mo 2% Baker grade II; no Baker
grade III–IV
Adams et al., 200649 Prospective 235 (172 cosmetic
primary
augmentation; 63
reconstructive)
14 mo Baker grade III–IV: 1.8% cosmetic
primary augmentation, 9.5%
reconstructive
Henriksen et al.,
200580 Retrospective 2277 19.5 mo 4.3% (Baker grade II–IV)
Brown et al., 200519 Retrospective 150 (118 cosmetic; 32
reconstructive)
21 mo Cosmetic, 2 cases; reconstructive,
3 cases; just Baker grade II; no
cases of Baker grade III–IV
Fruhstorfer et al.,
200413 Prospective 35 23 mo 0%
Henriksen et al.,
200314 Prospective 1090 2 yr 4.1% (Baker grade II–IV)
Cunningham et al.,
200747 Prospective 955 (572 primary
augmentation; 123
revision-augmentation;
191 reconstruction;
69 revision-
reconstruction)
2 yr Baker grade III–IV: 0.8% primary
augmentation, 5.4 revision-
augmentation, 2.2% primary
reconstruction, 6% revision-
reconstruction
Camirand et al.,
199975 Prospective 830 2.39 yr 0%
Seify et al., 200576 Retrospective 44 34 mo 20% (Baker grade II–IV)
Cunningham et al.,
200748 Prospective 1007 (551 primary
augmentation; 146
revision-augmentation;
251 reconstruction;
59 revision-
reconstruction)
3 yr Baker grade III–IV: 8.1% primary
augmentation, 18.9 revision-
augmentation, 8.3% primary
reconstruction, 16.3% revision-
reconstruction
Bengtson et al.,
200777 Prospective 941 (492 cosmetic
primary
augmentation; 225
reconstructive; 224
revisions)
3 yr Baker grade III–IV: 5.9%
Spear et al., 200750 Prospective 940 (455 cosmetic
primary
augmentation; 98
reconstructive; 162
revisions)
6 yr Baker grade III–IV: 14.8% primary
augmentation, 20.5% revision-
augmentation, 15.9% primary
reconstruction
Kjøller et al., 200173 Retrospective 754 7 yr 11.4% of implantations
Kulmala et al.,
200420 Retrospective 685 10.9 yr 17.7% (15.4% of implantations)
Baker grade II–IV
Ho¨lmich et al.,
200778 Retrospective 190 19 yr 62%
Handel et al.,
200679 Retrospective 1529 (825 cosmetic;
264 reconstructive)
23.3 yr Baker grade III–IV per 1000
patient-months: 1.99 cosmetic,
5.37 reconstructive, 4.36 revision
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peared just after 2 years; 10.1 percent and 37.5
percent of severe capsular contracture (Baker
grade III to IV) occurred in the aesthetic and
reconstructive cohorts, respectively, during the
8-year period of follow-up. Breiting et al.10 reported
an 18 percent rate of severe breast pain, indicative of
severe capsular contracture, and in a previous study
involving a subgroup of this population, they had
diagnosed a 45 percent rate of capsular contracture
(Baker grade II to IV) of the breast after a 5-year
period after breast implantation.82 Capsular contrac-
ture may also be symptomatic several years after
surgery.10,33,81,83
Using the CHAID decision tree, the determin-
ing factor for capsular contracture was the type of
cohort. The next splits indicated the best predic-
tor variables for the cohort reconstructive level
being the follow-up period; if one considered no
capsular contracture versus capsular contracture,
the follow-up period should be longer than 3 years
6 months. However, if considering no capsular
contracture including grade II subjects versus
grade III or IV subjects, a longer follow-up period
of 5 years 4 months was determined. It is inter-
esting that both CHAID tree decision analyses had
the same qualitative splits but with longer fol-
low-up periods in grade III or IV subjects. This is
expected, as breast capsule formation is thought
to develop from grade II to grade III, and from
grade III to grade IV. These results underscore the
importance of considering grade II as an impor-
tant clinical observation that should be included
in the capsular contracture analyses. Thus, we be-
lieve that a long follow-up period from grade II
and reconstructive patients should be considered
when studying local complications among women
receiving breast implants and other female age-
related factors such as menopause.
The protective role of estrogens in the pro-
gression of liver fibrosis84,85 and the fact that es-
trogen deprivation was being associated with de-
clining dermal collagen content and impaired
wound healing is well known86; nevertheless, there
are no reports concerned with menopause or es-
trogens versus capsular contracture. The main
limitation of this study is the relatively small sam-
ple size and thus limited statistical power for ob-
serving relationships with rare outcomes, espe-
cially in the cosmetic cohort.
The authors for the first time report no asso-
ciation between capsular contracture and meno-
pause or estrogen status. Therefore, the patho-
physiology of capsule formation and subsequent
contracture developing metabolic pathways are
not estrogen derived. Our data suggest that grade
II subjects should be included in a capsule con-
tracture analyses and a follow-up period longer
than 42 months should be considered. Our hope
is that the breast contracture “riddle” will be
solved in our lifetime so that our patients will not
have to confront recurrent and intractable capsu-
lar contractures.87
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Fibrosis is a major global health problem, but its cause, 
pathogenesis, and diagnosis are not completely under-
stood. Fibrosis may occur as a consequence of multiple 
pathologic conditions, including keloids, Dupuytren con-
tracture, postoperative adhesions, burns, postinfection 
liver fibrosis, silica dust, asbestos, antibiotic bleomycin, 
scleroderma, cardiac pacemakers, polypropylene meshes, 
and—of special interest to aesthetic surgeons—breast 
implant capsular contracture (CC).1-3
The cause of CC remains largely undetermined, with clini-
cally-reported incidences ranging from 8% to 45%.4-9 Prior 
investigations of CC have focused on microorganisms found 
in the capsule or outer implant surface,10-22 on inflammatory 
responses,1,23,24 and on histological characteristics of the cap-
sule.25-32 Two reports found correlations between CC and 
hematoma.32,33
Histologically, human CC tissue comprises an inner layer 
of fibrocytes and histiocytes, surrounded by a thicker layer 
Effects of Fibrin, Thrombin, and Blood on 
Breast Capsule Formation in a Preclinical Model
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Abstract
Background: The root cause of capsular contracture (CC) associated with breast implants is unknown. Recent evidence points to the possible role of 
fibrin and bacteria in CC formation.
Objectives: The authors sought to determine whether fibrin, thrombin, and blood modulated the histological and microbiological outcomes of breast 
implant capsule formation in a rabbit model.
Methods: The authors carried out a case-control study to assess the influence of fibrin, thrombin, and blood on capsule wound healing in a rabbit 
model. Eighteen New Zealand white rabbits received four tissue expanders. One expander acted as a control, whereas the other expander pockets 
received one of the following: fibrin glue, rabbit blood, or thrombin sealant. Intracapsular pressure/volume curves were compared among the groups, 
and histological and microbiological evaluations were performed (capsules, tissue expanders, rabbit skin, and air). The rabbits were euthanized at two or 
four weeks.
Results: At four weeks, the fibrin and thrombin expanders demonstrated significantly decreased intracapsular pressure compared to the control group. 
In the control and fibrin groups, mixed inflammation correlated with decreased intracapsular pressure, whereas mononuclear inflammation correlated 
with increased intracapsular pressure. The predominant isolate in the capsules, tissue expanders, and rabbit skin was coagulase-negative staphylococci. 
For fibrin and thrombin, both cultures that showed an organism other than staphylococci and cultures that were negative  were associated with decreased 
intracapsular pressure, whereas cultures positive for staphylococci were associated with increased intracapsular pressure.
Conclusions: Fibrin application during breast implantation may reduce rates of CC, but the presence of staphylococci is associated with increased 
capsule pressure even in the presence of fibrin, so care should be taken to avoid bacterial contamination.
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capsule, tissue expander, fibrin, thrombin, blood, coagulase-negative staphylococci
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of collagen bundles arranged in a parallel array.34,35 The 
outer layer is more vascular and contains loose connective 
tissue. From a clinical perspective, authors seems to agree 
that the degree of capsule thickness is proportionate to the 
severity of the CC, but this has never been definitively 
proven and some reports found no correlations among 
microbial contamination, thickness, and CC.36 However, we 
do know that transforming growth factor beta 1 (TGF-β1), 
connective tissue growth factor, osteopontin, interleukin-4 
(IL-4), IL-6, IL-10, IL-13, IL-21, basic fibroblast growth fac-
tor, epidermal growth factor, insulin-like growth factor 1, 
platelet-derived growth factor, oncostatin M, and endothelin 
1 (see Sticherling37) all promote fibrosis.1
Numerous reports have associated fibrin glue with 
improved parameters of wound healing38-41 and reduced 
quantity and consistency of adhesions, even in the case of 
polypropylene meshes.2,3 To the best of our knowledge, only 
one study focused on the impact of autologous fibrin glue on 
capsule formation as a contracture-inducing agent, and no 
reports exist for commercially-available fibrin products.26 In 
preclinical reports, several molecules were found to reduce 
CC27,42,43; nevertheless, these compounds are not currently 
available in clinical practice. However, the fibrin-containing 
commercial products are widely used clinically and are an 
attractive adjunct for patients receiving breast implants.
The purpose of this study was to perform a comprehen-
sive evaluation (based on a rabbit model26) of the relation-
ships among intracapsular pressure, histological characteristics, 
and infection surrounding the tissue expander in the capsule, 
in the rabbit skin, and in the operating room air. To clarify 
whether hematoma is associated with CC, the study was 
conducted with tissue expanders surrounded by rabbit blood 
to simulate a hematoma, as well as with tissue expanders in 
the presence of thrombin (FloSeal, Baxter US, Deerfield, 
Illinois), an absorbable hemostatic agent that contains no 
fibrinogen and requires contact with blood for the clot to be 
activated. To study the implications of wound healing in 
development of CC, the implant pocket was instilled with 
fibrin (Tissucol/Tisseel, Baxter US), a hemostatic agent with 
adhesive properties.
MethOdS
Eighteen New Zealand white female rabbits (3-4 kg) were 
implanted with textured saline tissue expanders (20 mL, 
Allergan, Santa Barbara, California) with intact connecting 
tubes and ports, in accordance with an approved institu-
tional animal care protocol. Before surgery, the animals 
were washed with Betadine surgical scrub (Purdue Pharma 
LP, Stamford, Connecticut), which contains 7.5% povidone-
iodine, and their skin disinfected with Betadine solution, 
which contains 10% povidone-iodine. The surgical procedure 
was performed in a veterinary operating room with aseptic 
techniques. Penicillin G (40,000 U/kg) was immediately 
administered intramuscularly to the subjects was intra-
operatively. Talc-free gloves were worn at all times during 
the procedure. Pockets were atraumatically dissected 
under direct vision in the subpanniculus carnosus along 
the back region of each rabbit. Attention was paid to 
hemostasis and blunt instrumentation was avoided; there 
was no obvious bleeding. A new pair of talc-free gloves 
was placed on the surgeon’s hands before tissue expander 
insertion, with minimal skin contact.
One control and three experimental tissue expanders 
were placed in each rabbit. The experimental expanders 
received one of the following: 1 mL of fibrin glue spray 
(Tisseel/Tissucol), 2 mL of rabbit blood to simulate a 
hematoma, or 5 mL of thrombin sealant (FloSeal) in the 
expander pocket. A pressure-measuring device (Stryker 
Instruments, Kalamazoo, Michigan) was connected to 
each tissue expander port. Intraexpander pressure was 
recorded immediately before filling and in 5-mL incre-
ments until the tissue expanders were overfilled. Each 
tissue expander was filled to 20 mL.
The rabbits were euthanized at two or four weeks. 
Beforehand, each animal was anesthetized and the dorsal back 
area was shaved. The pressure monitor was connected again 
to the tissue expander port, and intracapsular pressures were 
recorded in 5-mL increments as the expander was drained, 
before any incision in the capsule. Capsule samples were sub-
mitted for histological and microbiological evaluation.
Microbiological Assessments
Air. Operating room air samples (n = 36) were collected 
during all procedures with the MAS 100-Eco air sampler (EMD 
Chemicals, Inc., Gibbstown, New Jersey) at a flow rate of 100 
L per minute. Identification of bacterial and fungal isolates fol-
lowed standard microbiological procedures. Gram-positive 
cocci were characterized by biochemical methods. Catalase-
positive and coagulase-positive colonies were identified as 
Staphylococcus aureus; catalase-positive and coagulase-nega-
tive colonies were identified as coagulase-negative 
staphylococci. Gram-negative bacilli were characterized with 
Vitek 2 software (VT2-R04.02, bioMérieux, Inc., Durham, 
North Carolina). Fungi were characterized following their 
macroscopic appearance and microscopic morphology.
Rabbit skin. A total of 54 contact plates were pressed to 
shaved dorsal skin surfaces (18 brain-heart agar, 18 man-
nitol salt agar, and 18 Sabouraud agar). The brain-heart 
and mannitol salt contact plates were incubated for three 
days at 28°C; the Sabouraud contact plates were incu-
bated for seven days at 28°C. Bacterial and fungal colonies 
were counted and reported as colony-forming units per 
square centimeter. For the identification of the bacteria 
and fungi grown, the same methods listed above were 
applied.
Capsules and tissue expanders. Excised implants and rep-
resentative capsule samples were incubated at 37°C for 
three days in brain-heart agar plates and examined daily; 
changes in turbidity of the broth media were considered 
positive and were subcultured  in solid agar media. 
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Characterization of microbial isolates followed the above-
described procedures.
Histological Assessment
Capsule specimens were fixed with 10% buffered formalin 
and embedded in paraffin. Sections were stained with 
hematoxylin and eosin and histologically evaluated for tis-
sue inflammation and capsular thickness. The type and 
intensity of the inflammatory infiltrate were analyzed. 
Inflammation was grouped into three categories: mononu-
clear/chronic (lymphocytes, plasmocytes, and histiocytes), 
mixed/subacute (mononuclear cells and eosinophils), and 
polymorph/acute (eosinophils and heterophils). Inflamma-
tory infiltrate intensity was categorized according to the 
following criteria: absent (−), mild (+), moderate (++), 
and severe (+++).25
Samples were stained with Masson trichrome44 to char-
acterize the collagen (loose, slightly dense [≤ 25%] or 
more dense [> 25%]), the organization of collagen fibers 
(parallel or haphazard), the angiogenesis (absent, mild, 
moderate, or high), and the fibroblast density (mild, mod-
erate, or high). Histological sections were reviewed and 
graded by a pathologist blinded to the protocol.
Statistical Analysis
Data were grouped according to the type of product applied 
to the tissue expander: none (control), blood (blood), 
Tissucol/Tisseel (fibrin), and FloSeal (thrombin). Each was 
analyzed for the rabbits euthanized at two and four weeks 
after surgery, as well as for all 18 rabbits. One-way analysis 
of variance was applied to compare the intraexpander pres-
sure before insertion. A two-tailed paired t-test and the 
nonparametric alternative Wilcoxon signed rank test were 
applied to determine whether continuous variables (intrac-
apsular pressure and histologically measured thickness) 
were significantly different between the control and experi-
mental groups. Categorical variables were evaluated by chi-
square statistics and by phi, Cramer V, and contingency 
coefficients. Statistical significance was presumed at p ≤ .05. 
Major trends within each group were further examined by 
the chi-square automatic interaction detection (CHAID) 
method,45 based on the likelihood ratio chi-square statistic 
as growing criteria, along with a Bonferroni 0.05 adjustment 
of probabilities. All analyses were carried out with SPSS 
version 16 (SPSS, Inc., Chicago, Illinois).
ReSultS
Intracapsular Pressure
No significant differences were observed in the pressure- 
volume curves between the control and experimental groups 
at baseline (tissue expander introduction) or at two weeks. 
At four weeks, rupture was observed during pressure 
measurement with six capsules in the control group, five 
capsules in the blood group, and one capsule in thrombin 
group; no capsule ruptures in the fibrin group were noted. To 
avoid reducing the sample size, the ruptured capsules were 
not excluded from statistical analyses, but it is important to 
note that the pressure levels measured before capsule rupture 
were maintained after additional saline was added. At four 
weeks, significantly decreased intracapsular pressures were 
registered in the fibrin group (p ≤ .0006) and thrombin group 
(p ≤ .003) (Figure 1).
Histology
The average capsular thicknesses were similar among all 
groups at two and four weeks (Table 1). At two weeks, 
mixed types of inflammatory cells were predominant in the 
capsules, and no statistically significant differences were 
found among the groups. At four weeks, mononuclear cells 
were predominant in the control, blood, and thrombin 
groups; in the fibrin group, mixed cells were predominant. 
However, these differences were not statistically significant. 
At both two and four weeks, trends in the intensity of 
inflammation showed no significant difference (Table 2).
Fibrosis developed in all capsules at two and four 
weeks. No significant differences were observed regarding 
the organization of collagen fibers between the control and 
experimental groups. At two weeks, more dense collagen 
(> 25%) was found in the control group, whereas loose 
and slightly dense collagen (≤ 25%) was found in the 
blood group (p = .023). At both two and four weeks, 
Figure 1. Pressure-volume curves at four weeks. There 
was a significant difference in intracapsular pressure 
in the thrombin (FloSeal) and fibrin (Tissucol/Tisseel) 
experimental groups.
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increased angiogenesis was observed in the control group 
(moderate/ high) versus the blood group (negative/mild) 
(p = .018). At four weeks, significant differences were 
found in the fibroblast density between the control and 
blood groups (p = .047)—mild in the control group and 
moderate in the blood group.
Microbiology
At two and four weeks, bacteria were isolated in 53% of 
the capsules (38 of 72) and 47% of the tissue expanders 
(34 of 72). The specimens included coagulase-negative 
staphylococci (41%), Escherichia coli (10%), Staphylococcus 
aureus (8%), Pseudomonas spp (0.7%), and other gram-
negative bacilli (0.7%). In the capsules, the predominant 
isolated bacteria was coagulase-negative staphylococci, 
identified in 53% at two weeks (19 of 36), decreasing to 
33% at four weeks (12 of 36). In tissue expanders, coagu-
lase-negative staphylococci was identified in 44% at two 
weeks (16 of 36), decreasing to 22% at four weeks (eight 
of 36). Capsules yielded a single isolate in 43% (31) and 
more than one isolate in 10% (seven); tissue expanders 
yielded a single isolate in 32% (23) and more than one 
isolate in 15% (15). No fungi were recovered from the 
removed capsules or tissue expanders in any rabbits.
Similar bacterial isolates were cultured from rabbit skin. 
The predominant isolated bacteria was coagulase-negative 
staphylococci, in 16 of 18 euthanized rabbits (89%). A single 
skin sample was culture-negative, whereas two samples 
yielded more than one bacteria. Isolated bacteria from rabbit 
skin were not different from those removed from the capsules 
and tissue expanders. Coagulase-negative staphylococci were 
also isolated from all air samples. Other isolates included 
gram-positive bacilli and Staphylococcus aureus (although 
these were found much less frequently). Several species, 
such as Penicillium spp., Aspergillus niger, and zygomycetes, 
were recovered from the operating room air.
Statistical analyses revealed no significant differences 
in the frequency of culture positivity and the type of bac-
teria among all the groups and no significant correlation 
between the microbial presence and the histological char-
acteristics.
CHAID Modeling Associations
At four weeks, statistical analysis with CHAID modeling 
demonstrated association with intracapsular pressure at 20 
mL for the control and fibrin groups. The determining factor 
for intracapsular pressure at four weeks was the type of 
inflammatory cells (Figure 2). The CHAID analysis showed 
in both trees that mixed inflammation was related to 
decreased intracapsular pressure and that mononuclear 
inflammation was related to increased intracapsular pres-
sure. In the control tree, moderate inflammation was related 
to decreased pressure in the capsules with mononuclear 
Table 1. Average Capsular Thickness of Control Versus Experimental 
Groups
Group Two Weeks, mm Four Weeks, mm
Control 0.83 ± 0.085 0.64 ± 0.078
Blood 1.02 ± 0.207 0.78 ± 0.572
Fibrin: Tissucol/Tisseel 0.89 ± 0.082 0.72 ± 0.083
Thrombin: FloSeal 0.90 ± 0.064 0.71 ± 0.105
Table 2. Outcomes for Capsule Inflammation of Control Versus Experimental Groups
Group Type of Inflammatory Cells Two Weeks, % Four Weeks, % Intensity Two Weeks, % Four Weeks, %
Control Mononuclear: chronic 22.2 55.6 Mild 11.1 55.6
Polymorph: acute 0.0 0.0 Moderate 77.8 44.4
Mixed: active chronic 77.8 44.4 High 11.1 0.0
Blood Mononuclear: chronic 33.3 55.6 Mild 33.3 33.3
Polymorph: acute 0.0 0.0 Moderate 66.7 66.7
Mixed: active chronic 66.7 44.4 High 0.0 0.0
Fibrin: Tissucol/Tisseel Mononuclear: chronic 11.1 22.2 Mild 0.0 22.2
Polymorph: acute 0.0 0.0 Moderate 66.7 33.3
Mixed: active chronic 88.9 77.8 High 33.3 44.4
Thrombin: FloSeal Mononuclear: chronic 22.2 77.8 Mild 11.1 66.7
Polymorph: acute 0.0 0.0 Moderate 77.8 33.3
Mixed: active chronic 77.8 22.2 High 11.1 0.0
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inflammatory cells, whereas capsules with mild inflamma-
tion had increased pressure.
CHAID classification analyses with intracapsular pressure 
at 20 mL for the fibrin and thrombin groups showed that the 
determining factor for intracapsular pressure at four weeks 
was the kind of bacteria isolated from tissue expanders 
(Figure 3). Cultures showing an organism other than 
Staphylococcus (E. coli, Pseudomonas spp) and negative cul-
tures (those with no contamination) were correlated with 
decreased intracapsular pressure. Coagulase-negative staphy-
lococci and Staphylococcus aureus were correlated with 
increased intracapsular pressure.
diScuSSiOn
The major findings of our study were observed on capsules 
and tissue expanders in the rabbits euthanized at four weeks. 
Compared to the control group, the fibrin and thrombin 
groups showed significantly decreased intracapsular pres-
sures. The fibrin group was the only group with no capsular 
ruptures during pressure measurement. For the control and 
fibrin groups, mixed inflammation was associated with 
decreased intracapsular pressures, whereas mononuclear 
inflammation was associated with increased intracapsular 
pressures. For the fibrin and thrombin groups, cultures with 
bacteria other than staphylococci and negative cultures were 
associated with decreased intracapsular pressure, whereas 
staphylococci cultures were associated with increased intrac-
apsular pressure. In the blood group, increased fibroblast 
densities were observed as compared to the control group. 
Increased angiogenesis was observed in the control group 
compared to the blood group. Average capsular thicknesses, 
the type and intensity of the inflammatory infiltrate, and col-
lagen density and organization were similar among all groups. 
Also, the isolated bacteria in capsules, tissue expanders, and 
rabbit skin were similar among the groups. In capsules, tissue 
expanders, and rabbit skin, the predominant isolated bacteria 
was coagulase-negative staphylococci, which was also iso-
lated from all air samples. No fungi were recovered from 
capsules, tissue expanders, or rabbit skin, but they were iso-
lated from all air samples.
Of note, this study was performed with tissue expand-
ers to measure the capsule pressure directly46 to achieve 
more accurate results. Similar capsules and increased 
pressure levels were observed in both the control group 
and the blood group. On the basis of wound-healing prin-
ciples,47 we can conclude that increased pressure levels 
and capsule rupture rates correlate with contracture. That 
increased angiogenesis is associated with fibrosis has been 
documented,31,46,48 supporting the major trends observed 
in CC development in the control group of this study.
FloSeal requires blood for activity; therefore, given the 
thrombin group results, we may conclude that an active 
hemostasis is indispensable to preventing CC, although it is 
unnecessary with a hemostatic commercial product. 
However, the fibrin group demonstrated mixed inflamma-
tion, which correlated with decreased intracapsular pres-
sures as compared with the control group. This is consistent 
with other reports observing that the activation of fibrosis 
in the early implant period may be the major mechanism 
for CC development.25 
In our study, inflammation was not significantly corre-
lated with capsular thickness, which is consistent with the 
results reported by Siggelkow et al.25 Sead et al studied 
fibrin sealant prepared from a Tisseel kit without aprotinin 
and observed a reduction in the extracellular matrix and 
TGF-β1, especially from adhesion fibroblasts, which may 
indicate a role in the reduction of postoperative adhesion 
development.49 It is well known that fibrosis is associated 
with excessive collagen extracellular matrix formation, cell 
proliferation, and activation of myofibroblasts. In this con-
text, macrophages and mast cells have been implicated as 
important participants in the inflammatory process involv-
ing fibrosis.1 Macrophages contribute to this process by the 
production of TGF-β1 and IL-6.50
In a study by Ruiz-de-Erenchun et al,51 TGF-β1 inhibitor 
peptide applied in a matrix with tetraglycerol dipalmitate 
was significantly effective in achieving a reduction in 
periprosthetic fibrosis after placement of silicone implants. 
Interestingly, in our fibrin group, mixed inflammation was 
correlated with decreased intracapsular pressure, but intrac-
apsular pressure increased in the presence of Staphylococcus 
infection. Our results suggest that fibrin plays a role in pre-
venting CC, that the bacterial colonization of mammary 
implants may be partially responsible for CC, and that 
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Figure 2. Decision tree by CHAID algorithm for histology 
data at four weeks. (A) control group; (B) experimental 
fibrin group (Tissucol/Tisseel).
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coagulase-negative staphylococci may play a large role.52-66 
As reported in the literature, infection of implanted medical 
devices is commonly mediated by formation of bacterial 
biofilms.67-70 However, Pajkos et al13 reported that biofilm 
was found with scanning electron microscopy in a single 
culture-negative sample. It is interesting that extensive 
amorphous biological deposits were observed with scan-
ning electron microscopy, even in the absence of bacterial 
structures. Moreover, because of the low pathogenicity of 
coagulase-negative staphylococci and the existence of 
microorganisms in a dormant phase within the biofilm 
around the implant, CC does not usually clinically manifest 
until some remote time after placement of mammary 
implants.13,67-70 For all of these reasons, we did not consider 
biofilm investigation in this preclinical study. All the meth-
ods for biofilm investigation are expensive, not routinely 
used, and require a longer follow-up period.
We euthanized the rabbits at two or four weeks to 
study capsule formation and wound healing.47 Our study 
demonstrated wound-healing results at two weeks among 
all groups that were similar to those from a report by 
Adams et al.26 Our results differed in that intracapsular 
pressure decreased with fibrin glue application, whereas 
their results showed increased pressure.26 This may be 
explained in part by the fact that our data were collected 
at four weeks, whereas that study focused on capsules at 
eight weeks. Also, the Adams et al study utilized an 
autologous fibrin glue of unknown fibrin concentration, 
whereas our study utilized a commercial fibrin product 
widely studied and used in clinical practice (Tissucol/
Tisseel) to reduce polypropylene mesh adhesions.2,3 To the 
best of our knowledge, this is the first report examining CC 
with a commercially-available fibrin product. In addition, 
this study is the first to include an examination of bacterial 
contamination from rabbit skin and operating room air. 
Furthermore, our study (which is an extension of the 
Adams study) placed expanders in New Zealand white 
rabbits rather than mice, given that the rabbits had the 
capacity to support all four expanders. The data in porcine 
models are limited.
One limitation of this study was the use of tissue expand-
ers instead of commercial silicone breast implants, which are 
not available in an appropriate size for the rabbit model. One 
strength of our study was the statistical analyses among the 
four groups with the CHAID method, a sophisticated algo-
rithm widely used in other disciplines because it models a 
single variable among multiple variables. Future studies may 
expand upon our results by extending the follow-up period, 
by inserting breast implants, instead of tissue expanders, 
sprayed with fibrin, or by focusing on fibrosis that may influ-
ence or modulate CC.
cOncluSiOnS
Fibrin applied in the breast implant pocket may reduce 
CC. With its relatively-well-documented safety profile, 
fibrin-containing compounds can be considered an attrac-
tive adjunct in breast implant surgeries. Clinical strategies 
for preventing bacterial contamination during surgery are 
crucial, given that Staphylococcus (mainly, coagulase-
negative staphylococci) may promote CC even with fibrin.
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The investigation of various possible mechanisms for capsu-
lar contracture (CC) has been complicated by the lack of 
standardized animal models. Multiple reports have described 
the effects of bacteria on CC, and one report exists on the 
possible role of fibrin, but no single study has compared 
these parameters at one experimental time point.
There is evidence that bacterial colonization of breast 
implants is partially responsible for CC, and coagulase- 
negative staphylococci (CoNS; particularly Staphylococcus 
epidermidis) have been largely implicated.1-15 Adams et 
al16,17 showed that S. epidermidis colonization of breast 
implants was more likely to result from bacterial contami-
nation at the time of implantation than from ongoing 
contamination from the adjacent ductal system. Because 
of the low pathogenicity of CoNS and the existence of 
microorganisms in a dormant phase within the biofilm 
formed around the implant, CC does not usually clinically 
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Abstract
Background: The etiology and ideal clinical treatment of capsular contracture (CC) remain unresolved. Bacteria, especially coagulase-negative 
staphylococci, have been previously shown to accelerate the onset of CC. The role of fibrin in capsule formation has also been controversial.
Objective: The authors investigate whether fibrin and coagulase-negative staphylococci (CoNS) modulate the histological, microbiological, and clinical 
outcomes of breast implant capsule formation in a rabbit model and evaluate contamination during the surgical procedure.
Methods: Thirty-one New Zealand white female rabbits were each implanted with one tissue expander and two breast implants. The rabbits received (1) 
untreated implants and expanders (control; n = 10), (2) two implants sprayed with 2 mL of fibrin and one expander sprayed with 0.5 mL of fibrin (fibrin; n = 11), 
or (3) two implants inoculated with 100 µL of a CoNS suspension (108CFU/mL—0.5 density on the McFarland scale) and one expander inoculated with a CoNS 
suspension of 2.5 × 107 CFU/mL (CoNS; n = 10). Pressure/volume curves and histological and microbiological evaluations were performed. Operating room air 
samples and contact skin samples were collected for microbiological evaluation. The rabbits were euthanized at four weeks.
Results: In the fibrin group, significantly decreased intracapsular pressures, thinner capsules, loose/dense (<25%) connective tissue, and negative/mild angiogenesis 
were observed. In the CoNS group, increased capsular thicknesses and polymorph-type inflammatory cells were the most common findings. Similar bacteria in capsules, 
implants, and skin were cultured from all the study groups. One Baker grade IV contracture was observed in an implant infected with Micrococcus spp.
Conclusions: Fibrin was associated with reduced capsule formation in this preclinical animal model, which makes fibrin an attractive potential 
therapeutic agent in women undergoing breast augmentation procedures. Clinical strategies for preventing bacterial contamination during surgery are 
crucial, as low pathogenic agents may promote CC.
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manifest until some remote time after placement of breast 
implants.18-22
Fibrin glue consists of two components, a fibrinogen solu-
tion and a thrombin solution rich in calcium. Fibrin serves as 
a binding reservoir for several growth factors, such as vascu-
lar endothelial growth factor (VEGF),23 transforming growth 
factor–β1,24 and basic fibroblastic growth factor (bFGF).25 
Fibrin glue has been studied for decades for its applications 
both in a surgical setting and as an hemostatic and sealant 
agent. It is routinely used in gastrointestinal anastomosis, 
breast surgery, facelifts, abdominoplasty, nerve repairs, graft 
securing, neurosurgery, and ophthalmology.26-36 More 
recently, it has also gained attention as a possible delivery 
mechanism for drug therapies.37 For example, in a study by 
Zhibo and Miaobo,38 release of lidocaine through fibrin glue 
was tested for pain reduction in breast augmentation 
patients. Patients who received fibrin glue with lidocaine 
in the subpectoral pocket experienced less pain than those 
who received the same amount of lidocaine or fibrin glue 
alone. In another study,39 we applied an autologous fibrin 
to the implant pocket as a contracture-inducing agent and 
compared the results to a control group. The degree of 
fibrosis was greater in the fibrin-exposed groups in both 
the rabbit and human components of the study. Importantly, 
there was a significant increase in intracapsular pressure 
in the fibrin-exposed group. However, in another preclini-
cal study40 with fibrin (Tisseel/Tissucol; Baxter US, 
Deerfield, Illinois) sprayed onto the tissue expander and 
capsule pocket, a significant decrease in intracapsular 
pressures was found in the experimental fibrin group as 
compared to a control group at four weeks. For both the 
control and fibrin groups, mixed inflammation was corre-
lated with decreased intracapsular pressure, whereas 
mononuclear inflammation was correlated with increased 
intracapsular pressure. The predominant isolate in cap-
sules, tissue expanders, and rabbit skin was CoNS.
The purpose of this study was to perform a comprehen-
sive evaluation, in a New Zealand white rabbit model, of the 
relationships among intracapsular pressure (recorded directly 
by a tissue expander), histological characteristics, and infec-
tion of breast implants. Microbiological analysis of rabbit skin 
and operating room air was performed to account for con-
tamination during the surgical procedure. Our aim was to 
provide research data that could be translated into clinical 
practice. Therefore, we elected to (1) apply a commercial 
fibrin product (Tisseel/Tissucol) into the breast implant 
pocket to clarify the effect on capsule formation and (2) 
assess implants contaminated directly with CoNS, which 
were previously reported as CC-inducing agents. At present, 
there are no reports examining these two variables with a 
preclinical animal protocol for direct comparison.
Methods
Thirty-one New Zealand white female rabbits (3-4 kg) 
were each implanted with one 20-cc textured tissue 
expander (Allergan, Inc., Santa Barbara, California) and 
two textured breast implants (90 cc; Allergan, Inc., Santa 
Barbara, California), according to approved institutional 
animal care protocol. Prior to surgery, the skin of each 
rabbit was washed with Betadine surgical scrub (Purdue 
Pharma LP, Stamford, Connecticut), which contains 7.5% 
povidone-iodine, and their skin was disinfected with 
Betadine solution, which contains 10% povidone-iodine. 
The surgical procedure was performed in an animal oper-
ating theater following aseptic rules. Penicillin G 40,000 
U/kg intramuscularly (IM) was administered intraopera-
tively. Talc-free gloves were used at all times during the 
procedure.
Implant pockets were developed in the subpanniculus 
carnosis along the back region, with atraumatic dissection. 
Under direct vision, particular attention was paid to 
hemostasis, avoiding blunt instrumentation; there was no 
obvious bleeding. A sterile dressing was placed over the 
skin around the incision before the tissue expander and 
the implants were inserted to eliminate contact with the 
skin.41 A new pair of talc-free gloves was worn when 
inserting the tissue expander and the implants.
The rabbits were divided into three groups: (1) those 
that received untreated implants and expanders (control; 
n = 10), (2) those that received two implants sprayed with 
2 mL of fibrin and one expander sprayed with 0.5 mL of 
fibrin (fibrin; n = 11), and (3) those that received two 
implants inoculated with 100 µL of a CoNS suspension 
(108 CFU/mL—0.5 density on the McFarland scale) and 
one expander inoculated with a CoNS suspension of 2.5 × 
107 CFU/mL (CoNS; n = 10).
All rabbits were sacrificed at four weeks. Prior to sacri-
fice, each animal was anesthetized, and the dorsal back 
area was shaved. A pressure-measuring device (Stryker 
Instruments, Kalamazoo, Michigan) was connected to the 
tissue expander port, and intracapsular pressures were 
recorded in 5-mL increments prior to any incision in the 
capsule. All capsule samples were submitted for histologi-
cal and microbiological evaluation. All implants and 
expander devices were also submitted for microbiological 
evaluation.
Microbiological Assessments
Air. Operating room air samples (n = 36) were col-
lected as described in our previous study40 with a MAS 
100-Eco air sampler (EMD Chemicals, Inc., Gibbstown, 
New Jersey) at a flow rate of 100 L per minute. Identifica-
tion of bacterial and fungal isolates followed standard 
microbiological procedures. Gram-positive cocci were 
characterized by biochemical methods. Catalase-positive 
and coagulase-positive colonies were identified as Staphy-
lococcus aureus; catalase-positive and coagulase-negative 
colonies were identified as coagulase-negative staphylo-
cocci. Gram-negative bacilli were characterized with Vitek 
2 software (VT2-R04.02, bioMérieux, Inc., Durham, North 
Carolina). Fungi were characterized following their mac-
roscopic appearance and microscopic morphology.
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Rabbit skin. A total of 93 contact plates (31 brain-heart 
agar, 31 mannitol salt agar, and 31 Sabouraud agar) were 
pressed to the shaved dorsal skin surfaces, also as described 
in our previous study.40 Brain-heart and mannitol salt agar 
plates were incubated for three days at 28°C; Sabouraud 
plates were incubated for seven days at 28°C. Bacterial and 
fungal colonies were counted and reported as cfu/cm2. The 
identification of the bacteria and fungi followed the proce-
dures reported above.
Capsules/implants/tissue expanders. Excised implants, tissue 
expanders, and representative capsule samples were incu-
bated at 37°C for three days in brain-heart broth and examined 
daily; changes in turbidity of the broth media were consid-
ered positive and were subcultured in solid agar media. 
Characterization of microbial isolates followed the procedures 
described in the section on skin testing.
Histological Assessment
Capsule specimens were fixed with 10% buffered formalin 
and embedded in paraffin. Sections were stained with 
hematoxylin and eosin and histologically evaluated for tis-
sue inflammation and capsular thickness. The type and 
intensity of the inflammatory infiltrate were analyzed. 
Inflammation was grouped into three categories: mononu-
clear/chronic (lymphocytes, plasmocytes, and histiocytes), 
mixed/subacute (mononuclear cells and eosinophils), and 
polymorph/acute (eosinophils and heterophils). Inflammatory 
infiltrate intensity was categorized according to the follow-
ing criteria: absent (−), mild (+), moderate (++), and 
severe (+++).40,42
Samples were stained with Masson’s trichrome to char-
acterize the connective tissue (loose or dense), organiza-
tion of the collagen fibers (arranged in a parallel array or 
haphazard), angiogenesis (absent, mild, moderate, or 
high), and fusiform cell density (mild, moderate, or high). 
The density of the connective tissue was semiquantita-
tively separated into one of four groups: (1) less than 25%, 
(2) 25% to 50%, (3) 50% to 75%, and (4) >75%.
Histological sections were reviewed and graded by a 
pathologist blinded to the protocol.
Statistical Analysis
Data were grouped according to the type of product 
applied to the breast implants: control (none; n = 10 rab-
bits, 20 implants), CoNS (n = 10 rabbits, 20 implants), or 
fibrin (n = 11 rabbits, 22 implants). One-way analysis of 
variance test—either parametric or nonparametric 
(Kruskal-Wallis H test)—was performed to determine 
whether the continuous variables (intracapsular pressure 
and histologically measured thickness) were equal, fol-
lowed by post hoc range tests to identify homogeneous 
subsets across groups. Two-tailed independent paired t 
tests were used, along with the nonparametric alternative 
Mann-Whitney U tests. Categorical variables were evalu-
ated by chi-square statistics and by phi, Cramer’s V, and 
contingency coefficients. Statistical significance was calcu-
lated at p ≤ .05. Major trends within each group were 
further examined with the Chi-squared Automatic 
Interaction Detection (CHAID) method,43 using the likeli-
hood ratio chi-square statistic as growing criteria, along 
with a Bonferroni 0.05 adjustment of probabilities. All 
analyses were carried out with the Statistical Package for 
Social Sciences Version 16 (SPSS, Inc., an IBM Company, 
Chicago, Illinois).
Results
Statistical analyses revealed no significant differences in 
histological and microbiological results between breast 
implants and tissue expanders. Because no differences 
were found, these data are not shown.
Intracapsular Pressure
During pressure measurements, five (50%) capsules rup-
tured in the control group, and five (50%) capsules rup-
tured in the CoNS group. To avoid a prohibitively small 
sample size, the ruptured capsules were not excluded from 
our statistical analyses, but the pressure value measured 
before rupture was maintained after further additional mil-
liliters of saline were added. Significantly decreased intra-
capsular pressures were registered for the fibrin group as 
compared to the control and the CoNS groups (p ≤ .001 
and p ≤ .05, respectively; Figure 1). Statistical analyses 
revealed no significant differences between the CoNS and 
the control groups.
Histology
Average capsular thicknesses were 0.81 ± 0.21 mm, 0.47 ± 
0.13 mm, and 1.06 ± 0.29 mm in the control, fibrin, and 
CoNS groups, respectively. Capsular thickness was not 
Figure 1. Pressure-volume curves. Note the significant 
difference in intracapsular pressure in the fibrin group. 
CoNS, coagulase-negative staphylococci.
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statistically homogeneous across the three groups (p ≤ 
.001). Three subsets of similar means were found after 
applying post hoc range tests: the first one comprised the 
fibrin group (with the thinnest capsule), the second com-
prised the control group, and the third comprised the 
CoNS group (with the thickest capsule). CHAID statistical 
modeling showed a correlation between intracapsular 
pressure measured at 20 mL and thickness for the control 
and the fibrin groups (Figure 2). Decreased intracapsular 
pressure was associated with thinner capsules for both 
groups, and the converse was also true.
A mixed type of inflammatory cells was the most com-
mon finding in the control and fibrin groups, but in the 
CoNS group, the polymorph type of inflammatory cells 
was predominant (Table 1). For types of cells, significant 
differences were observed between the control and CoNS 
groups (p = .0001), as well as between the CoNS and 
fibrin groups (p = .0009), but not between the control and 
the fibrin groups. Intensity of inflammation was moderate 
in the control and fibrin groups and mild in the CoNS 
group (Table 1). Significant differences were also found 
with regard to inflammatory intensity between the control 
and CoNS groups (p = .011), as well as between the CoNS 
and the fibrin groups (p = .0058), but not between the 
control and the fibrin groups. Significant correlations 
between the intensity of inflammation and the type of 
inflammatory cells were observed for the control (p = 
.005) and the fibrin (p = .006) groups.
Fibrosis was detected in all capsules; no significant dif-
ferences regarding the fusiform cell density were observed 
in any of the groups. With regard to connective tissue, 
significant differences were found between the control and 
fibrin groups (p = .005) and between the CoNS and fibrin 
groups (p = .0007), with dense (>25%) connective tissue 
in the control and the CoNS groups and ≤25% connective 
tissue in the fibrin group.
Significant differences in the organization of the colla-
gen fibers were observed between the control and fibrin 
groups (p = .019) and between the CoNS and fibrin 
groups (p = .0039), with haphazard collagen fibers in the 
control and CoNS groups and fibers arrayed in parallel in 
the fibrin group. Significant differences in angiogenesis 
were found between the control and fibrin groups (p = .003) 
and between the CoNS and the fibrin groups (p = .016), 
with moderate/high in the control and CoNS groups and 
negative/mild in the fibrin group.
Microbiology
Bacteria were isolated in 31% (19 of 62) of the removed 
capsules and in 84% (56 of 62) of the removed implants 
(Table 2). The predominant isolates were CoNS, which 
were found in 16% of all culture-positive capsules (10 
of 62) and in 60% of culture-positive implants (37 of 
62). Overall, 97% of culture-positive capsules and 90% 
of culture-positive implants yielded a single isolate, 
whereas 3% and 10% (respectively) yielded two. No 
bacteria were detected on 69% of the removed capsules 
and on 16% of the removed implants. No fungi were 
recovered from the removed capsules or implants among 
all groups.
Statistical analysis revealed no significant differences 
in the type of bacteria or in the frequency of culture 
positivity among the study groups. Also, there was no 
significant association between microbial presence and 
histological data.
PRESSURE
≤ 173: 12 (60%)
>173: 8 (40%)
≤ 0.8 mm
≤ 173: 12 (80%)
> 173: 3 (20%)
> 0.8 mm
≤ 173: 0 (0%)
> 173: 5 (100%)
THICKNESS p < 0.002
PRESSURE
≥140: 14 (63.6%)
<140: 8 (36.4%)
≤0.5 mm
≥140: 12 (85.7%)
<140: 2 (14.3%)  
>0.5 mm
≥140: 2 (25%)
<140: 6 (75%) 
THICKNESS p < 0.004  
A B
Figure 2. Decision tree by Chi-squared Automatic Interaction Detection (CHAID) algorithm for pressure and thickness. (a) 
Control group and (b) fibrin group.
Table 1. Outcomes for Capsule Inflammation in Control vs Experimental 
Groups
Group
Type of  
Inflammatory Cells % Intensity %
Control Mononuclear 25.0 Mild 30.0
Polymorph 0 Moderate 70.0
Mixed 75.0 High 0
Fibrin Mononuclear 13.6 Mild 31.8
Polymorph 13.6 Moderate 59.1
Mixed 72.8 High 9.1
CoNS Mononuclear 35.0 Mild 70.0
Polymorph 50.0 Moderate 30.0
Mixed 15.0 High 0
CoNS, coagulase-negative Staphylococci.
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Similar bacteria were isolated from the rabbit skin. The 
predominant isolates were CoNS, which was found in 37 of 
all 45 sacrificed rabbits (82%), followed by gram-positive 
bacilli (60%), S. aureus (33%), and Micrococcus spp. (9%). 
Other isolates found were Enterococcus hermannii and 
Proteus mirabilis, although all occurred much less frequently 
than the others listed previously. No skin sample was culture 
negative; 35 samples yielded more than one isolate. The 
bacterial isolates from rabbit skin were similar to those from 
the removed capsules and implants. Finally, CoNS were also 
cultured from all of the air samples; other airborne isolates 
were gram-positive and gram-negative bacilli such as Micro-
coccus spp., Cryptococcus laurentii, Acinetobacter lwoffii, and 
Enterococcus agglomerans. Fungal species such as Penicillium 
spp., Aspergillus niger, Aspergillus flavus, and Aspergillus 
fumigatus were recovered from the operating room air, with 
Penicillium being the most common fungal isolate.
In the CoNS group, one animal developed a Baker 
grade IV contracture44 in one breast implant (Figure 3a). 
The capsular thickness measured 1.70 mm and was the 
largest among all capsules (Figure 3b). The type of inflam-
matory cells was polymorphous, with moderate intensity. 
Histological evaluation of fibrosis revealed 25% to 50% 
connective tissue density, haphazard collagen fibers, and 
moderate angiogenesis. The capsule and breast implant 
were both infected with a Micrococcus spp. isolate; no 
other bacteria or fungi were detected.
discussion
Significant results were demonstrated in each of our exper-
imental groups. In the fibrin group, the data showed sig-
nificantly decreased intracapsular pressures and capsular 
thicknesses without any capsule rupture, as compared to 
the control and CoNS groups. For the fibrin and control 
groups, decreased intracapsular pressures were correlated 
with thinner capsules. In terms of inflammation, mixed-
type inflammatory cells were the most common finding for 
both fibrin and control groups. In the fibrin group, ≤25% 
connective tissue density was observed, as compared to the 
control and the CoNS groups, which had >25% connective 
tissue density. In the fibrin group, negative/mild angiogen-
esis was observed; the control and the CoNS groups had 
moderate/high angiogenesis. No significant differences 
Table 2. Bacteria Isolated From Capsule and Implant Samples Removed 
From All Sacrificed Rabbitsa
Number (%) of Positive Cultures
Bacteria Groupb Capsules Implants
Coagulase-
negative 
staphylococci 
(CoNS)
Control 2 (10) 13 (65)
Fibrin 2 (9) 9 (41)
CoNS 6 (30) 15 (75)
Staphylococcus 
aureus
Control 2 (10) 2 (10)
Fibrin 1 (5) 7 (32)
CoNS 0 (0) 2 (10)
Bacillus gram-
positive
Control 1 (15) 1 (5)
Fibrin 3 (14) 4 (18)
CoNS 0 (0) 2 (10)
Micrococcus spp. Control 0 (0) 0 (0)
Fibrin 0 (0) 0 (0)
CoNS 2 (10) 1 (5)
aSixty-two capsule samples and 62 implant samples were obtained from 31 rabbits.
bControl (10 rabbits; 20 capsules and 20 implants), fibrin (11 rabbits; 22 capsules and 22 
implants), and CoNS (10 rabbits; 20 capsules and 20 implants).
Figure 3. (a) The one case of capsular contracture (Baker grade IV) is shown. (b) An extremely thick and opaque capsule was 
evident in the implant associated with the contracture.
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regarding fusiform cell density were observed between the 
fibrin and control groups.
In the CoNS experimental group, capsular thickness 
was increased as compared to the control. Polymorph-type 
inflammatory cells were the most common observation in 
the CoNS group, which was significantly different from 
the control group. Regarding fusiform cell density, connec-
tive tissue characteristics, organization of the collagen 
fibers, and angiogenesis, similar results were observed for 
both CoNS and control groups.
Similar bacterial isolates were observed among all the 
study groups for both implants and capsules. Implants were 
2.7 times more frequently infected than capsules. The pre-
dominant isolates were CoNS, which were present 3.8 times 
more frequently in implants than in capsules. There was no 
significant association between microbial presence and histo-
logical data. Bacteria isolates from rabbit skin were similar to 
those isolated from capsules and implants. As expected, the 
predominant isolate in rabbit skin, as in implants and cap-
sules, was CoNS. Unexpectedly, Micrococcus spp. was iso-
lated from rabbit skin specimens, operating room air samples, 
and one rabbit; in that specific rabbit, Micrococcus spp. was 
detected on the capsule but not on the implant surface, and 
this capsule did not develop CC. Interestingly, on the contral-
ateral implant in the same rabbit, a Micrococcus spp. isolate 
was detected on both the implant surface and the capsule, 
which demonstrated a Baker grade IV contracture.44 To the 
best of our knowledge, this is the first report that shows a 
direct association between the presence of Micrococcus spp. 
and clinical CC in a rabbit model. Fungi were isolated from 
the operating room air samples but not from the rabbit skin, 
capsules, or implants. As far as we know, this is also the first 
report examining microbial cross-contamination among air, 
rabbit skin, capsules, and implants.
Our results support the probable role of fibrin as an 
agent that may modify capsule formation and mitigate 
subsequent CC since it is associated with decreased cap-
sule thickness and pressure, ≤25% connective tissue den-
sity, and negative/mild angiogenesis. The decreased 
intracapsular pressure and thinner capsules were also con-
sistent with other clinical reports of CC.42,45-47 The relation-
ship of CC to dense collagen and increased angiogenesis 
has already been demonstrated in other reports45,48,49; this 
was also found in our control and CoNS groups. The rela-
tionship between the organization of the collagen fibers 
(parallel or haphazard) and CC is controversial; our results 
are similar to a study from Karaçal et al.47
The cytokine-transforming growth factor beta 1 (TGF-
β1) is a central mediator of fibrosis.50-52 Some reports have 
focused on fibrin’s properties for enhanced wound healing 
through the reduction of collagen extracellular matrix and 
decreased TGF-β1.53-56 The TGF-β1-inhibitor peptide was 
shown to be significantly effective in achieving a reduction 
in fibrosis in silicone breast implants.57 The use of fibrin-
containing preparations (Tisseel and Vi-Guard, Melville 
Biologics, Inc, Melville, New York) allows for the closure of 
dead space and approximation of the skin flaps, and it has 
been argued that fibrin-containing tissue adhesives produce 
a dense architecture that inhibits angiogenesis and vascu-
lar ingrowth.58 To the best of our knowledge, this is the 
first preclinical study with a commercial fibrin compound 
(Tissucol/Tisseel) applied to a textured silicone breast 
implant.
According to our results, bacterial infection of breast 
implants was more common than capsule infection, and the 
predominant isolates were CoNS. This is consistent with the 
fact that CoNS, a commensal bacteria of the skin, is the pre-
dominant cause of biomaterial-associated infection, com-
monly mediated by formation of biofilms.18-21,59,60 The major 
pathogenicity is related to extensive biofilm formation on 
solid surfaces, which is extremely difficult to treat with anti-
biotics, thereby necessitating invasive procedures to remove 
the infected tissue or devices.61-63 A strong correlation 
between the presence of biofilm (particularly by S. epider-
midis) and significant CC was reported by Pajkos et al.22 
They assumed that biofilm on the outer surface of the 
implant, once established, acts as a focus of irritation and 
chronic inflammation, leading to accelerated CC.22 However, 
our results are contradictory to that report.22 In the Pajkos et 
al22 study, the rate of recovery from bacteria from the implant 
surface was lower than the rate of recovery from the capsule 
surface, but the authors explain that there was a greater sen-
sitivity in detecting bacterial growth on capsules.
The Baker grade IV contracture in our study, which 
occurred in the implant with the thickest capsule, was 
unusual in that contracture developed quickly with an 
acute inflammation. Unexpectedly, both the capsule and 
implant were infected only with Micrococcus spp., a low 
pathogenic agent. As far as we know, there are few reports 
concluding that Micrococcus spp. may have a true etiologic 
role in infection64 or that it is mediated by formation of 
bacterial biofilms.65,66
Our fibrin results are contradictory to one of our previ-
ous reports39 but consistent with our previous preclinical 
study.40 This may be explained by the product we applied. 
In the first study,39 we applied an autologous fibrin glue of 
unknown fibrin concentration into the implant pocket; in 
the current experimental design and the previous preclini-
cal study,40 we sprayed a commercial fibrin product widely 
studied and used in clinical practice in Europe and the 
United States to reduce polypropylene meshes adhe-
sions,67,68 the incidence of posterior spinal epidural adhe-
sion formation,30 and the recurrence rate of pterygium 
after surgery.36 Another explanation may lie in the applica-
tion mechanism (manual with a syringe in the first study 
vs sprayed in the latter two). A previous study found that 
a thin layer of glue is preferable to a thick one69; a thin 
layer of fibrin glue (such as would occur with a spray) 
may support the healing process, whereas a thick layer of 
adhesive inhibits skin graft healing.70 Also, in this study, 
capsule pressure was measured directly in the tissue 
expanders to achieve more accurate results.47
Fibrin glue has been shown to act as an hemostatic 
agent,71 an agent for enhanced wound healing by the 
reduction of collagen extracellular matrix and decreased 
TGF-β1 (a mediator of fibrosis),53-56 an agent for adhesion 
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prevention,67,68 a widely used ophthalmology tool,31-36 and 
a drug delivery system for antibiotics.72 Fibrin glue was 
also specifically tested in a clinical model as a drug deliv-
ery system following breast augmentation.38 Our preclini-
cal animal model results also show it to be a promising 
agent for the prevention of CC.
The limitation of this study was the insertion of only one 
tissue expander per rabbit, which allowed for direct intercap-
sular pressure measurement through the port. To correlate 
intracapsular pressure from tissue expanders with histologi-
cal and microbiological results from breast implants, we 
performed statistical analyses that revealed no significant dif-
ferences in histological and microbiological results between 
breast implants and tissue expanders. It would have been 
better to measure the pressure directly through 90-cc silicone 
breast implants with ports to achieve more accurate results, 
but these are not commercially available. One strength of this 
study was the statistical analyses of the data among the three 
groups using the CHAID method, a sophisticated algorithm 
used in many other disciplines that allows the investigator to 
adjust for the probability of a single variable among multiple 
variables.
Future studies include a prospective clinical study com-
paring a female control group with an experimental group 
that had Tissucol/Tisseel sprayed on the implant or 
pocket, with a follow-up period longer than 42 months.73 
A preclinical study analyzing S. epidermidis and 
Micrococcus spp. biofilm development in silicone breast 
implants where the ports have been sprayed with Tissucol/
Tisseel and infected with bacteria would also be helpful.
conclusions
The results from this preclinical rabbit model suggest 
that fibrin applied to the breast implant pocket may 
reduce capsular contracture. Since their relatively safe 
profile has been well established, fibrin-containing 
compounds are therefore an attractive adjunct for use in 
women undergoing breast augmentation. Clinical strate-
gies for preventing bacterial contamination during sur-
gery are crucial, as low pathogenic agents may promote 
capsular contracture.
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Abstract
Background: The mechanism(s) responsible for breast capsular contracture (CC) remain unknown, but inflammatory pathways play a role. Various 
molecules have been attached to implant shells in the hope of modifying or preventing CC. The intrinsic antibacterial and antifungal activities of chitosan 
and related oligochitosan molecules lend themselves well to the study of the infectious hypothesis; chitosan’s ability to bind to growth factors, its 
hemostatic action, and its ability to activate macrophages, cause cytokine stimulation, and increase the production of transforming growth factor (TGF)–β1 
allow study of the hypertrophic scar hypothesis.
Objective: The authors perform a comprehensive evaluation, in a rabbit model, of the relationship between CC and histological, microbiological, and 
immunological characteristics in the presence of a chitooligosaccharide (COS) mixture and a low molecular weight chitosan (LMWC).
Methods: Eleven adult New Zealand rabbits were each implanted with three silicone implants: a control implant, one impregnated with COS, and one 
impregnated with LMWC. At four-week sacrifice, microdialysates were obtained in the capsule-implant interfaces for tumor necrosis factor alpha (TNF-α) 
and interleukin-8 (IL-8) level assessment. Histological and microbiological analyses were performed.
Results: Baker grade III/IV contractures were observed in the LMWC group, with thick capsules, dense connective tissue, and decreased IL-8 levels 
(p < .05) compared to control and COS groups. Capsule tissue bacterial types and microdialysate TNF-α levels were similar among all groups.
Conclusions: Chitosan-associated silicone implantation in a rabbit model resulted in Baker grade III/IV CC. This preclinical study may provide a model 
to test various mechanistic hypotheses of breast capsule formation and subsequent CC.
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breast implants, capsular contracture, chitosan, microdialysis, histology, microbiology, immunology
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The true etiology of breast capsular contracture (CC) asso-
ciated with implant devices, along with the most appropri-
ate course of treatment, remains elusive despite extensive 
study. Two prevailing theories have emerged in the litera-
ture1-18: the infectious hypothesis and the hypertrophic 
scar hypothesis. As a solution, various molecules have 
been applied to implant shells in the hope of modifying or 
preventing CC. Chitin, the polymer D-glucosamine in β 
(1,4) linkage, is the major component of the exoskeletons 
of crustaceous and cell wall fungi.19 Chitosan is a 
deacetylated product of chitin. In the literature, the term 
chitosan is used to describe chitosan polymers with differ-
ent molecular weights (50-2000 kDa), viscosities, and 
degrees of deacetylation (40%-98%).20 Material with lower 
levels of deacetylation degrades more rapidly.21-23 Chitosan 
has been a better-researched version of the biopolymer 
because of its ready solubility in dilute acids, which makes 
it more accessible for utilization and chemical reactions.24 
Chitooligosaccharides (COS) are degraded products of chi-
tosan, or the deacetylated and degraded products of chitin, 
by chemical and enzymatic hydrolysis.
Chitosan and related oligochitosan molecules have 
intrinsic antibacterial and antifungal activities25-28 that 
lend themselves well to the study of the infectious hypoth-
esis. Furthermore, chitosan’s ability to bind to growth fac-
tors,29,30 its hemostatic action,31 and its ability to activate 
macrophages, cause cytokine stimulation,31 and increase 
the production of transforming growth factor (TGF)–β132 
permit study of the hypertrophic scar hypothesis.
Data from a study by Khor and Lim,24 which included 
cell cultures and an animal model, indicated that chitin and 
chitosan processed in different shapes and in combination 
with different materials were noncytotoxic. The authors sug-
gested that inclusion of these materials might yield tissue- 
engineered implants that would be biocompatible and viable. 
These attributes make chitosan a promising biopolymer for 
modulating wound healing (full-thickness skin defects and 
dermal burns)26,29,33 and for use in orthopedics (cartilage, 
anterior cruciate ligament, intervertebral disk, bone, osteo-
myelitis)28,34 and otologic diseases (tympanoplasty).35
Fibrosis is a major global health problem, but its etiology, 
pathogenesis, diagnosis, and therapy have yet to be addressed. 
Fibrosis can occur as a consequence of many pathologic 
conditions: (1) spontaneously (keloids, Dupuytren’s contrac-
ture), (2) from tissue damage (postoperative adhesions, 
burns, alcoholic and postinfection liver fibrosis, silica dust, 
asbestos, antibiotic bleomycin), (3) as a result of inflamma-
tory disease (infections, scleroderma), (4) in response to 
foreign implants (breast implant capsular contracture, cardiac 
pacemakers), and (5) from tumors (fibromas, neurofibroma-
tosis). The early stages of fibrotic conditions are character-
ized by a perivascular infiltration of mononuclear cells and 
the subsequent imbalance of anti- and profibrotic cytokine 
profiles. One of the most prominent activators of mononu-
clear cells and fibroblasts is hyaluron fragments, which not 
only induce the expression of various cytokines (interleukin 
[IL]–1, IL-12, and tumor necrosis factor alpha [TNF-α]), 
chemokines (MPI-1A, MCP-1, IL-8), and inducible nitric 
oxide synthase (iNOS) but also trigger the expression and 
secretion of macrophage-derived matrix metalloproteinases 
(MMP), enzymes essential for extracellular matrix (ECM) 
cleavage.36 IL-8 is a neutrophil chemoattractant factor. Levels 
of IL-8 are increased in scleroderma skin biopsy specimens.37 
Cultured scleroderma dermal fibroblasts make more IL-8 
than normal fibroblasts. Studies in animal models of pulmo-
nary fibrosis have shown the importance of chemokines in 
promoting angiogenesis, which is necessary for the develop-
ment of pulmonary fibrosis.
Clues about the potential role of IL-8 in fibrosis come 
from studies of patients with idiopathic pulmonary fibro-
sis.38 A low concentration of TNF-α increases fibroblast 
proliferation, whereas high TNF-α concentration decreases 
fibroblast proliferation.39 However, TNF-α levels are mark-
edly elevated in liver fibrosis, considered a profibrinogenic 
cytokine such as TGF-β1.40 The immune inflammatory 
response and macrophage release of IL-8 and TNF-α 
induced by phagocytosis of periprosthetic wear debris 
stimulate bone reabsorption at implant or cement-bone 
interface. These cytokines directly induce fibroblast prolif-
eration and tissue necrosis. Increased concentrations of 
IL-8 and TNF-α in the peripheral circulation of patients 
with large joint prostheses would indicate aseptic loosen-
ing.41 As far as we know, there are no reports correlating 
capsule formation or CC with TNF-α and IL-8 levels. For 
all of these reasons, we believe that studying the role of 
these markers in capsule formation is important to the 
literature.
Microdialysis enables measurement of the molecules in 
the extracellular fluid around the capsule. Originally initi-
ated more than 30 years ago,42 microdialysis studies in 
humans have been mainly limited to head injury,43-46 sub-
arachnoid hemorrhage,47 epilepsy,48 and cerebral tumors.49,50 
IL-8 and TNF-α are known major biomarkers for inflamma-
tion,51-53 which can be examined through microdialysis. To 
date, no preclinical model has been reported to assess pos-
sible environmental challenges that may prevent or modu-
late the wound-healing response with chitosan and related 
oligochitosan molecules associated with silicone implants. 
Therefore, we performed a comprehensive evaluation, in a 
rabbit model, of the relationships among CC rates and his-
tological, microbiological, and immunological characteris-
tics in the presence of COS mixtures and low molecular 
weight chitosan (LMWC). To monitor levels of inflamma-
tory biomarkers in the breast capsule extracellular fluid, 
IL-8 and TNF-α were determined with the microdialysis 
technique.
Methods
Eleven New Zealand white female rabbits (3-4 kg) were 
each implanted with three different textured breast 
implants, according to an approved institutional animal 
care protocol. The implants were each 90 cc and were 
provided by Allergan, Inc. (Santa Barbara, CA). Prior to 
surgery, the skin of each rabbit was washed with Betadine 
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surgical scrub (Purdue Pharma LP, Stamford, Connecticut) 
that contained 7.5% povidone-iodine, and their skin was 
disinfected with Betadine solution that contained 10% 
povidone-iodine. The surgical procedure was performed in 
an animal operating theater following aseptic rules. 
Penicillin G 40,000 U/kg intramuscularly (IM) was admin-
istered intraoperatively. Talc-free gloves were used at all 
times during the procedure.
Implant pockets were developed in the subpanniculus 
carnosis along the back region, with atraumatic dissection. 
Under direct vision, particular attention was paid to 
hemostasis, avoiding blunt instrumentation; there was no 
obvious bleeding. A sterile dressing was placed over the 
skin around the incision before the tissue expander and 
the implants were inserted to eliminate contact with the 
skin.54 A new pair of talc-free gloves was worn when 
inserting the tissue expander and implants.
Each implant was placed beneath the panniculus carno-
sis along the back (Figure 1A). Each rabbit received an 
untreated implant (control), an implant impregnated with 
COS (molecular weight [MW] 1.4 kDa; Nicechem, 
Shanghai, China), and an implant impregnated with 
LMWC (MW 107 kDa; Sigma-Aldrich, Sintra, Portugal). 
Both chitosan mixtures possessed a deacetylation degree 
in the range of 80% to 85%. Implants were prepared by 
immersion in either COS (20.0 mg/mL) or LMWC (10.0 
mg/mL) solutions with pH adjusted to 5.8 to 5.9 for two 
hours. Implants were incubated at 37 °C in a flow cham-
ber for two days, then packed and sterilized by ethylene 
oxide.
Rabbits were sacrificed at four weeks. Prior to sacrifice, 
each animal was anesthetized, and a 5-mm incision was 
made directly over the implant, through the skin, panniculus 
carnosus, and capsule. A 100,000-MW cutoff microdialysis 
probe (CMA Microdialysis, Stockholm, Sweden) was placed 
by the capsule-implant interface, and microdialysates were 
collected with sterile, normal saline solution (6 µL/min) 
for one hour. Whole blood was obtained by venipuncture, 
Figure 1. (A) Rabbit is shown with control implant, chitooligosaccharide (COS) implant, and chitosan implant (contracture 
grade IV). (B) The chitosan implant is pictured. Baker Grade IV contracture is evident. (C) The chitosan implant’s extremely 
thick, dense, and opaque capsule can be seen. (D) Hematoxylin and eosin stain of the chitosan implant, at ×100 magnification, 
with apoptotic cells. These cells have hyperchromatic and fragmented nuclei.
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and serum was collected after centrifugation (2000 g 
min−1, 4 °C). Capsule samples were submitted to histo-
logical and microbiological evaluations.
Microbiological Assessments
Air. Operating room air samples (n = 20) were collected 
during all surgical procedures with the MAS 100-Eco air 
sampler (EMD Chemicals, Inc., Gibbstown, New Jersey) at a 
flow rate of 100 L/min. Identification of bacterial and fungal 
isolates followed standard microbiological procedures. Gram-
positive cocci were characterized by biochemical methods. 
Catalase-positive and coagulase-positive isolates were reported 
as Staphylococcus aureus; catalase-positive and coagulase-
negative isolates were reported as coagulase-negative 
staphylococci. Gram-negative bacilli were characterized with 
Vitek 2 software (VT2-R04.02; bioMérieux, Inc., Durham, 
North Carolina). Fungi (molds) were characterized according 
to their macroscopic and microscopic morphology.
Rabbit skin. A total of 33 contact plates (11 brain-heart 
agar, 11 mannitol salt agar, and 11 Sabouraud agar contact 
plates) were pressed to the shaved dorsal skin surfaces. 
Brain-heart and mannitol salt agar plates were incubated 
for three days at 28°C; Sabouraud plates were incubated 
for seven days at 28°C. Bacterial and fungal colonies were 
counted and reported as cfu/cm2. The identification of the 
bacteria and fungi followed the procedures reported above.
Capsules and implants. Excised implants and representa-
tive capsule samples were incubated at 37°C for three days 
in brain-heart broth and examined daily; changes in turbid-
ity of the broth media were considered positive and were 
subcultured in solid agar media. Characterization of micro-
bial isolates followed the procedures described above.
Histological Assessment
Capsule specimens were fixed with 10% buffered formalin 
and embedded in paraffin. Sections were stained with 
hematoxylin and eosin and evaluated histologically for tis-
sue inflammation and capsular thickness. Inflammatory 
cells were grouped into three categories by type: (1) 
mononuclear (lymphocytes, plasmocytes, and histiocytes), 
(2) mixed (mononuclear cells and eosinophils), or (3) 
polymorph (eosinophils and heterophils/neutrophils). 
Inflammatory infiltrate intensity was categorized accord-
ing to the following criteria: absent (−), mild (+), moder-
ate (++) , or severe (+++).55
Samples were stained with Masson’s trichrome56,57 to 
characterize the organization of the collagen fibers 
(arranged in a parallel array or haphazard), angiogenesis 
(absent, mild, moderate, or high), and fusiform cell den-
sity (mild, moderate, or high). The dense connective tis-
sue was semiquantitatively analyzed as (a) less than 25%, 
with thick collagen bundles less than 25%; (b) 25% to 
50%; (c) 51% to 75%; or (d)  more than 75%.
Histological sections were reviewed and graded by a 
pathologist blinded to the protocol.
Microdialysis Assessment
TNF-α levels were determined with the manufacturer’s 
instructions from a commercial kit (Invitrogen, Hu TNF-α 
cat. no. KHC3014:1; Life Technologies, Inc., Carlsbad, 
California). The assay was a solid-phase sandwich enzyme-
linked immunosorbent assay (ELISA) in which 100 µL of 
microdialysis fluid was pipetted into each well. The proto-
col for IL-8 was performed with the BioSource Hu IL-8 US 
kit (cat. no. KHC0083/KHC0084; Life Technologies, Inc.).
Statistical Analysis
Data were grouped according to the type of product 
applied to the implant: control (none), COS, and LMWC 
(chitosan). Group data were also analyzed separately for 
the 11 sacrificed rabbits at four weeks after surgery. A two-
tailed paired t-test and the nonparametric alternative 
Wilcoxon signed rank tests were applied to determine 
whether continuous variables (histologically measured 
thickness and dialysate levels of IL-8 and TNF-α) were 
significantly different among control and experimental 
groups. Categorical variables were evaluated by chi-square 
statistics and by phi, Cramer’s V, and contingency coeffi-
cient tests. Statistical significance was presumed at p ≤ .05. 
Major trends within each group were further examined by 
the chi-squared automatic interaction detection (CHAID) 
method,58 using the likelihood ratio chi-square statistic as 
growing criteria, along with a Bonferroni 0.05 adjustment 
of probabilities. All analyses were carried out with the 
Statistical Package for Social Sciences Version 17 software 
(SPSS, Inc., an IBM Company, Chicago, Illinois).
Results
Clinical
In the control group, one of the 11 implants was ulcerated; 
none had developed clinical CC. In the COS group, three of 
the 11 implants were ulcerated, and no cases of CC were 
observed. The chitosan group had one ulcerated implant, 
and all 11 implants had developed Baker grade III/IV capsu-
lar contracture (Figure 1B). All chitosan group capsules were 
extremely thick, opaque, stiff, and resistant to cutting (Figure 
1C). They were constricted, and surface folding was observed.
Histology
The average capsular thickness was 0.418 ± 0.160 mm in 
the control group, 0.6364 ± 0.216 mm in the COS group, 
and 2.746 ± 0.817 mm in the chitosan group. Capsular 
thicknesses were found to be statistically different among 
the three groups: capsular thicknesses from the control 
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group were different from both the COS group (p = .035) 
and the chitosan group (p = .003); capsular thicknesses 
were also different between the COS and chitosan groups 
(p = .003). No significant differences were observed 
regarding the type of inflammatory cells or the intensity of 
capsule inflammation among the groups (Table 1).
Apoptotic cells and necrosis (Figure 1D) were observed 
strongly in the chitosan group. Fibrosis was a component of 
all capsules, and no significant difference was found regard-
ing the organization of collagen fibers, fusiform cell density, 
or angiogenesis among all groups. Regarding the characteris-
tics of connective tissues (either loose or dense), significant 
differences were found between the control and the chitosan 
groups (p = .001). The control group had less than 25% 
density of connective tissue, and the chitosan group had 
more than 25% dense connective tissue.
Microbiology
Bacteria were isolated from 36.4% (12 of 33) of the cap-
sules and from 78.8% (26 of 33) of the implants. The 
organisms cultured (Table 2) included coagulase-negative 
staphylococci, S. aureus, gram-negative bacilli, and 
Enterococcus spp. Among capsules that yielded bacteria, 
11 of 12 harbored coagulase-negative staphylococci 
(91.7%); enterococci were associated with one capsule 
(8.3%). The same trend was observed in excised implants. 
In 20 of 26 implants that yielded bacteria, coagulase-neg-
ative staphylococci were cultured from 76.9%, and 
Enterococcus spp. was associated with one capsule (3.8%). 
In contrast to the capsules, four of 26 bacteria-contaminated 
implants harbored gram-negative bacilli (15.4%), and one 
of 26 demonstrated evidence of S. aureus (3.8%).
Overall, 39.4% (13 of 33) and 63.6% (21 of 33) of 
culture-positive capsules and implants, respectively, 
yielded a single isolate; 0% (zero of 33) and 9.1% (three 
of 33) yielded more than one. No fungi were recovered 
from either capsules or implants.
No significant differences in the frequency of culture 
positivity or the type of bacterial isolates were observed 
among all study groups, nor was any significant associa-
tion between microbial presence and histological data 
observed.
With regard to skin isolates, the predominant isolate 
was again coagulase-negative staphylococci, which were 
formed in all rabbits. Bacterial isolates from skin were 
similar to those from capsules and implants. Coagulase-
negative staphylococci and gram-positive bacilli were 
isolated from all operating room air samples, along with 
Penicillium spp. and Aspergillus spp.
Immunology
Interstitial fluid of IL-8 levels decreased to the following: 
89.4 ± 26.7 mg/mL in the control group, 78.3 ± 32.7 mg/
mL in the COS group, and 66.8 ± 17.9 mg/mL in the chi-
tosan group. Significant differences were observed in IL-8 
levels between the control and chitosan groups (p = 
.028).
Levels of TNF-α decreased to the following: 143.9 ± 
123.8 mg/mL in the control group, 96.8 ± 38.5 mg/mL in 
the COS group, and 81.5 ± 31.8 mg/mL in the chitosan 
group. Statistical analysis revealed no significant differ-
ences in the dialysate levels of TNF-α among all groups. 
There was a correlation between IL-8 and TNF-α in the 
Table 1. Outcomes for Capsule Inflammation of Control Versus 
Experimental Groups
Group
Type of Inflammatory 
Cells % Intensity %
Control Mononuclear 9.1 Mild 72.7
Polymorph 36.4 Moderate 27.3
Mixed 54.5 High 0.0
Chitooligosaccharide Mononuclear 9.1 Mild 54.5
Polymorph 27.3 Moderate 45.5
Mixed 63.6 High 0.0
Chitosan Mononuclear 0.0 Mild 36.4
Polymorph 45.5 Moderate 63.6
Mixed 54.5 High 0.0
Table 2. Bacteria Isolated From Capsule and Implant Samples Removed 
From All Sacrificed Rabbits
Number (%) of Positive Cultures
Bacteria Capsules Implants
Coagulase-negative staphylococci Control 4 (36.4) 9 (81.8)
COS 5 (45.5) 8 (72.7)
Chitosan 2 (18.2) 3 (27.3)
Staphylococcus aureus Control 0 (0) 0 (0)
COS 0 (0) 1 (9.1)
Chitosan 0 (0) 0 (0)
Bacillus gram-negative Control 0 (0) 2 (18.2)
COS 0 (0) 1 (9.1)
Chitosan 0 (0) 1 (9.1)
Enterococcus Control 0 (0) 1 (9.1)
COS 1 (9.1) 0 (0)
Chitosan 0 (10) 0 (0)
COS, chitooligosaccharide.
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control group (p < .001) but not in the COS group (p = 
.073) or the chitosan group (p = .099).
discussion
In this study, we report on the development of CC in a 
rabbit model associated with chitosan. All chitosan group 
implants demonstrated clinical Baker grade III/IV breast 
contractures with significantly thicker capsules than non-
treated implants. Chitosan-exposed capsules were opaque, 
stiff, and resistant to cutting, and considerable shrinkage 
and folding of the implant surfaces were observed. These 
characteristics may indicate the constricting nature of 
fibrous implant capsules. Control (untreated) capsules 
demonstrated thin capsule thicknesses, and the connec-
tive tissue had less than 25% dense tissue, compared to 
the more than 25% dense connective tissue observed with 
the LMWC-exposed capsules. This is consistent with the 
fact that the major component of chitosan, glucosamine, 
forms in cartilage tissue and is also present in tendons and 
ligaments.59
The collagenous layer of granulation tissue is increased 
with chitosan application; according to this finding, chi-
tosan may stimulate fibroblast proliferation and extracel-
lular matrix production.60 Chitosan has been shown to 
induce an accelerated wound-healing process that did 
increase TGF-β1, which had several proinflammatory reg-
ulatory influences such as cell migration, granulation tis-
sue formation, and increased collagen production32 and 
was a central mediator of fibrosis.61
A mixed/polymorph type of inflammatory cells was the 
most common finding in all rabbit capsules, and inflam-
mation was moderate/mild in all capsules. This finding 
was expected, as chitosan is a chemoattractant for neu-
trophils.28,62 Chitosan enhanced the function of inflamma-
tory cells such as polymorphonuclear leukocytes (PMN), 
macrophages, fibroblasts (production of IL-8), angioen-
dothelial cells,60 and had a systemic effect.63 Apoptotic 
cells and necrosis were observed strongly in chitosan 
implants, consistent with other reports.64,65
Statistical analyses revealed no significant differences 
in the frequency of culture positivity and bacteria type 
among the groups. Interestingly, no significant associa-
tions between microbial presence and histological data 
were observed in any group. Similar bacterial isolates 
were cultured from the rabbit skin and air samples, and 
the predominant isolates were coagulase-negative staphy-
lococci. The antimicrobial activity of chitosan and its 
derivatives against several bacterial species has been rec-
ognized and considered one of the most important proper-
ties linked directly to their possible biological 
applications25-28; however, recent studies investigating chi-
tosan as a delivery method for drugs such as antibiot-
ics66-69 questioned the high efficacy of chitosan alone as an 
antibacterial agent. This study supports the idea that CC 
formation is not the result of bacterial infection alone, in 
contrast to the infectious hypothesis that has been cham-
pioned and consistently supported by Burkhardt et al.1,3,70
To gain insight into the inflammatory process, major 
biomarkers TNF-α and IL-8 were measured. This is the 
first report examining extracellular levels of IL-8 and TNF-α 
in a breast capsule implant environment. Microdialysate 
levels of IL-8 were decreased (p < .05) in the chitosan 
group as compared to the control group. No significant 
differences in the microdialysate levels of TNF-α were 
observed among the groups. In the control group, a correla-
tion between IL-8 and TNF-α was observed; no significant 
correlation between IL-8 and TNF-α levels was observed 
in the experimental groups.
We originally hypothesized that serum concentrations 
of the inflammatory mediators would be significantly 
increased in the chitosan group due to the expected 
greater inflammatory response with chitosan, as this mol-
ecule promotes the production of IL-8.60 The actual data 
results did not support our hypothesis but were consistent 
with a study from Tilg et al,71 who reported increased IL-8 
and TNF-α levels in bacterial infection and decreased IL-8 
and TNF-α levels in acute rejection. Interestingly, we 
found clinical Baker grade III/IV breast capsule contrac-
tures in all rabbits exposed to chitosan associated with 
acute (polymorph) and subacute (mixed) inflammation, 
not due to a bacterial infection.
Not all chitosan implants were infected, and IL-8 and 
TNF-α were decreased in the chitosan group. Molecular 
regulation of IL-8 production has been studied in vitro, 
and TNF-α has proven to be a major regulatory molecule. 
It is not surprising that in vivo IL-8 and TNF-α serum lev-
els were also significantly correlated in the control group. 
The correlation between IL-8 and TNF-α has been well 
established in the case of bacterial infection, less pro-
nounced in cytomegalovirus hepatitis, and not apparent in 
acute cellular liver rejection episodes. Lack of correlation 
in acute rejection was also associated with low levels of 
IL-8.71 This suggests that, in contrast to bacterial infection, 
countering cytokines may be active in CC (at least pro-
moted by chitosan), downregulating IL-8 transcription 
and/or translation.
So far, no reports exist on the production and regulation 
of IL-8 in CC. Recent studies have demonstrated that COS 
displayed anti-inflammatory properties in immunocytes, 
including the inhibition of nitric oxide, the downregula-
tion of IL-6 and TNF-α, and the increase of cell viability of 
neutrophils.72,73 Additionally, IL-8 was induced by a wide 
range of stimuli, including lipopolysaccharide (LPS), a 
component of the outer membrane of gram-negative bac-
teria and TNF-α. Lund et al74 concluded that LPS induced 
IL-8 release in monocytes, whereas TNF-α was a good 
inductor of IL-8 in PMN. In the chitosan contracture 
model, we found decreased levels of IL-8, and it was pos-
sible to conclude that there was no gram-negative bacteria 
infection to induce IL-8. On the other hand, chitosan 
increased the production of TGF-β1,32 a central mediator 
of fibrosis; the degree of CC is directly related to an 
increased level of TGF-β.55 Even with contradictory studies 
about the role of TNF-α, Morimoto et al75 concluded that 
TNF-α played a pivotal role in the maintenance of hemos-
tasis and tissue repair by inhibiting TGF-β1.
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Our data support the theory that chitosan initiates CC 
response due to a toxic local effect that results in an 
impaired wound-healing response. An earlier series of 
pilot studies were performed with much higher levels of 
chitosan (data not shown). Using a similar experimental 
protocol in the rabbit model, implants exposed to 25.0-
mg/mL levels were implanted. The majority of animals 
expired within a short time period; surviving animals had 
decreased weight (15%-25.8%) compared to baseline 
body weights, with leukocytosis and decreased hemo-
globin. At autopsy, fat biopsies were atrophied, and liver 
specimens had lymphoid infiltration in the portal spaces. 
We found toxicity with 25.0 mg/mL of implanted LMWC 
per rabbit. The study design was modified to test decreased 
chitosan levels that were not systemically toxic to the ani-
mals. In the reported data, all animals were clinically 
healthy. Literature data reporting general toxicity testing 
for chitosan are limited,31 and our results are consistent 
with the few studies about chitosan toxicity.60,63,76-78
In several important studies,15,79 each rabbit received dif-
ferent implants. Darouiche et al,15 with the objective of 
examining in vivo the antimicrobial efficacy of minocy-
cline/rifampin–impregnated saline-filled silicone implants, 
placed four implants in each rabbit (two antimicrobe-
impregnated and two control implants). Shah et al,79 who 
examined the infectious hypothesis in vivo, gave each rab-
bit a Staphylococcus epidermidis–contaminated implant and 
a control implant. Despite the fact that this type of protocol 
is well supported in the literature, due to the systemic influ-
ence of chitosan, the use of three different implants in the 
same rabbit in our study obviously had the potential to 
confound the results.
To clarify this issue, a control limb study was performed 
(data not shown) and compared with the control group 
from this study. Using a similar experimental protocol, 10 
rabbits were implanted with two textured breast implants. 
Interestingly, results from the control group in the main 
study showed a lower capsular thickness than the control 
limb group (0.81 ± 0.21 mm; p = .001). No significant dif-
ferences were observed regarding the intensity of inflamma-
tion, characteristics of connective tissue (either loose or 
dense), fusiform cell density, or angiogenesis between the 
groups. However, significant differences were observed 
with respect to the type of inflammatory cells, with a mixed 
type of inflammatory cells found in 54.5% of the control 
group in this study and mononuclear type of inflammatory 
cells found in 55.6% of the control limb group (p = .017). 
Significant differences were also observed in the organiza-
tion of the collagen fibers, which were arrayed in sequence 
in the control group of this study and haphazard in the 
control limb group (p = .007). Statistical analysis revealed 
no significant differences in the type or frequency of bacte-
ria between the control group of this study and the control 
limb group. Decreased levels of IL-8 (p = .016) and TNF-α 
(p = .001) were observed in the control group of this study 
when compared with the control limb group, which proves 
the systemic influence of chitosan.
In a previous commentary,70 Burkhard considered that if a 
rabbit model must be used for research, a more appropriate 
model was the one reported by Shah et al,79,80 who used 
bacterial contamination to produce contracture. In the Shah 
et al study,79 16 New Zealand white rabbits each received a 
S. epidermidis–contaminated implant and a control implant. 
The capsules were dissected at two, four, six, and eight 
weeks. Capsules on the contaminated side were two to three 
times thicker than those on the control side, and they did not 
change thickness with time. Capsules on the contaminated 
side consisted of densely packed, longitudinally oriented 
thick bundles of collagen fibers; there was a large cellular 
infiltration with leukocytes and macrophages. By contrast, 
the capsules on the control side were thinner and consisted 
of loosely organized connective tissue fibers predominantly 
parallel to the prosthesis surface. Bacteriological cultures on 
the contaminated side consistently yielded S. epidermidis 
with occasional diphtheroids, whereas the control side 
showed no bacterial growth.
As reported in the Prantl et al81 study, we believe that 
subclinical infection with chronic inflammation represents 
one of the possible important reasons for the development 
of CC. We also hypothesize that all possible causes of 
fibrosis result in the common key factor of pathological 
response with the development of chronic inflammation. 
The Prantl et al81 study included only those implants with 
high gel cohesiveness (third-generation implants); in these 
implants, silicone filler presumably does not leak from the 
shell into the tissue in the case of implant rupture. 
Surprisingly, in 67% of their specimens, the authors 
detected vacuolated macrophages with microcystic struc-
tures containing silicone. Also, in 54% of the specimens, 
the capsular tissue contained empty spaces with varying 
sizes of silicone particles. It remains unclear whether 
these silicone structures represented friction particles from 
the surface of the implant or particles from the implant 
filler. Heppleston and Styles82 performed in vitro experi-
ments demonstrating that silica damages macrophages, 
which subsequently produce TGF-β1 and stimulate fibrob-
lasts to produce collagen. However, since the Shah et al79 
study, even with the many publications on infected 
implants, we were unable to find any translation of the 
Baker classification into a preclinical model.
An infection-induced contracture limb study was per-
formed (data not shown) and compared with the chitosan 
group of this study. Using a similar experimental protocol, 
10 rabbits were implanted with two textured breast implants, 
each one with a suspension of 100 µL of coagulase-negative 
staphylococci (108 CFU/mL; 0.5 density on the McFarland 
scale). Histologically, the average capsular thickness was 
1.065 ± 0.287 mm in the infection-induced contracture 
limb group (CoNS group) and 2.746 ± 0.817 mm in the 
chitosan group. Capsular thicknesses were found to be sta-
tistically different among the two groups 
(p = .00003). A significant difference was also observed 
regarding the type of inflammatory cells among the two 
groups (p = .021), with the polymorph type being 
predominant in the CoNS group and the mixed type being 
predominant in the chitosan group. No significant differ-
ences were found between the two groups regarding the 
intensity of capsule inflammation. Significant differences in 
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angiogenesis were found between the CoNS and chitosan 
groups (p = .004)—with absent/mild and moderate/ high 
being equally present in the CoNS group but only high in 
the chitosan group—as well as in the synovial metaplasia (p 
= .043), which was always absent in the chitosan group 
but present in some cases of the CoNS group. However, no 
significant differences were found between the two groups 
regarding the characteristics of the connective tissue (loose 
or dense), the organization of the collagen fibers (parallel or 
haphazard), or fusiform cell density (mild, moderate, or 
high). Histologically, the type of CC induced by chitosan 
was different from that induced by infection, in that (1) the 
capsule was thicker, (2) the mixed type of inflammatory 
cells was predominant, (3) angiogenesis was high, and (4) 
the synovial metaplasia was absent. Our results contribute 
a preclinical noninfectious model of CC to the literature, but 
further studies are necessary.
We sacrificed the rabbits at four weeks to study early 
capsule formation and to understand the possible models 
of wound healing.39 A longer term study would be impor-
tant and is planned. However, long-term differences in 
capsule structures under these experimental challenges 
result from different wound-healing trajectories from Day 
0. Our strategy was to examine these early differences 
with methods that were sensitive to detecting histological 
or biomarker changes. There is no consensus about the 
length of time necessary in a preclinical model. In a clini-
cal mode, we proposed a follow-up period longer than 42 
months.83 However, it might be expected that the finding 
of a dense collagenous capsule would increase with time, 
reflecting a continued stimulus toward a fibroplasia and 
ultimate collagen remodeling.84-86
The weaknesses of this study include the relatively 
small size and the lack of capsule immunohistochemistry 
detection of IL-8 and TNF-α in tissue specimens. 
Nevertheless, the release of IL-8 and TNF-α represented a 
“spillage” of factors rather than a direct signal driving 
inflammation and leukocyte recruitment; the use of micro-
dialysis was appropriate for determining tissue concentra-
tion of cytokines such as IL-8 and TNF-α. Because of the 
proximity of the sampling site to the source of the 
cytokine, microdialysis provided a means of sensitively 
detecting relative changes of inflammatory mediator con-
centration with experimental treatments.
Possible future studies would include a model in which 
one silicone breast implant with ports (to measure the cap-
sule pressure directly) impregnated with LMWC is implanted 
per rabbit, as well as a model designed for detection of IL-8, 
TNF-α, TGF-β1, and determination of a fibrosis index. We 
previously reported complementary studies in which the 
same protocol is used to analyze silicone breast implants 
with ports impregnated with LMWC and those sprayed with 
Tissucol/Tisseel (Baxter International, Deerfield, Illinois).87,88
conclusions
Baker grade III/IV CC was observed in a rabbit model 
when implants were impregnated with chitosan; the CC 
was not due to a bacterial infection. This preclinical study 
may provide a model to test various mechanistic hypoth-
eses of breast capsule formation and subsequent CC and 
suggests an approach of studying CC with a preclinical 
animal model.
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Abstract
Background The etiology and clinical treatment of cap-
sular contracture remain unresolved as the causes may be
multifactorial. Triamcinolone acetonide applied in the
pocket during surgery was reported to be ineffective in
prevention of capsular contracture. However, if injected
4–6 weeks after surgery or as a treatment for capsular
contracture, decreased applanation tonometry measure-
ments and pain were observed. It was assumed that intra-
operative application of triamcinolone was not effective
because its effect does not last long enough. However,
betadine, antibiotics, and fibrin were found to be effective
in preventing capsular contracture with intraoperative
applications and are more effective in the early phases of
wound healing than in later stages. The role of triamcino-
lone acetonide in capsule formation is unknown. The
purpose of this study was to determine if triamcinolone
acetonide modulates breast capsule formation or capsular
contracture in the early phases of wound healing in a rabbit
model.
Methods Rabbits (n = 19) were implanted with one tis-
sue expander and two breast implants and were killed at
4 weeks. Implant pocket groups were (1) Control (n = 10)
and (2) Triamcinolone (n = 9). Pressure/volume curves
and histological, immunological, and microbiological
evaluations were performed. Operating room air samples
and contact skin samples were collected for microbiologi-
cal evaluation.
Results In the triamcinolone group, a decreased capsular
thickness, mild and mononuclear inflammation, and nega-
tive or mild angiogenesis were observed. There were no
significant differences in intracapsular pressure, fusiform
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cell density, connective tissue, organization of collagen
fibers, and microbiological results between the groups.
There was no significant difference in the dialysate levels
of IL-8 and TNF-a, but correlation between IL-8 and TNF-
a was observed.
Conclusion Triamcinolone acetonide during breast
implantation influences early capsule formation and may
reduce capsular contracture.
Level of Evidence III This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors at www.springer.com/00266.
Keywords Breast capsule  Triamcinolone acetonide 
Pressure  Histology  Microbiology  Immunology
Capsule formation is a foreign body reaction that occurs in all
patients who have breast implants. Normally not thicker than
1-mm [44], the capsule is part of the normal healing process
and may help keeping the implant in place [21, 22]. Capsular
contracture (CC) remains the most severe complication with
silicone and saline breast implants, with an incidence rang-
ing from 8 to 45 % [8, 23, 29, 33, 41]. The etiology of CC is
not completely understood, but it is thought to be multifac-
torial [4, 34]. Factors related to wound healing [49] and
infection [2, 3, 14, 18, 41, 47] are known to influence the
development of this clinical condition.
Etiology, prevention, and treatment measures for CC
have been extensively discussed, but there is no agreement
on a generally accepted therapeutic pathway. All the
reported clinical procedures used to minimize points of
contamination are crucial, and many plastic surgeons fol-
low the general principles of the ‘‘Betadine Era’’ [2] and
the ‘‘Post-Betadine Era’’ [3, 5] to prevent CC. Betadine [2],
antibiotics [3, 5], and fibrin [35, 36] are clinically associ-
ated with a low incidence of CC and are more effective in
the early phases of wound healing. However, even when
following all the procedures proven to be effective for
diminishing this complication, it is still an important late
complication of breast implant surgery [41].
In preclinical studies, treatment with mesna [6], mi-
tomicina C [24], zafirlukast [9, 46], pirfenidone [25], or
halofuginone [51] reduced capsule thickness, fibroblast cell
proliferation, and collagen deposition. Nevertheless, these
drugs are not commonly used in clinical practice, with the
exception of the zafirlukast. This drug is currently
approved for the treatment of asthma, but its role in the
treatment of CC is limited to severe cases due to the pos-
sibility of severe side effects [11, 28].
The capsule is known to be composed of a layer of
fibrous dense connective tissue [17] and is an integral part
of the wound-healing process. Although initially beneficial,
the healing process can become pathogenic if it continues
unchecked, leading to considerable tissue remodeling and
the formation of permanent scar tissue [13], as in CC.
Corticosteroids administered during wound healing have
been shown to stop the growth of granulation completely,
stop the proliferation of fibroblasts, diminish new out-
growths of endothelial buds from blood vessels, and stop
the maturation of the fibroblasts already present in con-
nective tissue [7]. Also, when administered early after
injury, corticosteroids delay the appearance of inflamma-
tory cells, fibroblasts, the deposition of ground substance,
collagen, regeneration of capillaries, contraction, and epi-
thelial migration [20]. These data raised interest in the use
of steroids in the treatment and prevention of CC.
The data available in the literature regarding the role of
steroids in the prevention and treatment of CC is sparse and
contradictory. Perrin [38] reported less than 5 % of sig-
nificant capsule formation in patients who underwent
augmentation mammaplasty with inflatable breast pros-
theses filled with saline and a cortisone derivative, with no
evidence of wound complications attributable to the ste-
roid. These results were reinforced by those of Ksander
[31], who, in a preclinical model with rats, showed that
saline implants filled with saline solution were harder and
surrounded by a thicker capsular membrane than those
filled with methylprednisolone sodium succinate at 60 and
120 days.
On the other hand, Caffee et al. [16] reported in a pre-
clinical study that putting triamcinolone in the pocket
during surgery was ineffective in the prevention of CC, but
if injected 4 and 8 weeks postoperatively (invasive
method), the drug was able to completely eliminate CC.
Caffee [15] also reported the effectiveness of postoperative
injection of triamcinolone in reducing the risk of recurrent
contracture in a high-risk group of patients. Sconfienza
et al. [43] demonstrated that US-guided injection of 40 mg
of triamcinolone acetonide (TA) into the peri-implant
pouch of women with augmented or reconstructed breasts
affected by Baker grade IV CC was effective in reducing
capsular thickness and the patient’s discomfort.
Although the data have been presented, the role of ste-
roids in the treatment and prevention of CC is not com-
pletely understood. It is not clear whether steroids are
effective in preventing CC when placed in the implant
pocket, as the data available are inconsistent and contra-
dictory. None of the clinical studies are prospective or
randomized. Moreover, none of the studies discussed here
established a clearly comprehensive role and mechanism of
steroids in the development of CC. Steroids have an
important role in the earlier phases of wound healing [20],
and the role of those effects on the early phase of breast
capsule formation are also not understood nor explored.
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The main objective of this study was to perform a
comprehensive evaluation of the role of TA in capsule
formation in the early phases of wound healing [13] and the
histological, microbiological, and immunological charac-
teristics in a rabbit model [4].
Materials and Methods
In an approved institutional animal care protocol, 19 New
Zealand white female rabbits were implanted with one
textured tissue expander (nonfilled; Allergan, Inc., Santa
Barbara, CA, USA) and two textured breast implants
(90 ml, Allergan). Prior to surgery, rabbit skin was washed
with Betadine Surgical Scrub, which contains 7.5 %
povidone-iodine, followed by Betadine solution, which
contains 10 % povidone-iodine (Purdue Pharma LP,
Stamford, CT, USA). The surgical procedure was per-
formed in an animal operating theatre following aseptic
rules. Penicillin G 40,000 U/kg was administered intra-
muscularly intraoperatively. Talc-free gloves were used at
all times during the procedure. Two 5 cm incisions and one
2.5 cm incision were made directly over the skin and
subpanniculus carnosus to introduce the implants and the
expander, respectively. Pockets were developed in the
subpanniculus carnosus with atraumatic dissection along
the back region. Particular attention was paid to hemostasis
under direct vision, avoiding blunt instrumentation, and
there was no obvious bleeding. A sterile Op-site dressing
was placed over the skin around the incision before
inserting the tissue expander and the implant to avoid
contact with the skin. Wearing a new pair of talc-free
gloves, the surgeon introduced the implants and the tissue
expander with intact connecting tube and port. In the
experimental group, triamcinolone acetonide (Trigon
depot, Bristol-Myers Squibb, New York, NY, USA) was
introduced into the implant and expander pocket. All
wounds were closed with two planes of interrupted suture.
The rabbits were divided into two groups: (1) the control
group with untreated implants and expander (n = 10), and
(2) the triamcinolone group which had the introduction of
1 ml (40 mg) of TA into each implant pocket and 0.25 ml
(10 mg) of TA into each expander pocket (n = 9). No fluid
suction was performed to retain the TA (Trigon depot) in
the surgical pocket.
Rabbits were killed at 4 weeks. Before that, each animal
was anesthetized and the dorsal back area was shaved. A
pressure-measuring device (Stryker Instruments, Kalama-
zoo, MI, USA) was connected to the tissue expander port
and intracapsular pressures were recorded at each 5 ml
increment before any incision made to the capsule. Then, a
5-mm incision was made directly over the implant through
skin, panniculus carnosus, and capsule. A 100,000
molecular weight cutoff microdialysis probe (CMA
Microdialysis, Stockholm, Sweden) was placed near the
capsule–implant interface and microdialysates were col-
lected using sterile normal saline solution (6 ll/min) for
1 h. Whole blood was obtained by venipuncture and serum
was collected after centrifugation (2,0009g min-1, 4 C).
All capsule samples underwent histological and microbio-
logical evaluation and all implants and expander devices
also underwent microbiological evaluation.
Microbiological Assessments
Air
Operating room air samples (n = 24) were collected during
all surgical procedures using the MAS 100-Eco air sampler
(EMD Chemicals, Inc., Gibbstown, NJ, USA) at a flow rate
of 100 l/min. Identification of bacterial and fungal isolates
followed standard microbiological procedures. Gram-posi-
tive cocci were characterized by biochemical methods.
Catalase-positive and coagulase-positive isolates were
reported as Staphylococcus aureus; catalase-positive and
coagulase-negative isolates were reported as coagulase-
negative Staphylococci. Gram-negative bacilli were char-
acterized with Vitek 2 software (VT2-R04.02, bioMerieux,
Inc., Durham, NC, USA). Fungi (molds) were characterized
according to macroscopic and microscopic morphology.
Rabbit Skin
A total of 57 contact plates were pressed to the shaved
dorsal skin surfaces (19 brain–heart agar, 19 mannitol salt
agar, and 19 Sabouraud agar contact plates). Brain–heart
and mannitol salt agar plates were incubated for 3 days at
28 C, and Sabouraud plates were incubated for 7 days at
28 C. The identification of the bacteria and fungi followed
the procedures reported above.
Capsules/Implants/Tissue Expanders
Excised tissue expanders/implants, and representative cap-
sule samples were incubated at 37 C for 3 days in brain–
heart broth and examined daily. Changes in the turbidity of
the broth media were considered positive and were subcul-
tured in solid agar media. Characterization of microbial
isolates followed the above-described procedures.
Histological Assessment
Capsule specimens were fixed with 10 % buffered formalin
and embedded in paraffin. Sections were stained with
hematoxylin and eosin and evaluated histologically for
tissue inflammation and capsular thickness. Both the type
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of inflammatory infiltrate and the intensity were analyzed.
The inflammatory cells was grouped into three categories:
(1) mononuclear (lymphocytes, plasmocytes, and histio-
cytes), (2) mixed (mononuclear cells and eosinophils), and
(3) polymorph (eosinophils and heterophils/neutrophils).
Inflammatory infiltrate intensity was categorized according
to the following criteria: absent (-), mild (?), moderate
(??), and severe (???) [44].
Samples were stained with Masson’s trichrome to
characterize the connective tissue (loose or dense), the
organization of the collagen fibers (arranged in a parallel
array or haphazardly), angiogenesis (absent, mild, moder-
ate, or high), and fusiform cell density (mild, moderate, or
high). The dense connective tissue was semiquantitatively
analyzed as (a) B25 % with thick collagen bundles less
than 25 %, (b) 25–50 %, (c) 50–75 %, and (d) [75 %.
Microdialysis Assessment
TNF-a levels were determined using Invitrogen’s Hu
TNF-a (catalog No. KHC3014:1; Life Technologies, Inc.,
Carlsbad, CA, USA). The assay was a solid-phase sand-
wich enzyme-linked immunosorbent assay (ELISA) in
which 100 ll of microdialysis fluid was pipetted into each
well. The protocol for IL-8 was performed using the Bio-
Source Hu IL-8 US kit (catalog No. KHC0083/KHC0084;
Life Technologies).
Data Analysis
Data were analyzed by groups: Control (n = 20) and Tri-
amcinolone (n = 18). One-way analysis of variance
(parametric or nonparametric) was performed to check
whether the several means of continuous variables (histo-
logically measured thickness and dialysate levels of IL-8
and TNF-a) were equal, followed by post hoc range tests to
identify homogeneous subsets across groups. A two-tailed
independent paired t-test and the nonparametric alternative
Mann–Whitney U test were used to determine whether
such continuous variables were likely to show differences
between control and experimental groups. Categorical
variables were evaluated by v2 statistics and by /,
Cramer’s V, and contingency coefficients. Statistical sig-
nificance was presumed at p B 0.05, and all analyses were
carried out with SPSS software (SPSS, Inc., Chicago, IL,
USA).
Results
Statistical analyses revealed no significant differences in
the histological, immunological, and microbiological
results between breast implants and tissue expanders (data
not shown). The expanders were included in the protocol to
determine the pressure–volume curves.
Clinical
In the triamcinolone group (Fig. 1), the capsules were thin-
ner and more transparent than those of the control group.
Pressure
During pressure measurements, five (50 %) capsules rup-
tured in the control group. To avoid too little sampling, the
ruptured capsules were not excluded from statistical anal-
yses; however, in such cases, the pressure value measured
before rupturing was maintained after further additional
saline was added. Pressure–volume curves were generated
for all rabbits that were killed. Statistical analyses revealed
no significant differences between the triamcinolone group
and the control group (Fig. 2).
Histology
Significant decreased capsular thickness was registered for
the triamcinolone group compared with the control group
(p B 0.001) (Table 1). A mixed cells were the most com-
mon finding in the control group and mononuclear cells
were the most common finding in the triamcinolone group
(Table 1). Significant differences were found between the
control group and the triamcinolone group (p = 0.0003).
A significant difference was observed between the triam-
cinolone and control groups (p = 0.009) with respect to the
Fig. 1 Capsule in the triamcinolone experimental group
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intensity of inflammation, which was mild in the triamcin-
olone group and moderate in the control group (Table 1). No
significant differences in the fusiform cell density, connec-
tive tissue, and organization of the collagen fibers were
observed between the control and triamcinolone groups.
Significant differences were found in angiogenesis between
the control group, where it was basically moderate or high,
and the triamcinolone group (p = 0.007), where it was
negative or mild.
Microbiology
Statistical analysis revealed no significant difference in the type
of bacteria and in the frequency of culture positivity for bacteria
between the control and triamcinolone groups with respect to
either implants or capsules. Also, there was no significant
association between microbial presence and histological data.
The predominant isolate was undoubtedly coagulase-negative
Staphylococci, which was identified predominantly in the
removed implants (Table 2). Isolated bacteria from the rabbits’
skin and from the operating room air were statistically similar
to those from the removed capsules and implants, with coag-
ulase-negative Staphylococci prevailing.
No fungi were recovered from the removed capsules,
implants, or skin samples of all rabbits. Fungal species,
such as Penicillium spp. and Aspergillus, were recovered
from the operating room air.
Immunology
The dialysate levels of IL-8 decreased from 115.56 ±
128.03 mg/ml in the control group to 54.41 ± 31.21 mg/
ml in the triamcinolone group. Statistical analysis revealed
no significant difference in the dialysate levels of IL-8
between the control group and the triamcinolone group.
The dialysate levels of TNF-a decreased from 328.62 ±
307.55 mg/ml in the control group to 148.9177 ± 211.
92273 mg/ml in the triamcinolone group. Statistical anal-
ysis revealed no significant difference in the dialysate
levels of TNF-a between the control group and the triam-
cinolone group. There is a correlation between IL-8 and
TNF-a in the control group (p \ 0.001) and in the triam-
cinolone group (p = 0.036).
Table 1 Outcomes for capsular thickness and inflammation of control vs. triamcinolone groups
Group Capsular thickness (mm) Type of inflammatory cells (%) Intensity (%)
Control 0.81 ± 0.209 Mononuclear (chronic) 25.0 Mild 30.0
Polymorph (acute) 0 Moderate 70.0
Mixed (active chronic) 75.0 High 0
Triamcinolone 0.53 ± 0.136 Mononuclear (chronic) 83.3 Mild 72.2
Polymorph (acute) 0 Moderate 27.8
Mixed (active chronic) 16.7 High 0
Table 2 Bacteria isolated from capsule and implant samples removed from all sacrificed rabbits
Bacteria Group No. of positive cultures
Capsules (%) Implants (%)
Coagulase-negative Staphylococci Control 2 (10) 13 (65)
Triamcinolone 6 (33) 14 (78)
Staphylococcus aureus Control 2 (10) 2 (10)
Triamcinolone 2 (11) 2 (11)
Bacillus gram-positive Control 1 (15) 1 (5)
Triamcinolone 2 (11) 2 (11)
Data collected from control (10 rabbits; 20 capsules and 20 implants) and triamcinolone (9 rabbits; 18 capsules and 18 implants) groups
Fig. 2 The pressure–volume curves
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Discussion
The capsule that forms around the breast implant is com-
posed by a layer of fibrous dense connective tissue [17],
and is an integral part of the wound-healing process. To
understand the formation of this late complication and the
potential therapeutic roles of both pharmacological and
nonpharmacological treatment approaches, it is crucial to
know the physiological mechanisms that are behind the
process that causes the formation of capsules.
Wound healing has been divided into three distinct
phases: inflammation, proliferation, and maturation [42].
The first phase of wound healing, which begins immedi-
ately upon injury through day 4–6, is characterized first by
hemostasis, an important event that serves as the initiating
step of the healing process; and an inflammatory response.
The second phase of wound healing (proliferative phase) is
characterized by epithelialization, angiogenesis, and pro-
visional matrix formation and courses from day 4 through
14, overlapping phases 1 and 3. Fibroblasts and endothelial
cells are the predominant proliferating cells during this
phase. The maturation and remodeling (phase 3), which
occurs from day 8 through 1 year, is characterized by the
deposition of collagen in an organized and well-mannered
network [13].
As seen before, corticosteroids are known to have an
important role in wound healing, as they can stop the
growth of granulation completely, stop the proliferation of
fibroblasts, diminish the new outgrowths of endothelial
buds from blood vessels, and stop the maturation of the
fibroblasts already present in connective tissue [7]. Also,
when administered soon after injury, corticosteroids delay
the appearance of inflammatory cells and fibroblasts; the
deposition of ground substance, collagen, and regenerating
capillaries; contraction; and epithelial migration [20]. Ste-
roids can have an important role in CC formation in both
the early and the late phase of fibrous phase formation.
The efficacy of triamcinolone in treating and preventing
CC in women has been reported [15, 43]. However, this
still represents an off-label practice and further studies are
required to validate the efficacy of this approach. Both
works have limitations: they were nonrandomized, with no
control group, had a limited follow-up period [15, 43], and
neither had as an objective the determination of the
mechanism of action of TA in capsular contracture for-
mation. A comprehensive understanding of the effects of
TA on the mechanisms of capsular formation, the systemic
side effects, and the potential adverse events are, in our
opinion, crucial for the improvement of TA in clinical
activity.
This study is the first to analyze the impact of TA in early
capsule formation. We examined the effects of TA on pres-
sure and histological, microbiological, and immunological
characteristics of capsules in an animal model to understand
the role of this steroid in early capsule formation and its
possible role in the prevention of CC. In our study, TA was
found to decrease capsular thickness upon macroscopic and
microscopic examination when compared to the control
group. These findings were also associated with decreased
inflammation and angiogenesis, as was expected, as steroids
are anti-inflammatory drugs capable of delaying the
appearance of inflammatory cells and they diminish the
proliferation of endothelium from blood vessels [7] and
regeneration of capillaries [20]. Although no significance
was found in the intracapsular pressure between the groups, a
tendency to lower pressures (and no capsule rupture during
the pressure measurement) was observed in the triamcino-
lone group compared to the control group (Fig. 2). Also, both
cytokine markers (IL-8 and TNF-a) were lower in the tri-
amcinolone group, even without statistic significance. No
significant differences were observed in fusiform cell den-
sities, connective tissue, or organization of collagen fibers.
Taken together, these results suggest that the introduction of
TA in the pocket intraoperatively has a role in capsule for-
mation and might prevent CC.
Like Caffee et al. [16], we were not able to observe a
significant decreased capsular pressure in the group treated
with triamcinolone at the time of implant placement.
However, in our study we went further and analyzed not
only the pressure, an unquestionable indicator of capsular
contracture, but also other characteristics that are related to
the formation of this pathology as a continuous process.
The breast capsule begins to be formed after implant
placement; however, in clinical practice, the contracture is
a late complication, and follow-up, as long as 42 months
[33], is required to diagnose this entity. In preclinical
models, there is no consensus on the timing for sacrifice
and for representative stages for capsule formation. We
were not able to observe significant differences in pressure
between the groups, probably because we killed animals
too early. However, we were able to observe the early
alterations that are characteristic of capsule formation as
thinner and more transparent capsules on macroscopic and
microscopic evaluation and decreased inflammation and
angiogenesis. It might be expected and is reasonable to
assume that a more dense collagenous capsule with
increased thickness would be present with longer incuba-
tion times, reflecting a continued stimulus toward fibro-
plasia and ultimately collagen remodeling [10, 12, 45].
Caffee et al. reported in both preclinical [16] and clin-
ical [15] studies that triamcinolone injected postoperatively
was able to eliminate CC and prevent the recurrence of this
condition. Those findings were confirmed by Sconfienza
et al. [43], who were able to demonstrate that US-guided
injection of triamcinolone acetonide in the peri-implant
pouch of women with augmented or reconstructed breasts
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affected by Baker grade IV CC is effective in reducing
capsular contracture. Both authors concluded that triam-
cinolone was effective in the late stages of capsule for-
mation. With our study we were able to observe that
triamcinolone is probably not only effective when injected
postoperatively, but also has a role in the early phases of
the development of capsular contracture.
In a previous report [36] that used the same protocol, the
authors were also able to find another compound, fibrin
(Tissucol/Tisseel) that was associated with a lower inci-
dence of CC when sprayed in the pocket/implant during
surgery and was more effective in the early phases of
wound healing than in the later phases. It was found that
fibrin [36] was able to decrease intracapsular pressures
when compared to control (p B 0.001, data not shown),
and the capsular thickness was decreased (0.47 ± 0.129-
mm) (p B 0.001) as in triamcinolone group.
TNF-a plays an important role in the wound-healing
process. It is produced by activated macrophages, platelets,
keratinocytes, and other tissues and it stimulates mesen-
chymal, epithelial, and endothelial cell growth and endo-
thelial cell chemotaxis [27, 32]. During the inflammatory
phase, it draws neutrophils into the injured area [39], gen-
erates NO [26] from macrophages, and digests damaged
extracellular matrix via matrix metalloproteinase [1]. During
the second phase, TNF-a upregulates KGF gene expression
in fibroblasts; upregulates integrins, a matrix component that
serves to anchor cells to the provisional matrix; stimulates
epithelial proliferation [32]; and is also a potent promoter of
angiogenesis. TNF-a is known to be a growth factor for
normal human fibroblasts and promotes the synthesis of
collagen and prostaglandin E2. IL-8 enhances neutrophil
adherence, chemotaxis, and granule release and enhances
epithelialization during wound healing [30, 32]. TNF-a
levels were reported to be markedly elevated in fibrotic
diseases such as liver fibrosis and is considered a mediator of
fibrosis like TGF-b1 [19]. Moritomo et al. [37] concluded
that TNF-a played a pivotal role in the maintenance of
hemostasis and tissue repair by inhibiting TGF-b1. We were
not able to find significant differences in IL-8 and TNF-a
levels, although decreased levels were observed in the group
treated with triamcinolone, possibly reflecting a role for this
drug in the modulation of the wound-healing process and
fibrotic response in the presence of the implant. More studies,
with longer follow-up and increasing doses of the compound,
are needed to confirm these data.
On the other hand, a significant correlation was also
found between IL-8 and TNF-a in both groups. This was
not unexpected, as correlations between IL-8 and TNF-a
with bacterial infections have been reported [48]. We did
not find any differences in the microbiology cultures
between groups, but further studies are necessary to clarify
whether triamcinolone increases the risk of infection.
With fibrin, a significant decrease in TNF-a
(140.9 ± 165.9 mg/ml) and IL-8 (23.9 ± 43.4 mg/ml)
levels (p = 0.003 and p = 0.048) was observed, support-
ing the possible role of this compound in early capsule
formation and in reduction of the collagen extracellular
matrix. No correlation between IL-8 and TNF-a was
observed in the fibrin group, which suggests a possible
antibacterial role of fibrin [36].
The main limitations of this study were (1) inappropriate
dosage in this model system; rabbits have much faster basal
metabolic rates than humans, and, as such, it is presumed
that rabbits have shorter drug half-lives [50]; (2) unknown
pharmacokinetics of triamcinolone in the capsule pocket
and subsequent metabolism, although triamcinolone mod-
eling may be based on systemic steroid modeling [40]; (3)
short follow-up, as capsular contracture usually takes more
than 4 weeks to develop; and (4) the use of one tissue
expander per rabbit to directly measure the internal
expander pressures using the port. Silicone breast implants
with ports with a 90 ml volume capacity would be optimal
to achieve more accurate results but are not commercially
available. In addition, the preclinical model would not
support the use of multiple large expanders or implants
over long time periods. Our data do support future studies
examining triamcinolone as a potential agent for prevent-
ing CC.
Possible future studies may include (1) a preclinical
study using silicone breast implants with ports (to measure
the capsule pressure directly) and with introduction of
1.5 ml (60 mg) of triamcinolone acetonide into each
implant pocket and sacrifice of the animals at a much
longer time point with detection of IL-8, TNF-a, and
TGF-b1 and determination of fibrosis index; and (2) with
the same protocol, assessment of the effects of saline or
other vehicles of triamcinolone acetonide on pressure/vol-
ume curves. We believe that in a preclinical study, a higher
dose of triamcinolone acetonide introduced into the
implant pocket and a longer follow-up time period will
support the growing body of evidence that triamcinolone
acetonide mitigates capsular contracture.
In summary, our results suggest that triamcinolone has a
role in early capsule formation and it may have a role in the
prophylactic management of this complication. Obviously,
its role is centered on the management of the factors related
to wound healing [49], and it is important to exclude a
deleterious role in the factors related to infection that are
also known to increase CC [2, 3, 14, 18, 41, 47]. The
clinical intraoperative use of triamcinolone acetonide may
prove to be a reliable and safe way to prevent capsular
contracture in women undergoing breast implantation. The
ultimate goal is to translate these preclinical results to the
clinic, as these findings may help not only patients with
breast implants, but all patients with any device in which
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capsule contracture around that device may lead to an
adverse clinical event.
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Metamorphosis
Marketa Duskova (Department of Plastic Surgery, Charles University,
Srobarova 50, 10034 Prague, Czech Republic,
email: duskova@fnkv.cz)
The main aim of the aesthetic surgery is to improve quality of life. It
is known that less attractive people find it harder to obtain a good
personal and professional position in the society. The main point of
interest and the most important aspect is the face because human
attractiveness is specifically connected with facial appearance. In
considering correction of the facial visage with a great change, the
surgeon must pay attention, prepare meticulously with analysis of the
situation, and choose a suitable approach according to the circum-
stances as a whole. Then surgery must be performed with perfect
surgical technique, and the postoperative care must be carried out in
close cooperation with patient, perhaps also with other specialities or
even nonmedical experts.
The concrete process is shown in the case of a woman who
underwent complete profiloplasty (rhinoplasty, chin reduction), teeth
reconstruction, upper and lower blepharoplasty, augmentation of both
lips by synthetic implant, and application of injectable fillers into
facial wrinkles and rhytides. In addition, the beautician, hairdresser,
image consultant, and stylist put the last touches on the outcome.
Only such complex treatment may increase the patient’s mental
stability, self-confidence, and quality of life. The more perfect the
elimination of functional problems and stigmatizing disharmony, the
better are the preconditions for patients’ success and their assertion in
society.
Capsular Contracture After Cosmetic Breast Augmentation:
Do Topical Antibiotics Matter?
Salvatore Giordano (Department of Plastic Surgery, Turku University
Hospital, Turku, Finland), Asko Salmi (Department of Plastic
Surgery, KL Hospital, Helsinki, Finland)
Introduction: Antibacterial lavage with topical antibiotics may reduce
the occurrence of capsular contracture in breast implant surgery. A
retrospective analysis was performed to investigate this effect.
Materials and Methods: The study participants included 308 women
who underwent cosmetic breast augmentation during two different
periods: 2004–2008 (n = 168, group A) and 2009–2010 (n = 140,
group B). The same surgeon performed the surgery for all the women
using the inframammary approach and the dual-plane pocket. All the
patients had McGhan/Allergan 410 form stable textured implants. The
group A patients received antibiotics as a single perioperative intra-
venous dose of cephalothin 1.5 g and cephalexin 750 mg as an oral
course twice a day for 1 week after discharge. In the group B, peri-
operatively, 750 mg of cefuroxime was administrated intravenously.
Implants and pockets were irrigated with 10 ml of 10 % povidone–
iodine solution mixed with 750 mg of cefuroxime and 40 mg of
gentamicin. After discharge, 500 mg of levofloxacin was adminis-
tered as an oral course once a day for 10 days. The postoperative
complications included occurrence of infection, seroma, and capsular
contracture. We considered capsular contracture significant when it
was graded Baker 3 or 4.
Results: The average postoperative follow-up period was 11 ± 13
months for group A and 3 ± 8 months for group B. No postoperative
infections or seroma were detected. Group B had no capsular con-
traction cases. The capsular contraction rate was significantly higher
in group A (5.9 vs. 0 %; p = 0.003).
Conclusions: The use of topical antibiotics in cosmetic breast surgery is
recommended because a significant increase in capsular contracture
was observed in patients not treated with topical antibiotics.
The Middle Third of the Face: Analysis, Techniques,
and Indications
Henry Delmar (90 Boulevard Du Cap, 06160 Cap D’Antibes, France,
email: info@henry-delmar.com)
The Aging Process: The aging process of the face acts in many modes
including squeletization, ptosis, and desequilibrium of muscular
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balance, with loosened tissues and lack of firmness and structure. This
gives modelization of the aging process in three modes: squeletiza-
tion, ptosis, and fattening. This modelization gives the surgeon the
opportunity to propose an adequate association of techniques.
Malar Elevation: The indication of the ptosis mode is elevation of the
malar region. In 1994, we described, with F. Trepsat, a technique of
low malar suspension with the buccal approach, which allows cor-
rection of the ptosis and transfer of volume from low to high. The
aging process of the cheekbone is more superficial than deep. To
address this, many authors improve the technique with a suspension
of the orbicularis oculi by the palpebral approach. The goal for
traction of the orbicularis is a superficial lifting of the skin of the
cheekbone. But the weak point is a high traction in the palpebral
region, which results in a deformation of the glance, with palpebral
deformity. To enable correction for the superficial modification of the
cheekbone without palpebral deformity, we propose a new technique
with medical devices as follows:
• Subperiosteal dissection of the cheekbone using the buccal
approach
• Installation of medical devices both superficially and deep
• Palpebral surgery and temporal lifting adapted to the indication.
This technique is called malar isolated positioning (MIP).
Indications: The indications for suspension of the cheekbone depend
on the aging lower eyelid and its treatment. Without treatment of the
lower eyelid, a buccal technique is recommended. In the situation of a
blepharoplasty, an eyelid approach and bone fixation are proposed.
The indications relate to the highness of the cheekbone. Indications
and results are shown.
What Can Be Achieved Through an Upper-Lid Incision?
Dirk F. Richter (Bonner Straße 84, Dreifaltigkeits-Krankenhaus,
50389 Wesseling, Germany, email: d.richter@krankenhaus-
wesseling.de)
Upper-lid blepharoplasty, one of the most demanded aesthetic proce-
dures, is not just treatment for dermatochalasis. The upper bleph-
aroplasty incision can be used to adjust retro-orbicularis oculi fat and for
glabellar myotomy, lateral cantopexy, and browpexy (i.e., brow-lift).
The transblepharoplasty brow-lift is suitable for the lateral two thirds of
the brow. This technique is less invasive and allows an anchoring of the
underlying brow soft tissue to the bone. This permits stabilization or
elevation of the eyebrow without an endoscope because the nerves are
under direct vision.
Another approach is corrugator supercilii muscle resection through
a blepharoplasty incision, which is suitable for patients who have
significant corrugator hyperactivity and deep frown lines without
eyebrow or forehead ptosis. This procedure can be performed with or
without a concomitant blepharoplasty.
Through an upper-lid incision, the blepharoplasty as well as the
cantopexy, brow-lift, and resection of the corugator muscle can be
performed with a less invasive technique and fewer scars, which leads
to a high patient acceptance rate and satisfaction.
The Challenging Lower Eyelid Correction: The Aesthetic Effect
of Lateral Orbicular Muscle Tightening
Csaba Viczian and Huba Bajusz (St. Gellert Private Clinic, 6722
Szeged, Kalvaria sgt 14, Hungary, email: bajuszhuba@gmail.com)
Introduction: Aesthetic correction of the lower eyelids often is more
difficult and challenging than correction of the upper eyelids. The
characteristics of facial aging result not only from elastosis and
sagging but also from atrophy of soft tissues, particularly the orbital
septum and orbital fat. The evolution of orbital fat preservation and
the midfacial volumetric concept taught clinicians to treat the lower
eyelid with the midface as one aesthetic unit.
Methods: Besides the popular methods (arcus marginalis release, fat
medialization, septorhaphy, fat transfer), the authors present their
results with additional lateral tightening of the orbicularis oculi
muscle.
Discussion and Conclusion: To recreate a youthful appearance of the
lower lid, a clear indication for the choice of the correct operating
method is needed. Before the procedure, the anatomy around the
orbit, the eyelid laxity, the fat pads, the lid–cheek junction, and the
position of the midface must be analyzed. The lower lid vectors will
show the relationship between the anterior projection of the globe, the
lower lid, and the malar bony eminence. The authors give special
interest to the moderate elevation effect on the midface created by
additional lateral tightening of the orbicularis oculi muscle. The
authors present their algorithm, which may help in selecting the
correct procedures for the lower eyelid and midface operations.
Animation Deformities by Pectoralis Muscle: The Cinderella
of Submuscular Mammaplasty
Mario Pelle Ceravolo (Via Giovanni Severano 35, 00161 Rome, Italy,
email: mario.pelleceravolo@libero.it)
Animation deformities are present in almost every patient submitted
to subpectoral augmentation mammaplasty. These deformities rep-
resent the most common complication related to the reported
operation and yet are the least known.
Animation deformities have been studied by the author in more
than 1,000 patients and classified according to clinical criteria in six
different categories. Many patients treated with the dual-plane tech-
nique present with animation deformity despite the ability of this
technique to avoid its occurrence.
The physiopathology of the deformity is related to the pulling
action of the muscle on the breast mass and not to implant dislocation
during the muscle contraction. The author presents his algorithm of
different techniques used for submuscular augmentation mamma-
plasty based on different anatomic preoperative situations.
Preservation of pectoralis muscle costal insertions, medial pecto-
ralis nerve section for muscle denervation, and horizontal muscle
splitting are the main maneuvers used to avoid breast dynamic dis-
tortion. Horizontal muscle splitting consists of a horizontal incision
performed in the pectoralis muscle that splits it in two flaps. The
upper flap provides good coverage for the implant, whereas the lower
flap may be left attached to the chest to improve the projection of the
breast lower pole, or it may be rotated laterally or medially depending
on the clinical demand.
Horizontal muscle splitting is a personal technique that the author
has used during the last 10 years in more than 350 cases with aes-
thetically good results and a substantial decrease in the occurrence of
animation problems.
Conservative Rhinoplasty
Georges J. Ghanime´ (Division of Plastic and Reconstructive Surgery,
Lebanese University, Faculty of Medicine, Lebanese Hospital,
Getawi, Beirut, Lebanon)
Currently, rhinoplasty is one of the most popular aesthetic surgical
procedures. This has led to refinement of the techniques, making them
simpler and more reliable and minimizing soft tissue trauma by using
the least invasive technique to accomplish the predetermined goals.
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Our experience includes more than 4,000 rhinoplasties performed
since 1992. The majority of the cases are managed by same-day
surgeries performed with the patient under general anesthesia using
only the closed approach. Because form and function work together, a
septoplasty is performed when there is septal deviation.
Our experience has led us to the conclusion that conservative
rhinoplasty is indicated in most cases.
Effects of Fibrin (Tisseel/Tissucol) on Breast Capsule Formation
in a Rabbit Model
Marisa Marques (Hospital de Sao Joao, Servic¸o de Cirurgia Plastica
(piso 7), Alameda Prof. Hernaˆni Monteiro. 4202 Porto, Portugal,
email: marisamarquesmd@gmail.com)
Background: The etiology and clinical treatment of capsular con-
tracture remain unresolved because causes may be multifactorial. The
previously described environmental challenges that accelerate capsule
contracture have been bacteria, especially coagulase-negative staph-
ylococci. The role of fibrin in capsule formation was controversial in
various independent studies. Study 1 aimed to influence capsule
wound healing with blood, fibrin, and thrombin, and to make a
comparison with a control group in a rabbit model implanted with
tissue expanders. To clarify the results of this first study, study 2 was
performed to determine whether fibrin and coagulase-negative
staphylococci modulated capsule formation in a rabbit model
implanted with a tissue expander and breast implants.
Methods: Study 1: Each New Zealand white rabbit (n = 18) received
four different tissue expanders and then was killed at 2 or 4 weeks.
The four study groups were the control, fibrin, thrombin, and blood
cohorts. Study 2: Rabbits (n = 31) were implanted with one tissue
expander and two breast implants and then were killed at 4 weeks.
The implant pocket groups included the control (n = 20), fibrin
(n = 22), and coagulase-negative staphylococci (CoNS) cohorts
(n = 20). Pressure and volume curves as well as histologic and
microbiologic evaluations were performed. Operating room air sam-
ples and contact skin samples were collected for microbiologic
evaluation.
Results: Study 1: At 4 weeks, significantly lower intracapsular
pressures were measured in the experimental fibrin and thrombin
groups than in the control group. For the control and fibrin groups,
mixed inflammation was correlated with decreased intracapsular
pressures, whereas mononuclear inflammation was correlated with
increased intracapsular pressure. The predominant isolates in cap-
sules, tissue expanders, and rabbit skin were coagulase-negative
staphylococci. For the fibrin and thrombin groups, cultures other than
staphylococci and negative cultures were correlated with decreased
intracapsular pressures, whereas staphylococci isolation was corre-
lated with increased intracapsular pressures. Study 2: In the fibrin
group, significantly decreased intracapsular pressures, thinner cap-
sules, loose or dense (\25 %) connective tissue, and negative or mild
angiogenesis were observed. In the CoNS group, increased capsular
thicknesses and a polymorph type of inflammatory cells were the
most common findings. Similar bacteria in capsules, implants, and
skin were cultured from all the study groups. A Baker grade 4
contracture was observed in an implant infected with Micrococcuss
spp.
Conclusion: Fibrin (Tisseel/Tissucol) was associated with reduction
of capsule formation in our preclinical animal model, which makes
fibrin an attractive potential therapeutic agent for women undergoing
breast implants. Clinical strategies for preventing bacterial contami-
nation during surgery are crucial because low pathogenic agents may
promote capsular contracture.
Face and Neck Rejuvenation Using Combined Techniques: Laser
Lipolysis, Fractional Laser, Liposuction, and Lipofilling
Dana Jianu, M. Filipescu, S. Adetu (ProEstetica Medical Center, 38–
40. Tudor Stefan Street, Bucarest, Romania, email:
djianu02@gmail.com)
Background: This study assessed the role for the combined use of
fractional laser (CO2 laser) and laser lipolysis (980-nm diode laser)
for face and neck rejuvenation.
Methods: From September 2008 to February 2011, 39 subjects
underwent laser treatments for facial and neck rejuvenation. The
treatment consisted of using laser lipolysis (980-nm diode laser Me-
dArt), sometimes with additional facial fractional laser CO2 MedArt.
Laser lipolysis was performed to restore the jaw line and the man-
dible–neck angle respectively for laxity of the jaws and the anterior
cervical part. After tumescent anesthesia, a 1.5-mm-diameter needle
(80 mm long) housing a 600-lm optical fiber was inserted into the
subcutaneous fat. The cannula was moved in predetermined lines to
obtain a homogeneous distribution in the treated area. The laser set-
tings were 10–11 W in relation to the thickness of the subcutaneous
fat and dermis. In some cases, additional fine liposuction and lipo-
filling were necessary. The settings for the fractional laser used in
face rejuvenation usually provided a 10-W, medium-density beam for
4 ms. For eyelids, the settings provided an 8-W, high-density beam
for 5 ms.
Results: A total of 108 laser lipolysis procedures were performed for
39 patients. The areas treated were the jaws (9 patients) and the jaws
together with the anterior part of the neck (30 patients). The mean
cumulative energy was 1,800 J for the jaw area and 3,000 J for the
neck. Contour correction and skin retraction were noted after
4–7 days for almost all the patients.
Conclusion: This clinical study demonstrates that removal of fat in
small volumes with concurrent subdermal tissue contraction can be
performed safely and effectively using a 980-nm diode laser. Addi-
tional benefits include excellent patient tolerance and a quick
recovery time. The study also confirms that accumulated energy
derived from fractional laser combined with laser lipolysis is safe and
can improve the contraction and skin regeneration, leading to a better
rejuvenation of the face and neck.
Combined Mastopexy and Breast Augmentation
Teresa Bernabeu (avda. Benidorm 19, Ed. Arena piso 8, 03540,
Alicante, Spain, email: info@teresabernabeu.com)
Background: Combined mastopexy and breast augmentation, first
described by Gonzalez Ulloa [1] and Regnaul [2] in 1960, has seen an
increase in demand in recent years. Whereas a woman previously was
satisfied with a mastopexy alone, currently, the patient herself
demands the combination of filling and lifting of the breast in a single
procedure with the smallest possible scar. These patients are, without
doubt, influenced by the increasingly widespread images of the aes-
thetic appearance conferred by breast implants and the growing trend
to maintain C- or D-cup breasts. Driven by these demands, plastic
surgeons have increased the indications for this type of intervention
and the frequency of their use. These interventions present difficulties
and potential risks and can become absolute disasters [3]. The steps to
follow are selection of the patient, selection of the mastopexy tech-
nique, glandular resection, and implant selection, with all these steps
aimed at achieving the aesthetic objectives while leaving minimal and
inconspicuous scars.
Methods: The literature contains different rules [4–7] regarding the
selection of mastopexy technique based primarily on the distance
from the sternal notch and nipple to the areola and inframammary
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fold together with the degree of breast ptosis. These rules are helpful,
although they may vary from one procedure to another and become
modified over time according to this author’s experience. In addition
to this, before surgery, there is a degree of uncertainty regarding the
choice of technique, which in many cases does not become clear until
the breast implant is in place. The method used to achieve a longer-
lasting result of mastopexy combines three factors: an anatomic
implant with its different projections and heights to help prevent
recurrence of ptosis, glandular resection as required, and the subfas-
cial placement of the prosthesis, which produces greater concordance
and harmony between the implant and the mammary gland.
Results: The results obtained in the last 2 years with the aforemen-
tioned method are aesthetically better and have lower rates of
complications than those previously obtained by the author.
Conclusion: Subfascial positioning of anatomic implants with maxi-
mum projection and glandular resection as required help to provide
greater durability in mastopexy.
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Of Form, Function, and Aesthetics in Nose Surgery
Selahattin O¨zmen (Department of Plastic, Reconstructive,
and Aesthetic Surgery and Hand Surgery, Faculty of Medicine, Gazi
University, Ankara, Turkey)
Traditional rhinoplasty operations depend on cartilage, bone, or both,
and sometimes soft tissue resections. In modern nose surgery, how-
ever, the function and the aesthetic appearance should be seized
together.
Resections could be limited mainly to three cartilaginous areas,
with cartilages reconstructed in these areas: lower lateral (alar) car-
tilages, upper lateral cartilages, and septal cartilage.
Nasal Tip Region: Providing a natural-appearing nasal tip contour has
always been a key component of a successful rhinoplasty. One pre-
requisite for a successful rhinoplasty is nasal tip support and its
influence on nasal tip projection. Alar cartilages are the chief pro-
viders of structural support to the tip of both the nose and the external
nasal valve.
To reshape the nasal tip, we use the sliding alar cartilage (SAC)
flap, a novel technique for nasal tip contouring and support. The SAC
technique [1]
• Provides an aesthetically acceptable and naturally good-looking
nasal tip and alar contour
• Supplies effective nasal tip support and could be used for ‘‘pinch
nose’’ deformity
• Does not require any cartilage graft and thus results in no donor-
site morbidity
• Involves minimal or no risk for malposition, distortion, or
resorption because it is a flap secured with sutures
• Results in a nonpalpable cartilage graft, in contrast to other
cartilage grafts, because it is prepared from the original alar
cartilage and placed under the caudal alar cartilage
• Produces no unwanted effect on the external nasal valve function
because the connection between the upper lateral cartilages and
the alar cartilages is not broken
• Reserves the cranial parts of the alar cartilages, allowing for their
use in the future whenever there is a need (e.g., septal
perforations)
• Uses a flap with a double-layered alar cartilage, which can supply
more resistance against the thick tip in some noses that poses a
real challenge.
Middle Vault: Another point is the resection of the upper lateral
cartilages. Upper lateral cartilages are attached to the septum in an
obtuse angle forming a T shape. Dorsal hump reduction during rhi-
noplasty almost always breaks this connection and can create both
functional and aesthetic problems if performed incorrectly. We pre-
serve the upper lateral cartilages using the upper lateral cartilage fold-
in flap technique [2]. This technique has a combined spreader or splay
graft effect without cartilage grafts.
The upper lateral cartilage fold-in flap technique might be appli-
cable for almost all primary rhinoplasty patients because the previous
physiologic structure is reconstructed. It also is suitable for patients
who have not undergone previous dorsal hump removal.
To have a splay effect, only mucoperichondrial sutures should be
used, and at least a 1–2-mm middle nasal vault reduction is necessary.
For narrow noses, to prevent a very wide appearance in the middle
nasal vault, transcartilaginous mattress sutures should be used.
Suturing the mucoperichondrium over the cartilages could supply a
smoother dorsum at the middle vault.
Although it is possible to use this technique with closed rhino-
plasty approaches, it is easier with the open approach. This technique
is not suitable for secondary rhinoplasty cases, in which upper lateral
cartilage resection has already been performed. In these cases,
spreader or splay grafts might be applied.
Nasal Septum: Septoplasty: Excessive resection of the septal cartilage
or bone leaving an L-strut is the technique most surgeons prefer. But
the weakened septum could collapse in a relatively minor trauma.
In most septal deviations, the problem is mostly related to the
bony septum, including the maxillary crest and the perpendicular
plate of the ethmoid bone or vomer. The cartilage usually is not
broken, only bent in an anteroposterior or craniocaudal direction. In
most cases, just releasing these bonding factors by removing deviated
bones and bone spurs leads to a relaxation in the cartilage, with
cartilaginous resection unnecessary or minimal.
On the other hand, the cartilage should be excised or reconstructed
if there is a fracture or cartilage excess.
Consequently, septal deviations should be corrected very meticu-
lously, and septal cartilages and bones should not be excised when it
is not necessary. They should be reconstructed in-site and in an
extracorporeal fashion whenever needed.
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